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In addition to its canonical role in aminoacylation, threonyl-tRNA synthetase 
(TARS) possesses pro-angiogenic activity that is susceptible to the TARS-specific 
antibiotic borrelidin. However, the therapeutic benefit of borrelidin is offset by its strong 
toxicity to living cells. The removal of a single methylene group from the parent 
borrelidin generates BC194, a modified compound with significantly reduced toxicity but 
comparable anti-angiogenic potential. Biochemical analyses revealed that the difference 
in toxicities was due to borrelidin’s stimulation of amino acid starvation at ten-fold lower 
concentrations than BC194. However, both compounds were found to inhibit in vitro and 
in vivo models of angiogenesis at sub-toxic concentrations, suggesting a similar 
mechanism that is distinct from the toxic responses. Crystal structures of TARS in 
complex with each compound indicated that the decreased contacts in the BC194 
structure may render it more susceptible to competition with the canonical substrates and 
permit sufficient aminoacylation activity over a wider concentration of inhibitor. 
Conversely, both borrelidin and BC194 induce identical conformational changes in 
TARS, providing a rationale for their comparable effects on angiogenesis. The 
mechanisms of TARS and borrelidin-based compounds on angiogenesis were 
subsequently tested using zebrafish and cell-based models. These data revealed ectopic 
branching, non-functional vessels, and increased cell-cell contracts following BC194-
treatment or knockdown of TARS expression, suggesting a role for the enzyme in the 
maturation and guidance of nascent vasculature. Using various TARS constructs this 
function was found to be dependent on two interactions or activities associated with the 
TARS enzyme that are distinct from its canonical aminoacylation activity. Furthermore, 
observations that TARS may influence VEGF expression and purinergic signaling 
suggest the possibility for a receptor-mediated response. Taken together, the results 
presented here demonstrate a clear role for TARS in angiogenesis, independent of its 
primary function in translation. Although the exact molecular mechanisms through which 
TARS and borrelidin regulate this activity remain to be determined, these data provide a 
foundation for future investigations of TARS’s function in vascular biology and its use as 
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CHAPTER 1: INTRODUCTION 
 
1.1 Functions of Aminoacyl-tRNA Synthetases 
1.1.1 Aminoacyl-tRNA synthetases translate the genetic code 
The aminoacyl-tRNA synthetases (ARSs) are a family of enzymes responsible for 
the covalent attachment of amino acids to their corresponding tRNA through a process 
known as aminoacylation. They were first discovered in 1954 by their activation of 
amino acids with AMP and subsequently found to transfer the amino acid to its 
corresponding tRNA molecule (1,2).  ARSs are thought to be among the first proteins to 
evolve and their ubiquitous distribution throughout all cellular life can be ascribed to 
their critical roles in translation (3,4).  In order to ensure translational fidelity each amino 
acid is associated with a specific ARS. These enzymes are highly discriminatory of the 
amino acids and tRNA molecules used as substrates. Despite their profound structural 
differences, all ARS catalyze the core aminoacylation reaction through a two-step 
mechanism described below: 
 
1) AA + ATP  AA~AMP + PPi 
2) AA-AMP + tRNAAA  AA-tRNAAA + AMP 
 
The first step, or adenylation, activates the amino acid (AA) through condensation 
with ATP to form an enzyme-bound adenylate intermediate (AA-AMP) along with the 
release of inorganic pyrophosphate (PPi). Subsequently, the activated amino acid is 
 2 
transferred to the 2’- or 3’-hydroxyl of the terminal adenosine on the acceptor arm of the 
tRNA molecule, releasing charged-tRNA and AMP as products.  
 The ARSs can be subdivided into two, evolutionarily distinct classes, referred to 
as Class I or Class II, each containing about half the available species. In general, the 
ARS for each AA/tRNA pairing fall into one of the two categories, with the notable 
exception of lysyl-tRNA synthetase (KARS) which has varieties associated with either  
class. These classifications were originally categorized on the basis of conserved 
sequence and tertiary structure motifs but have expanded to include substrate binding and 
quaternary structure as well. Class I ARSs are mostly monomeric and characterized by a 
Rossman dinucleotide binding domain and consensus HIGH and KMSKS sequences. 
Conversely, Class II ARSs are multimeric, ususually homodimers, and defined by a 
conserved fold of antiparallel β-strands and three complex sequence motifs. These 
structural differences also contribute to varying biochemical properties between the two 
classes. The Rossman fold of Class I enzymes binds ATP in an extended conformation in 
contrast to the bent conformation adopted in Class II. Additionally, amino acids are 
transferred to the 2’-hydroxyl of terminal adenosine moiety in tRNA in Class I ARS 
while Class II varieties transfer to the 3’-hydroxyl group (with the exception of the Class 
II phenylalanyl-tRNA synthetase (FARS) which also uses the 2’-hydroxyl) (5,6).      
 
1.1.2 Maintenance of aminoacylation fidelity  
High fidelity translation is an essential component for life as misincorporation of 
amino acids can be detrimental to cell survival. Consequently, errors in translation are 
rare under normal circumstances, occurring at a rate of 1 for every 103 or 104 translated 
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codons (7,8). A major contributing factor to this fidelity is ARS substrate specificity for 
both amino acids and cognate tRNA. Discrimination between tRNA molecules is 
achieved through mutually exclusive interactions with specific tRNA bases, referred to as 
identity elements, and the respective ARS (reviewed in (9)). Errors in tRNA specificity 
are quite rare under normal circumstances, with some reports suggesting a 1 in 107 
misidentification events, and likely represent a minor factor in overall translation error 
rate (10). Conversely, specific binding of the much smaller amino acid provides a greater 
challenge.  
Using structurally or chemically restrictive active sites most ARSs are able to 
distinguish their target amino acid from the majority of others within the cell. However, 
the close physiochemical properties of certain amino acids makes it nearly impossible for 
complete discrimination without further processing. In example, several pairs of amino 
acids differ only by a single methyl group, such as threonine and serine, valine and 
isoleucine, or alanine and glycine. The smaller molecule of each of these pairs should be 
able to fit into the binding pocket available to the other with only a modest reduction of 
binding affinity. Specifically, the loss of hydrophobic interactions from a methyl group is 
estimated to decrease binding affinity by 14.2 kJ/mol on average, which would reduce 
discrimination, at best, to 1 in 200 (11). Therefore, to obtain the discrimination actually 
observed for ARSs, secondary editing functions would have to evolve to reduce the 
misincorporation of false cognate amino acids.  
 Editing by ARSs is often described through the use of the classical “double-
sieve” model proposed by Fersht and Dingwall in 1979 (12). In this mechanism, the 
active site of the ARS functions as the “course-sieve” by permitting the binding and 
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catalysis of the cognate and near-cognate amino acids but precluding interactions with 
most others through steric or incompatible chemical contributions (such as the steric 
occlusion of leucine observed with isoleucyl-tRNA synthetase (IARS) (13)). The 
subsequent and specific hydrolysis of false cognate products or intermediates relative to 
the intended amino acid then constitutes the “fine-sieve”. These “fine-sieve” processes 
can be further divided into one of two categories, termed pre-transfer or post-transfer 
editing, based on when the editing event occurs in the reaction scheme. While some 
ARSs show a preference for one of these methods, others will switch between the two 
under certain conditions, indicating the possibility of redundant fidelity mechanisms (14-
16). In pre-transfer editing aminoacyl-adenylates generated from reactions with false 
cognates are hydrolyzed prior to transfer onto awaiting tRNA molecules as is 
demonstrated in the editing of homocysteine by methionyl-tRNA synthetase (MARS) 
(17). Cleavage of the adenylate intermediate in these situations appears to be kinetically 
driven and occurs under conditions of reduced aminoacylation activity (14,16).  
In contrast, post-transfer editing involves the cleavage of false cognates from 
tRNA subsequent to the aminoacyl-transfer reaction. Unlike pre-transfer editing, this 
reaction occurs within an active site separate from the one involved in aminoacylation. In 
Class I ARSs this site is composed of a conserved CP-1 domain associated with the 
invariant Rossman fold (6). In contrast, Class II ARSs do not share a common editing 
domain structure (18-20). Following aminoacylation, the charged-tRNAs are immediately 
transferred to a second active site dedicated to editing. Transfer RNA charged with the 
cognate amino acid lack the physiochemical properties required for binding to this site 
and are subsequently released. False cognates, however, are readily admissible and 
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cleaved, generating uncharged-tRNA and free amino acid. Features that facilitate this 
discrimination can utilize the false cognates’ chemical properties, like the Zn2+ atom in 
alanyl-tRNA synthetase (AARS) which coordinates serine’s hydroxyl group, or size, as 
demonstrated by steric occlusion of isoleucine but not valine, by IARS’s editing site 
(13,21).  
The importance of these editing activities is emphasized by the detrimental effects 
associated with their loss or dysfunction. In cell culture, the increased burden of 
mistranslation can lead to the activation of cellular stress responses and apoptosis (22). 
Conversely, the effects in whole organisms are more complicated. Editing disrupting 
mutations in AARS have been associated with the accumulation of misfolded proteins in 
mice, which leads to the loss of Purkinje cells (23). In contrast, while mutations in human 
ARSs have been associated with diseases, none have been specifically linked to editing 
domain mutations. In example, the peripheral neuropathy Charcot Marie Tooth syndrome 
has been associated with mutations in several ARSs. However, these mutations seem to 
be unrelated to the aminoacylation and editing functions of the proteins (24). Instead 
these effects appear to be related to yet unknown noncanonical functions of these ARSs. 
Interestingly, the field of ARS secondary functions has expanded rapidly in recent times 
and have been associated with a variety of different processes, one of which serves as the 
basis for this work.   
 
1.2 Aminoacyl-tRNA synthetases as regulators of angiogenesis 
In addition to their canonical functions in aminoacylation, a growing body of 
evidence has identified several secondary activities associated with ARSs. Among the 
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earlier reported non-translational functions were effects on RNA splicing. Mitochondrial 
varieties of tyrosyl-tRNA synthetase (YARS) and leucyl-tRNA synthetase (LARS) 
possess splice factor-like activities and assist in the excision of group I introns (25,26). 
Transcriptional and translational regulatory properties have also been identified in ARSs 
through association with transcription factors or the binding of tRNA-like structures 
within mRNA promoter regions (27,28). Furthermore, ARSs in higher-order eukaryotes 
have evolved roles in both internal and external cellular signaling responses, including 
apoptosis and inflammation (29,30).  
 
1.2.1 Aminoacyl-tRNA synthetases as nutrient sensors 
As catalysts for the aminoacylation reaction, ARS are sensitive to intracellular 
concentrations of amino acids and ATP. This feature opens opportunities for ARSs to be 
used as nutritional and energy sensors within the cell. One of the best examples of this 
concept was observed in recent investigations of LARS, in which the synthetase 
regulated the activities of the mammalian target of rapamycin (mTOR) signaling 
pathway. The mTOR pathway serves to transduce a variety of internal and external 
signaling events into the regulation of translation, cell growth, metabolism and autophagy 
(reviewed in (31)). Notably, mTOR is required for the initiation of translation in 
eukaryotic cells by phosphorylating 4E-BP1 and preventing its inhibition of eIF-4E’s 
interaction with the 5’- cap of mRNA (32). These responses are primarily mediated by 
two multi-protein complexes termed mTOR complexes 1 (mTORC1) and 2 (mTORC2). 
Of particular interest, the functions of mTORC1 are highly responsive to cellular nutrient 
levels, specifically amino acids. High concentrations of amino acids facilitate the 
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association of the complex to the lysosomal membrane through activation of the Rag 
family GTPases (33,34). This translocation permits mTORC1 to interact with its primary 
activator, Rheb, which is attached to the lysosome membrane, thereby initiating 
downstream signaling events (35). Interestingly, mTORC1 activation is particularly 
sensitive to the essential amino acid leucine (36). Subsequent investigations revealed that 
the mechanism through which leucine regulates mTORC1 was dependent on LARS 
(37,38). When leucine is plentiful, LARS activates the GTPase activity of the mTOR 
regulating protein RagD. Activated RagD joins with the mTORC1 and stimulates its 
relocation to the lysosomal membrane. Conversely, leucine depletion deactivates mTOR, 
which arrests translation and restores amino acid homeostasis through the degradation of 
cellular proteins. 
In addition to their roles as protein building blocks some amino acids are required 
as precursors in other biosynthetic pathways. In particular, glutamine is an important 
component in nitrogen metabolism and a major source of malic acid used in NADPH 
synthesis (39,40). Likely owing to its intimate role in basic metabolic pathways, high 
levels of glutamine contributes to anti-apoptotic signaling in cells (30,41,42). One of 
these mechanisms involves the glutamine-dependent association of glutaminyl-tRNA 
synthetase (QARS) and the apoptosis signal-regulating kinase 1 (ASK-1). ASK-1 is 
activated in response to FAS-ligand signaling and oxidative stress, which eventually 
leads to apoptosis through the c-jun N-terminal kinase (JNK) associated pathways 
(43,44). High levels of glutamine, however, can attenuate this effect by encouraging the 
binding of QARS to ASK1 and inhibiting its pro-apoptotic signaling. Interestingly, this 
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QARS-ASK1 interaction requires the binding of glutamine to the QARS active site and 
emphasizes the role of the ARS as a nutrient sensor (30).    
Similar to LARS and QARS, tryptophanyl-tRNA synthetase (WARS) also 
possesses non-canonical signaling functions sensitive to the levels of its cognate amino 
acid. This effect is dependent on the conformation of an N-terminal WHEP domain. 
These helix-turn-helix domains are exclusive to ARSs and are named for tryptophanyl 
(W), histidyl (H), and glutamlyl-prolyl (EP) ARSs in which they are found. When the 
active site of WARS is occupied by its canonical substrates, the WHEP domain closes 
over it like a cap. However, when this active site is unoccupied (apo-WARS), this 
domain is unstructured and remains available for mediating protein-protein interactions. 
Since WARS is a functional homo-dimer this allows for two separate WHEP interactions. 
Specifically, the exposed WHEP domains of apo-WARS dimers form the central 
component of a complex with the poly-(ADP-ribose) polymerase 1 (PARP1) and DNA-
dependent protein kinases (DNA-PKcs) following stimulation by interferon γ (IFNγ). 
Formation of this complex encourages the poly-ADP ribosylation of DNA-PKcs and 
activates its kinase activity against p53. As such, WARS appears to possess a function in 
the regulation of p53 activity (45). Previously, IFNγ has been shown to activate p53-
dependent pathways involved in cellular senescence and apoptosis, suggesting that 
WARS’s association with p53 may also be another nutritional stress response (46,47). 
However, the full extent of this signaling remains to be determined.  
In addition to activating responses related to senescence and apoptosis, amino 
acid concentrations can be linked to other signaling events as well. For all ARSs, the 
deprivation of amino acids can activate the general control nonderepressible 2 (GCN2) 
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amino acid starvation and ER-stress pathways through the accumulation of uncharged 
tRNA molecules (a pathway that will be discussed in Chapter 3 at greater detail) (48).  Of 
particular interest is the dysregulation of mTOR signaling or induction of ER-stress by 
nutrient deprivation that has been observed to influence the expression of vascular 
endothelial growth factor A (VEGFA, originally vascular permeability factor) through 
the regulation of the hypoxia-inducible factor α (HIFα) transcription factor (see Appendix 
I for more details on HIFα signaling) (49,50). Since VEGFA is a key signaling molecule 
in the regulation of angiogenesis (see below), these observations provide an indirect 
mechanism for ARS-regulation of angiogenesis. More relevant to this dissertation, 
however, is the observation of direct angiogenic regulation by specific ARSs.  
 
1.2.2 Basics of angiogenic signaling pathways 
Angiogenesis, or the growth of new blood vessels from preexisting ones, is a 
multifaceted process governed by the balance of pro-angiogenic and quiescent signals. 
The factors mediating these effects consist of various extracellular matrix (ECM) 
components, soluble growth factors, cell-cell adhesion proteins, and associated receptors 
(reviewed in (51,52)). Under normal conditions vessels maintain a quiescent state 
through the release of angiopoetin-1 and other survival signals from mural cells (53).  
However, the spatially and temporally regulated expression of other factors can tip the 
balance positively or negatively with respect to proliferation, migration, and maturation 
of nascent vasculature. Many of these factors, such as fibroblast growth factor (FGF) and 
platelet-derived growth factor (PDGF), are functionally redundant and associated with a 
variety of biological functions (53). Conversely, VEGFA and its corresponding receptor 
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VEGFR2 (also referred to as the kinase insert domain receptor (KDR) or fetal liver 
kinase 1 (Flk1)) are indispensable for the process of angiogenesis and are highly specific 
to endothelial cell signaling (54). VEGFA is released from tissues in response to hypoxia, 
inflammation, or wound healing and activates VEGFR2’s receptor tyrosine kinase 
activity in endothelial cells. Consequently, proliferation, migration, and survival are 
enhanced by the activation of downstream signaling targets, including ERK1/2, p38-
MAPK, and AKT (55). While these various kinases may elicit overlapping effects, their 
differences allow for the fine tuning of the angiogenesis process by favoring specific 
responses, such as migration or proliferation.  
To date, angiogenesis-associated activities have been observed in tyrosyl-tRNA 
synthetase (YARS), tryptophanyl-tRNA synthetase (WARS), seryl-tRNA synthetase 
(SARS), glutamyl-prolyl-tRNA synthetase (EPRS) and one closely associated protein,  
aminoacyl-tRNA synthetase interacting multifunctional protein 1 (AIMP1, also known as 
p43) (Table 1). Similar to growth factors, YARS, WARS, and AIMP1 function 
extracellularly and are thought to be secreted. Once outside the cell, receptor interactions 
vary with each ARS and elicit different responses related to inflammation, proliferation, 
migration, and cell-cell contacts. Alternatively, SARS and EPRS regulate angiogenesis 
intracellularly through interactions with DNA and mRNA associated with the 
transcription and translation of VEGF and other angiogenic genes (56,57). While this 
 11 
variety of mechanisms 
complicates our understanding of ARS secondary function, it also opens up opportunities 
for the development of drugs targeting specific aspects of angiogenesis. Therefore, 
further progress in this field would improve our knowledge of mammalian physiology 
and provide new therapeutic targets for vascular-based therapies.  
 
Table 1. Angiogenesis-associated activities of aminoacyl-tRNA synthetases 
Aminoacyl-tRNA synthetases (ARSs) are subdivided based on whether they elicit angiogenesis-
based responses outside the cell, inside the cell, or are ARS-associated proteins. Effects on 
angiogenesis are reported as “Pro” for pro-angiogenic responses (i.e., stimulate new blood vessel 
growth), “static” for angiostatic responses (i.e., inhibit new blood vessel growth), and “Anti” for 
anti-angiogenic responses (i.e., reduce current number of vessels). Abbreviations used in 
Table 1: AIMP1 - Aminoacyl-tRNA synthetase interacting multifunctional protein 1; ARS – 
Aminoacyl-tRNA synthetases; EC – Endothelial cell; ELR – Glutamate-leucine-arginine 
sequence motif;  EMAP II – Endothelial monocyte activating polypeptide II; EPRS – 
glutamyl-prolyl-tRNA synthetase; GAIT – Interferon--activated inhibitor of translation; IFN 
– Interferon-; MSC – Multi-synthetase complex; NLS – Nuclear localization signal; SARS – 
Seryl-tRNA synthetase; WARS – Tryptophanyl-tRNA synthetase; WHEP-domain – a unique 
domain named or its association with tryptophanyl-, histidyl-, and glutamyl-prolyl-tRNA 
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1.3 Angiogenic signaling by extra-cellular ARSs 
The process of angiogenesis requires the collaborative effort of numerous cells and 
cell-types. Coordination of their activities relies heavily on the secretion of various 
chemokines and growth factors to disseminate information throughout the local 
microenvironment. The balance of these factors determines the overall stimulatory or 
inhibitory nature of the signals (53). Two of the angiogenesis-associated ARSs, YARS 
and WARS, utilize a similar mechanism in which the enzymes are secreted from the cell 
in response to certain stimuli to engage in autocrine and paracrine type signaling (Figure 
1).  
 
1.3.1 Tyrosyl-tRNA Synthetase 
The angiogenic properties of YARS are mediated by pro-inflammatory features 
that were incorporated into the protein during the evolution of higher eukaryotes. Early 
sequencing of YARS revealed an appended C- terminal domain in eukaryotes that shares 
40% homology with endothelial monocyte activating polypeptide II (EMAP II), a pro-
cytokine that is released from cells in response to apoptotic signals (58). Under similar 
conditions, YARS is secreted into the extracellular space. While no signaling activity is 
observed for the full length protein, cleavage by extracellular polymorphonuclear 
leukocyte (PMN) elastase generates two separate fragments: an N-terminal catalytic 
domain fragment, termed “mini-YARS”, and a C-terminal EMAP II-like domain. Similar 
to EMAP II, the C-terminal domain promotes chemotaxis in immune cells and stimulates 
the release of tumor necrosis factor-α (TNFα) and tissue factor cytokines. While no direct 
connection between angiogenesis and the YARS C-terminal domain has been reported, 
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EMAP II itself originates from an ARS associated protein with ties to angiogenesis and 
will be discussed in greater detail below. Interestingly, exposure to the mini-YARS 
fragment also elicits chemotactic responses in leukocytes similar to α-chemokines (Cys-
X-Cys (CXC)-chemokines), suggesting that it possesses cytokine activity as well (59). 
Therefore, the rest of this section will focus on the mini-YARS fragment. 
Like other members of the CXC-chemokine family, mini-YARS possesses a 
highly conserved Glu-Leu-Arg (ELR) motif essential for receptor interactions. Scatchard 
analysis of 125I-labeled mini-YARS binding to PMNs revealed saturable binding, 
indicative of a specific receptor. This interaction is not observed in mutants with a Glu-
Leu-Gln (ELQ) sequence suggesting that the association is dependent on an intact ELR 
motif. Furthermore, this binding is susceptible to competition by increasing amounts of 
the CXC-chemokine interleukin-8 (IL-8), suggesting that the IL-8 receptor type A 
(CXCR1) is the likely mini-YARS receptor. These results are supported by the 
observation that mini-YARS bound to cells transfected with the gene for CXCR1 but not 
those with the CXCR2 gene (59). Although these studies focused on YARS signaling in 
immune cells, the ELR-motif bearing CXC chemokines also exhibit pro-angiogenic 
activities (60).  
The angiogenic potential of mini-YARS has been investigated through a battery 
of in vitro and in vivo studies. Similar to other CXC-chemokines, mini-YARS induces 
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pro-
angiogenic responses related to endothelial cell migration and proliferation. Transwell 
migration assays indicate a significant increase in the migration of endothelial cells when 
mini-YARS is present in the lower chamber (60,61). Similarly, endothelial cell cultures 
treated with mini-YARS show increased migration of cells to scratch sites in wound 
migration assays. Together, these studies suggest that YARS invokes chemotactic 
responses in endothelial cells similar to those observed with immune cells. Additionally, 
 
Figure 1. Mechanisms of angiogenesis by extracellularly acting ARS. 
Left-Full-length tyrosyl-tRNA synthetase (YARS) is secreted from the cell by an unknown 
mechanism. Outside the cell it is cleaved by polymorphonuclear leukocyte (PMN)-elastase 
or other protease molecules into N- and C-terminal fragments which stimulate angiogenesis 
or immune responses respectively. Right-Full-length tryptophanyl-tRNA synthetase 
(WARS) or mini-WARS are generated from alternative splicing of WARS mRNA and are 
subsequently secreted into the extracellular space by unknown mechanisms. Full-length 
WARS is further processed by PMN-elastase or other proteases to form fragments like mini-
WARS. The WARS fragments disrupt endothelial cell–cell contacts and angiogenic 
signali g molecules, eliciting an a gi static effect. 
 15 
treatment of endothelial cells with mini-YARS stimulates proliferation and organization 
of vessel networks according to commercial dye and tube formation assays respectively. 
Interestingly, the extent of these angiogenic effects by mini-YARS is comparable to that 
demonstrated by VEGF, indicating a potent response (61). These observations are 
supported by several in vivo models as well. Exposure to mini-YARS increases basal 
vessel formation in chorioallantoic membrane (CAM) and mouse matrigel models of 
angiogenesis (60).  
The pro-angiogenic responses observed for the migration, tube-formation, and 
CAM assays are dependent on an intact ELR motif as mutation of any of these residues in 
mini-YARS appears to inhibit these processes. Given the importance of the ELR for the 
binding of mini-YARS to CXCR1, these results implicate this receptor as the mediator of 
angiogenesis. While there was originally some doubt of this due to the lack of a murine 
CXCR1 homolog, subsequent studies have since identified a potential rodent CXCR1 
candidate (62), suggesting that this receptor pathway may still be viable in mouse 
models. In addition, the similar angiogenic effects demonstrated by mini-YARS and 
VEGF led investigators to examine the involvement of another receptor, VEGFR2. 
Treatment with mini-YARS stimulates phosphorylation of Y1054, activating the 
receptor. Because VEGF expression is not stimulated by exposure to mini-YARS, the 
authors believe that signaling by the ARS activates VEGFR2 through a trans-activation 
mechanism (61). 
Investigation of down-stream mini-YARS signaling cascades revealed 
phosphorylation of ERK, Src, and AKT which have been previously demonstrated to 
initiate pro-angiogenic responses including endothelial cell migration, proliferation, and 
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survival (reviewed in (63)). To further investigate the importance of ERK signaling, the 
downstream kinase MEK was inhibited using the compound U0126. Interestingly, this 
treatment blocks mini-YARS induced migration, suggesting that the ERK signaling 
cascade is important for mini-YARS mediated angiogenesis. In addition to kinases, mini-
YARS activates endothelial nitric oxide synthase (eNOS) through phosphorylation of 
Ser-1179, leading to increased nitric oxide (NO) production (61). Previous studies have 
demonstrated significant effects by NO on vascular permeability and other angiogenic 
responses, suggesting that it could be another contributing factor to YARS’s pro-
angiogenic activity (64). Overall, the combination of these various signaling cascades 
establishes a clear angiogenic mechanism for extra-cellular YARS that is characteristic of 
its similarities to the CXC-chemokine family. 
 
1.3.2 Tryptophanyl-tRNA Synthetase 
Aspects of WARS secondary functions were observed as early as 1969 with the 
appearance of alternatively spliced fragments in preparations from bovine pancreas 
extracts (65). Later, the presence of WARS within exocrine cells provided evidence of 
secretion (66). Subsequently, a truncated, alternative splice-form of WARS, termed mini-
WARS, was discovered. Interestingly, the structure of the WARS catalytic core closely 
resembles that of YARS and the discovery of pro-angiogenic functions by fragments of 
YARS indicates that WARS fragments may also possess possible biological functions 
separate from aminoacylation (67). Some of the general mechanisms governing WARS’s 
secondary functions appear similar to YARS; however, the two proteins elicit opposing 
responses on angiogenesis. Expression of both mini-WARS and the full-length protein is 
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regulated by interferon-γ (IFNγ), a cytokine that stimulates the expression of angiostatic 
chemokines and suppresses the expression of the pro-angiogenic cytokine IL-8. This 
correlation between the structures of WARS and YARS coupled with the biological 
connection with IFNγ led to investigations of potential angiogenic effects of WARS.  
Like YARS, full-length WARS has no influence on endothelial cell migration and 
proliferation assays prior to the cleavage of the appended WHEP domain. This can be 
accomplished through alternative splicing, as in mini-WARS, or through limited 
proteolysis, such as by PMN elastase, which generates T1 and T2 WARS fragments.  
However, whereas the active YARS fragments are pro-angiogenic, WARS fragments 
inhibit both VEGF- and YARS-induced migration and proliferation in endothelial cells, 
suggesting an angiostatic function (60,67). Similar attenuation of angiogenic responses 
are observed in the CAM, mouse matrigel plug, and mouse retinal models indicating that 
these effects can be recapitulated under in vivo conditions.  
To better understand the inhibitory effects of WARS, the effect of the T2-WARS 
fragment on downstream, angiogenic kinase cascades was investigated. The presence of 
extracellular, T2-WARS inhibits the VEGF- and shear stress-mediated phosphorylation 
of ERK, AKT, and eNOS (68,69). The localization of T2-WARS to the cell periphery 
(68) coupled with the susceptibility of treated endothelial cells to shear induced 
detachment (69) led to the hypothesis that WARS fragments interacted with cell-cell 
contacts. Subsequently it was determined that knockdown of vascular endothelial 
cadherin (VE-cadherin) disrupts the interaction between WARS and endothelial cells, 
implicating it as the putative extracellular mediator of WARS’s non-canonical activities 
(68). Molecular modeling studies suggest that the basis of this interaction was the 
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insertion of Trp2 and Trp4 from the N-terminal EC1 domain of VE-cadherin into the 
active site of the WARS core. This is supported by mutational analyses in which 
substitution of Trp2 and Trp4 on EC1 or essential binding residues in WARS abolish the 
interaction between the proteins. Interestingly, the binding of VE-cadherin to full-length 
WARS is occluded by the presence of the N-terminally appended WHEP domain in full-
length WARS. The loss of this domain in WARS fragments allows VE-cadherin to access 
the WARS active site, providing a mechanism for the cleavage-dependence of WARS’s 
angiostatic activity (70).  
As with both YARS and TARS (see below), the mechanism of WARS exocytosis 
remains unknown. The fact that WARS-secretion is not affected by brefeldin A or 
A23187 indicates that it is not dependent on Golgi- or calcium-dependent transport 
respectively (71). The lack of a canonical export sequence led to the hypothesis that 
secretion may be dependent on protein-protein interactions. Yeast two-hybrid and co-
immunoprecipitation experiments revealed an interaction between WARS and p11 (also 
referred to as S100A10), a protein member of the annexin II complex (71). Previously 
p11 had been found to be important for the cellular retention of the TASK-1 transcription 
factor (72).  Similarly, the connection of this complex to WARS’s retention was 
confirmed by demonstrating that knockdown of either p11 or annexin II increases the 
secretion of WARS (71). Taken together, these data suggest a model in which angiostatic 
signals stimulate the release of WARS from p11 allowing for its subsequent secretion 
from the cell through unknown mechanisms. Once in the extra-cellular milieu WARS can 
then be processed into active fragments that inhibit angiogenesis by disrupting 
endothelial cell-cell contacts.  
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1.4 Transcriptional and translational regulation of angiogenesis by ARSs 
As part of their role in aminoacylation, ARSs possess features necessary for 
interactions with nucleic acids. Although normally limited to tRNA, adaptations of this 
feature can allow for interactions with other molecules bearing the necessary recognition 
motifs. In particular, seryl-tRNA synthetase is able to bind to the vegfaa gene promoter 
and reduce its transcription while glutamyl-prolyl-tRNA synthetase is able to bind to the 
3’ UTR of VEGFA mRNA and inhibit its translation (73,74). In contrast to the inter-
cellular communication propogated by the secreted ARSs, SARS and EPRS mediate 
intracellular responses to angiogenesis through regulation of canonical angiogenic factors 
at the transcriptional and translational level (Figure 2). 
 
1.4.1 Seryl-tRNA Synthetase 
The connection between SARS and angiogenesis was first noticed based on two 
independent investigations of vascular deficient zebrafish mutants related to the adrasteia 
(adr) gene (75) and ko095 locus (56). These mutations were associated with the dilation 
of aortic arch vessels (AAV) and the presence of ectopic branching in the cranial and 
intersegmental vessels (ISV). These effects appeared after 60 and 72 hours post 
fertilization (hpf) for the ko095 and adr mutants respectively. Genetic mapping using 
select SSLP markers subsequently identified two of the adr (76) and one of the ko095 
(56) mutations within the sars gene. All three mutations correspond to single nucleotide 
changes with the ko095 (56) and one of the adr mutants resulting in a premature stop 
codon and the second adr mutant converting a conserved phenylalanine (Phe383) to a 
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valine (76). In further corroboration of the importance of SARS in vascular development, 
a third study reported circulation restriction in zebrafish containing sars retroviral 
insertional mutants (77). The fact that these separately reported mutations in sars present 
with similar deficiencies in vascular development supports the hypothesis that sars is the 
likely source of this phenotype. 
Although the above mutations fall within the catalytic core of the enzyme, the 
effects on the vasculature appear to be unrelated to the canonical aminoacylation 
function. Knockdown of SARS in endothelial cells using siRNA results in concentration-
dependent cell death after 48 hours. This effect is attributed to loss of SARS 
aminoacylation activity and, thus, is non-specific towards cell type. In contrast, SARS 
knockdown in tube-formation experiments at earlier time points results in increased, 
albeit disorganized, branching of the tube networks, indicating a endothelial cell-specific 
function (56). These results are supported by investigations using the catalytically 
inactive T429A SARS mutant. Despite its deficiency in aminoacylation injections of 
T429A SARS mRNA into ko095 mutant fish completely rescues the aberrant vessel 
phenotype, thereby separating the two functions (56).  
To date, the mechanism through which SARS elicits angiogenesis remains to be 
elucidated; however, it appears to be dependent on signaling by the VEGFA-VEGFR2 
and VEGFC-VEGFR3 pathways. Inhibition of VEGFR2 and 3 with the inhibitors 
SU5416 or MAZ51 respectively blocks the dilation of AAVs and ISV ectopic branches. 
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Similar 
effects are not observed with the EGFR-specific inhibitor AF1478, indicating a VEGF-
mediated response (76). Likewise, knockdown of VEGFA and VEGFC or their 
respective receptors, VEGFR2 and VEGFR3, in zebrafish by morpholino injection 
prevents the development of ectopic branches as well (56).  
 
Figure 2. Mechanisms of angiogenesis by intracellularly acting ARS. 
(1) seryl-tRNA synthetase (SARS) is transported into the nucleus via a canonical nuclear 
localization sequence (NLS) sequence and binds to the vascular endothelial growth factor A 
gene (vegfaa) promoter. The binding of SARS inhibits c-Myc-mediated expression of vascular 
endothelial growth factor A (VEGFA) through modification of vegfaa epigenetics. This effect 
is angiostatic; (2) glutamyl-prolyl-tRNA synthetase (EPRS) is phosphorylated upon treatment 
of the cell with IFNγ, releasing it from the multisynthetase complex (MSC). Phospho-EPRS 
binds with L13a, GAPDH, and NSAP1 to form the interferon-γ-activated inhibitor of 
translation (GAIT) complex. This complex then binds to mRNA containing stem-loop, 3' UTR 
GAIT elements via EPRS WHEP domains, thereby blocking their translation. As VEGFA 
contains a GAIT element, this effect is angiostatic. 
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Despite this link to the VEGF receptor family, the necessity of the VEGF ligands 
for SARS-mediated angiogenesis indicates that the ARS is unlikely to be a direct 
activator of VEGFR2 or 3. Investigation of mRNA expression changes in vascular-
related genes as a result of the ko095 mutation provides some clarification. Similar to 
TARS, the ko095 SARS mutant induces no changes in Notch gene expression while 
vegfaa shows significant increases. Interestingly, the augmented vegfaa expression is 
attenuated by the injection of the aminoacylation-deficient T429A SARS mRNA, 
suggesting that this effect is due to SARS’s non-canonical function. These findings led to 
the conclusion that SARS mediates angiogenesis by suppressing VEGFA expression with 
the dependence on the VEGFC-VEGFR3 pathway explained simply due to the fact that it 
is essential for angiogenesis in general (56).  
Similar to what was observed for YARS, SARSs secondary activity is found to 
depend on a C-terminal, appended domain that arose during vertebrate evolution. This 
domain, termed UNE-S, encompasses residues 470 to 514 and contains a functional 
nuclear localization signal (NLS) (78). Interestingly, both the ko095 and adr non-sense 
mutations completely abolish the presence of this domain. Similarly, while not located in 
UNE-S, the vascular-deficient F383V SARS mutant does not localize to the nucleus 
while the catalytically inactive, but vascular-functional, T429A SARS mutant possesses a 
clear nuclear distribution. The importance of SARS localization on VEGFA mRNA 
expression in zebrafish was investigated by knocking down endogenous zebrafish SARS 
with anti-SARS morpholinos and complementing with mRNA for various SARS 
constructs. Interestingly, F383V and Δ482-514 SARS (SARS lacking UNE-S domain) 
exhibit threefold increased expression of vegfaa compared to wildtype human SARS and 
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all other constructs with a functional NLS (78). These results were later recapitulated in 
both endothelial cells and human embryonic kidney (HEK293) cells in which 
endogenous SARS was knocked down with shRNA and replaced by WT SARS or SARS 
lacking the NLS sequence (ΔNLS-SARS) (74). Similar to zebrafish studies, vegfaa 
expression is increased two-fold in cells treated with SARS shRNA relative to cells 
treated with control shRNA. Furthermore, SARS knockdown cells complemented with 
expression of ΔNLS-SARS exhibit a four-fold increase in VEGFA mRNA levels when 
compared to those complemented with wildtype SARS. As a functional consequence of 
the increased VEGFA expression, complementation of sh-SARS-treated endothelial cells 
with ΔNLS-SARS promotes angiogenesis in an endothelial tube-formation assay in 
contrast to complementation with wildtype SARS.  Together, these data suggest a model 
in which nuclear SARS suppresses expression of vegfaa and downstream angiogenesis 
through a system that is conserved from zebrafish to humans.  
Recent investigations have presented a new mechanism for SARS-mediated 
regulation of vegfaa expression (74). Affinity precipitation of purified SARS with calf-
thymus DNA demonstrates that the synthetase is capable of direct interactions with DNA. 
Chromatin immunoprecipitation (ChIP) and DNA foot-printing analyses narrows this 
interaction to the vegfaa promoter region within -62 to -38 bp from the start site. Of note, 
this site overlaps with the c-Myc binding site in the vegfaa promoter, suggesting that 
SARS may inhibit the pro-angiogenic activities of c-Myc. Specifically, c-Myc recruits 
histone acetyltransferase (HAT) proteins to acetylate histones in the vegfaa locus, 
generating transcriptionally active euchromatin  (79).  Direct competition between SARS 
and c-Myc for binding to the vegfaa promoter was subsequently demonstrated using an 
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electrophoretic mobility shift assay (74). Once bound to the DNA, SARS facilitates the 
formation of heterochromatin through the recruitment of the histone deacetylase SIRT2, 
thereby counteracting c-Myc-mediated acetylation and inhibiting vegfaa transcription.  
 
1.4.2 Glutamyl-Prolyl-tRNA Synthetase 
Glutamyl-prolyl-tRNA synthetase (EPRS) is unique among the ARSs due to its 
bifunctional nature, a characteristic that first originated in higher eukaryotes. The enzyme 
possesses a modular structure consisting of an N-terminal elongation factor 1β-like 
domain, a glutamyl-tRNA synthetase catalytic domain (EARS), a linker region composed 
of three tandem WHEP domains, and a C-terminal prolyl-tRNA synthetase catalytic 
domain (PARS) (73). Additionally, EPRS is associated with the aminoacyl 
multisynthetase complex (MSC), a heterocomplex composed of nine ARSs (D, EP, I, K, 
L, M, Q, and R) and three non-catalytic scaffolding proteins (AIMP1-3). Both the 
WHEP-linker region and association with the MSC contribute to EPRS’s non-canonical 
functions. 
The connection between EPRS and angiogenesis arose from investigations of a 
phenomenon in which prolonged exposure of cells to IFNγ induces a marked reduction of 
translation in specific genes. Termed the interferon-gamma-activated inhibitor of 
translation (GAIT), its mechanism involves the binding of a proteinaceous complex 
(termed GAIT complex) to stem-loop structures, or GAIT-elements, in the 3’-
untranslated region (UTR) of a specific mRNA, thereby preventing its translation (80,81). 
Yeast three-hybrid and RNA-affinity purification experiments using GAIT element 
sequences as bait identified the four comprising members of the GAIT complex: 
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ribosomal protein L13a (L13a), EPRS, NS1-associated protein-1 (NSAP1), and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (82,83). Stimulation of cells by 
IFNγ results in the phosphorylation and release of EPRS and L13a from the MSC and 
large ribosomal subunit, respectively, and initiates the formation of the active GAIT 
complex (83). Binding of the complex to mRNA GAIT elements is primarily mediated by 
the three tandem WHEP domains in EPRS, emphasizing the ARS as a critical component 
of the GAIT system (73). 
The mechanism used by the GAIT complex to inhibit translation was initially 
determined in studies of the ceruloplasmin (Cp) protein expression and then expanded to 
transcripts associated with other proteins, including VEGF. In Cp, treatment of 
monocytic cells with INFγ for more than 24 hours results in the attenuation of Cp 
translation. Since the reduction of protein levels are not associated with a concurrent drop 
in mRNA expression, regulation must occur at the translational level (80). Binding of the 
GAIT complex to GAIT element in mRNA 3’ UTR inhibits the assembly of the 43S 
ribosome, preventing the translation process (81,82,84). Using the pattern analysis 
algorithm software PatSearch several other genes have since been identified with similar 
predicted 3’ UTR GAIT elements, including death associated protein kinase (DAPK), 
zipper-interacting protein kinase (ZIPK), C-C motif ligand factor-A (CCL22), and 
VEGFA (57). In particular, the presence of GAIT elements in VEGFA mRNA suggested 
the possibility that the GAIT complex could be important for the regulation of angiogenic 
processes. 
To better understand the possible role of the GAIT complex in angiogenesis, the 
effects of IFNγ-treatment on VEGFA expression and downstream angiogenic activities 
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were investigated with respect to the putative VEGF mRNA GAIT element.  The 
interaction between the GAIT complex and VEGFA mRNA was confirmed using 
electrophoretic mobility shift assays of 32P labeled VEGF riboprobes containing the 
VEGFA GAIT element. U937 monocyte lysates treated with IFNγ for 16 or 24 hours 
exhibit interactions with all four components of the GAIT complex. Furthermore, the 
effect of this interaction on VEGF translation was investigated using a luciferase reporter 
assay. Incubation of luciferase mRNA containing the VEGFA 3’UTR GAIT element with 
U937 lysate treated with IFNγ for 24 hours show a significant reduction in luciferase 
activity relative to untreated lysate or mRNA lacking the GAIT element. However, 
translation can be rescued regardless of IFNγ-treatment through the immunodepletion of 
EPRS, confirming that the suppression was mediated by the GAIT complex. The effect of 
reduced VEGF levels on angiogenesis was subsequently investigated using endothelial 
cell proliferation and tube formation assays (85). Exposure of endothelial cells to 
conditioned media from U937 monocytes treated with IFNγ for 8 or 12 hours exhibits a 
marked increase in proliferation whereas only basal tube formation is observed with 
treatments of 16 or 24 hours. Similarly, tube formation of endothelial cells cultured on 
matrigel is enhanced 2.5 fold relative to basal levels in U937 conditioned media treated 
for 8 hours with IFNγ while no change is observed in media treated for 16 or 24 hours. 
These changes in angiogenic activities are consistent with the kinetics for GAIT complex 
activation and support a role for the complex in the time-dependent attenuation of VEGF-
signaling by IFNγ following the initial induction period.  
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1.5 Regulation of angiogenesis by ARS-associated proteins. 
1.5.1 Aminoacyl-tRNA synthetase interacting multifunctional protein 1 
The aminoacyl-tRNA synthetase interacting multifunctional protein 1 (AIMP1; also 
known as p43) is one of three auxiliary proteins that combines with nine ARSs to make 
up the MSC heterocomplex. Isolation of the AIMP1 gene from Chinese hamster ovary 
(CHO) cDNA led to the discovery that the exact sequence for EMAP II, a pro-
inflammatory cytokine released from apoptotic cells, is contained within the C-terminal 
region, suggesting that it may serve as the EMAP II precursor molecule and possess 
potent signaling activity (86). As indicated above, an EMAP II-like domain is found in a 
C-terminal fragment of YARS and may possess similar signaling functions. During 
apoptosis, activated caspase 7 catalyzes the cleavage of the C-terminal EMAP II domain 
of AIMP1 and subsequently releases it from the MSC complex (Figure 3) (87). Once 
freed, EMAP II is secreted from the cell and stimulates the recruitment of macrophages 
and initiates other signaling cascades associated with the regulation of inflammation and, 
of particular interest, angiogenesis.  
Both EMAP II and full-length AIMP1 have been observed to regulate angiogenesis 
in a variety of assays. However, the nature of this regulation is not straightforward as 
they exhibit both dose-dependent and biphasic characteristics (88). Low concentrations 
(0.25 to 1 nM) of either EMAP II or AIMP1 induce endothelial cell migration in 
transwell migration assays and AIMP1 stimulates angiogenesis in the CAM assay (the 
effects of EMAP II in CAM assays remain to be investigated). Conversely, 
concentrations of 10 nM and above exhibit dose-dependent inhibition in the same assay 
and appear to be related to the induction of endothelial cell specific apoptosis (88). 
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Additional studies with EMAP II revealed similar anti-angiogenic responses in both tube 
formation and rat aortic ring assays at concentrations of 20 µg/ml (0.6 µM) and greater 
(89). The cause of this biphasic signaling may be linked to the varying sensitivities of 
specific kinase cascades (88,90). Interestingly, full-length AIMP1 appears to be a more 
 
Figure 3. The biphasic responses of aminoacyl-tRNA synthetase interacting 
multifunctional protein 1 (AIMP1) and endothelial monocyte activating polypeptide 
II (EMAP II) on angiogenesis. 
(1) Caspase 7 cleaves the C-terminal EMAP II peptide from AIMP1, releasing EMAP II 
from the multi-synthetase complex; (2) Alternatively, AIMP1 is released by unknown 
processes; (3) Both EMAP II and AIMP1 are secreted from the cell by mechanisms that 
remain to be determined; (4) At low concentrations (perhaps corresponding to early 
portions of the AIMP1/EMAP II signaling responses in vivo) EMAPII and AIMP1 bind 
to surface receptors, activating various kinase cascades; (5) These kinase cascades induce 
the expression of tumor necrosis factor α (TNFα); (6) TNFα is secreted from the cell and 
mediates angiogenesis through canonical TNFα pathways; (7) At high concentrations 
(perhaps corresponding to prolonged exposure in vivo), AIMP1 and EMAP II induce the 
expression of the TNFα-receptor (TNFR); and (8) Over-stimulation of TNFR by TNFα 
induces apoptosis through signaling by the TNFR death-domain, resulting in an anti-
angiogenic response. 
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potent inducer of migration and apoptosis than the processed EMAP II peptide (88) 
suggesting a role for the whole protein in signaling events.  
Several lines of evidence implicate TNFα in the AIMP1 angiogenic signaling 
pathway. AIMP1 elicits a striking increase in the expression of TNFα, a potent regulator 
of both pro- and anti-angiogenic activities (91). In terms of pro-angiogenic activities, 
TNFα increases expression of VEGF via NF-κB activation (92). Conversely, TNFα can 
also induce apoptosis in endothelial cells, lending itself to an anti-angiogenic role (93). 
AIMP1-stimulated secretion of TNFα initiates the downstream phosphorylation and 
activation of ERK1/2, a well-known angiogenic signal. The necessity of ERK1/2 
activation for AIMP1 regulation of TNFα was subsequently confirmed using the MEK 
inhibitor U0126, which was shown to attenuate the induction of TNFα (91). As such, the 
TNFα activation of ERK1/2 likely contributes to the initial, pro-angiogenic phase of 
AIMP1 and EMAP II signaling. However, higher concentrations or sustained secretion of 
AIMP1 or EMAPII enhances the surface representation of TNF receptor 1 (TNFR1) on 
endothelial cells, thereby facilitating TNFα-induced apoptosis through the TNFR1 death 
domain (94). Therefore, TNFα-signaling may contribute to the second, anti-angiogenic 
portion of AIMP1 and EMAPII’s biphasic response.   
In addition to its role in inflammatory signaling, several different studies have 
revealed that EMAP II is capable of effecting canonical angiogenic pathways. Treatment 
with EMAP II inhibits endothelial cell migration by disrupting interactions between 
fibronectin and alpha5 beta1 integrins (95). ELISA-based assays also determined that 
EMAP II directly interacts with VEGFR1 and 2 and inhibits the binding of VEGF. 
Functionally, EMAP II inhibition of VEGFRs prevents the phosphorylation of 
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downstream signal mediators, including AKT, ERK1/2, p38MAPK, and Raf as well as 
VEGF-dependent endothelial cell migration (96). Furthermore, over expression of EMAP 
II in cells increases the proteasome subunit alpha type-7 (PSMA7)-dependent 
proteasomal breakdown of HIF1α even under hypoxic conditions and, consequently, 
reduces hypoxia-induced tube formation in endothelial cells at concentrations of 20 µM 
(97). It should be noted, however, that most of the above functions were investigated at 
EMAP II concentrations that would induce the inhibitory portion of EMAP II’s biphasic 
response. Therefore, under normal conditions, it is possible that these inhibitory effects 
would be delayed relative to the initial induction of angiogenesis associated with VEGF- 
and hypoxia-based signaling. 
 
1.6 General characteristics of angiogenesis-associated aminoacyl-tRNA 
synthetases 
1.6.1 Aminoacyl-tRNA synthetases may connect angiogenesis to nutrient sensing. 
As indicated in section 1.2.1 above, the dependence of the aminoacylation 
reaction on ATP and amino acid concentrations opens opportunities for ARSs to function 
as nutrient sensors within the cell. Perhaps the best example of this was demonstrated in 
recent studies of leucyl-tRNA synthetase (LARS) in which LARS was found to regulate 
mTOR-mediated autophagy in a leucine-dependent manner (37,38). Alternatively, the 
accumulation of uncharged-tRNA due to amino acid depletion or inhibition of any ARS 
can activate the GCN2-mediated amino acid starvation response, leading to translational 
arrest and apoptosis (48). Since nutritionally starved cells would benefit from the 
increased vasculature, the acquisition of angiogenesis-related functions by these enzymes 
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would complement their roles as intracellular sensory mechanisms. While no direct 
nutrient sensing has been observed in angiogenesis-related ARSs, substrate-induced 
conformational changes are well documented among ARSs in general (98,99). These 
changes may regulate important interactions responsible for the transport of the ARSs 
and down-stream signaling events essential for their non-canonical activities and would 
warrant further study.  
 
1.6.2 Mechanistic separation of angiogenesis-associated ARSs. 
Relevant ARSs use a wide variety of mechanisms in their regulation of 
angiogenesis. However, these enzymes can be subdivided into two broad categories 
based on the location of their actions. The first, consisting of YARS, WARS, and 
AIMP1, function extracellularly and must be secreted from the cell. While little is known 
of the secretion mechanisms these events are able to accommodate full-length proteins. 
Since the canonical function of ARSs in translation is catalyzed in the cytoplasm, the 
export of these proteins likely serves as an important regulatory step in their non-
canonical functions. The identification of this system is critical to understanding these 
secondary functions and their regulatory process.    
Conversely, SARS and EPRS regulate angiogenesis intracellularly through 
interactions with DNA or mRNA (73,74). Unlike their secreted counterparts, the 
regulation methods of the intracellular-acting ARSs are better understood. EPRS interacts 
with mRNA in the cytoplasm and does not require a transport mechanism. Instead, 
phosphorylation initiates its dissociation from the MSC, thereby acting as a switch 
between the primary and secondary functions. SARS, on the other hand, interacts with 
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nuclear DNA and must undergo nuclear transport. While the processes regulating this 
event are not completely known, a nuclear localization signal has been identified within 
the C-terminal domain of SARS that is essential for its regulation of VEGFA 
transcription. Taken together, these findings would suggest that all of the angiogenic 
ARSs appear to separate their canonical and non-canonical functions by sequestration. 
Therefore, undesired angiogenic activity can be limited by regulating the translocation of 
the ARSs from the cytoplasm or their dissociation from a protein complex. 
 
1.6.3 Associations of angiogenesis-related ARSs to inflammation 
Except for SARS, all angiogenesis-associated ARSs possess some connection to 
inflammation. Both YARS and AIMP1 are associated with the pro-inflammatory EMAP 
II or ELR domains which activate receptors from the CXC-receptor (CXCR) family. 
These receptors mediate chemokine signaling pathways important for the coordinated 
regulation of inflammatory and angiogenic responses during wound healing (reviewed in 
(100)). Consistent with other ELR containing chemokines, mini-YARS stimulates pro-
angiogenic signaling through interactions with CXCR1 expressed by endothelial cells. 
Interestingly, while all other known ELR chemokines also stimulate CXCR2, knockdown 
of the receptor has no effect on angiogenesis by mini-YARS, suggesting that mini-YARS 
may be specific to CXCR1 or possesses yet unknown activities associated with CXCR2. 
Similarly, EMAPII, as suspected for other ELR-lacking chemokines, regulates 
angiogenesis through CXCR3. Knockdown of CXCR3 inhibits EMAP II-mediated 
migration by endothelial cells, a response that would be anticipated for an angiogenic 
molecule.  However, these results appear atypical since CXCR3 is primarily a mediator 
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of angiostasis. Given EMAP II’s biphasic response, it is may be possible that EMAP II’s 
angiogenic and angiostatic activities are both mediated through CXCR3 but are 
differentially regulated. Additionally, the EMAP II precursor, AIMP1, regulates 
production of TNFα and its receptor, TNFR, through interations with CD23. Connections 
of TNFα to angiogenesis and inflammation are well established in the literature (101). Of 
particular interest, TNFα exhibits a dose-response effect, stimulating angiogenesis at 
lower concentrations and inhibiting it at higher (102), consistent with the biphasic 
response observed for EMAP II. Given the sequence homology between EMAP II, 
similar connections to TNFα may exist with the C-terminal domain of YARS and may 
play an important role in YARS-mediated angiogenesis. 
The non-canonical functions of WARS and EPRS appear to be regulated by 
signals from inflammatory factors rather than initiating them like YARS and AIMP1. 
Treatment of cells with IFNγ stimulates the secretion of WARS and releases EPRS from 
the MSC, initiating translational control by the GAIT complex. In contrast to other 
inflammatory signals, like TNFα, IFNγ is anti-angiogenic, consistent with its association 
with WARS and EPRS signaling. Overall, the connection to inflammation underlies a 
complex association of ARSs with responses to cellular stress separate from their better 
known, house-keeping roles in translation.   
 
1.6.4 The role of appended domains in ARS-mediated angiogenesis.  
The angiogenesis regulatory mechanisms exhibited by the ARSs described above 
are often dependent on appended domains or sequences not found in the prokaryotic 
enzymes (reviewed in (103)). These features include EMAP II-domains in YARS and 
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AIMP1, an ELR motif in YARS, WHEP domains in WARS and EPRS, and an NLS in 
SARS. The WHEP domain is exclusive to the ARS family of enzymes and is associated 
with RNA interactions. The RNA binding affinity of the WHEP domain increases with 
the number of tandem repeats and is essential for the non-canonical functions associated 
with EPRS (104). Conversely, the single WHEP domain of WARS does not have a 
known RNA-binding function but instead regulates angiogenesis by blocking access of 
N-terminal E-cadherin to the WARS active site. Interestingly, the ELR and EMAP II 
domains appear to have arisen in insects, whose blood diffuses throughout the body 
cavity instead of within defined vessels (105). Likewise, WHEP domains have been 
observed in organisms as early as choanoflagellates, the closest unicellular ancestor to 
animals (106). Therefore, it is likely that these domains developed for a separate purpose 
and expanded to include angiogenesis following the development of a complex vascular 
system. 
 
1.6.5 ARSs as targets for anti-angiogenic therapy.  
Given the importance of angiogenesis in the growth and metastatic progression of 
several solid tumors, many of the most prominent angiogenic factors, such as VEGF, 
have been investigated as potential targets for anti-metastatic therapies. Unfortunately, 
the benefits of these approaches are often temporary owing to adaptive responses by the 
target tissue (107). Therefore, better understanding of ARS angiogenic activities may 
allow for the development of new small molecule inhibitors for use in combinatorial 
cancer therapies.  
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Several natural and synthetic ARS inhibitors have been reported that exhibit anti-
microbial or immunosuppressant activity by inhibiting canonical functions of aminoacyl-
tRNA synthetases (108-111). More relevant to anti-cancer treatments, disruption of an 
interaction between lysyl-tRNA synthetase (KARS) and the laminin receptor by a small 
molecule inhibitor was found to inhibit the metastatic progression of a mouse breast 
cancer model (112). Considering that chemical intervention of KARS non-canonical 
functions influenced cancer progression it would not be surprising if similar results could 
be obtained through the manipulation of other angiogenesis-associated ARSs. Therefore, 
these efforts can be enhanced through the better understanding of regulation and 
mechanistic processes.  
 
1.6.6 Concluding remarks for aminoacyl-tRNA synthetase functions in angiogenesis 
The above observations provide clear evidence for a role of ARSs in 
angiogenesis. Their very different mechanisms suggest that these functions developed 
separately for each enzyme over the course of evolution. This is not completely 
surprising as ARSs are among the most ancient and essential enzymes to come into 
existence and have had a long evolutionary window to acquire secondary functions. 
Furthermore, their connection to the nutritional and translational status of the cell makes 
them prime candidates for the development of homeostatic functions, like angiogenesis, 
that are essential for the survival of complex, multicellular organisms.  Nonetheless, 
many features of the molecular mechanisms associated with ARS-mediated angiogenesis 
remain to be determined. With the exception of EPRS, little is known about the 
regulatory signals separating the canonical and non-canonical functions. Notably, the lack 
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of a clear secretory mechanism for the extracellularly active ARSs has confounded 
investigations focused on the initiation of their angiogenesis-associated activities.  
Furthermore, future drug design would benefit from improvements in knowledge of 
downstream signaling pathways and structural studies of ARS-partner interactions. 
Overall, the connection between ARSs and angiogenesis emphasizes the importance of 
their characterization to the field of vascular biology and opens up new and exciting areas 
for future research.  
 
1.7 Threonyl-tRNA Synthetase 
1.7.1 Introduction to threonyl-tRNA synthetase 
 Threonyl-tRNA synthetase (TARS) is an 83 kDa (human, monomer; 76 kDa E. 
coli) class II ARS that catalyzes the attachment of threonine to its corresponding tRNA 
for use in translation. However, like other class II ARSs, the protein is typically found as 
a homodimer (6). The structure of TARS is modular with four core domains that have 
been conserved from prokaryotes to eukaryotes (Figure 4A) (18). The most N-terminal of 
these is the N1-domain (residues 83-144 human, 1-62 E. coli), an ubiquitin-like domain 
of unknown function. This domain is adjacent to the N2 (or editing) domain (residues 
145-303 human, 63-224 E. coli), which functions in the post-transfer editing of tRNAThr 
aminoacylated with the false cognate serine (113). This structure is connected to the 
aminoacylation (or catalytic) domain (residues 319-607 human, 240-528 E. coli) by a 
large linker helix (residues 304-321 human, 225-242 E. coli).  
The aminoacylation domain contains all the conserved structural elements 
characteristic of class II ARSs as well as the three substrate binding sites (5,6). While 
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numerous residues contribute to substrate binding, a Class II conserved arginine, R442 in 
human TARS (R383 in E. coli), is perhaps the most important (Figure 4B). R442 
interacts with both the α-phosphate of ATP and the carboxyl group of threonine and 
stabilizes transition state for the adenylation reaction (114).  Additionally, a Zn2+ is 
coordinated within the active site by two histidines and a cysteine. Crystallographic 
evidence suggests that this ion is important for interacting with the threonine substrate’s 
hydroxyl and removing it results in loss of TARS aminoacylation activity (18). The role 
of the Zn2+ atom in discrimination of amino acids with hydroxyl groups is further 
supported by kinetic evidence of alanyl-tRNA synthetase (AARS) editing, which appears 
to use a Zn2+ atom to preferentially bind serine (21).  The most C-terminal domain is 
referred to as the anti-codon binding domain (residues 614-723 human, 535-642 E. coli), 
which selects and binds anticodons corresponding to the substrate tRNAThr (18). 
Together, the aminoacylation and anticodon binding domains form the dimer interface. In 
addition to these core domains, eukaryotic TARS species possess an unstructured, N-
terminal extension (residues 1-81 in humans). While the length of this region can vary 
greatly between organisms some sequence features, such as a lysine rich region, appear to 
be conserved amongst most species. The function of this region, however, remains 
unknown. 
 
1.7.2 Non-canonical functions of threonyl-tRNA synthetase 
Prior to the work presented herein, the connection between TARS and 
angiogenesis had not been well established. However, evidence of its connection to 
vascular biology was identified concurrently with studies of the TARS-specific inhibitor 
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borrelidin, a naturally occurring polyketide anti-microbial, and anti-fungal compound 
from Streptomyces rochei. Characterizations of borrelidin-resistant bacterial strains and 
Chinese hamster ovary cells with selective amplification of tars genes established TARS 
as the principal target of borrelidin (115,116). Subsequent investigations revealed that 
borrelidin inhibits tube formation of rat aortic ring fragments with an IC50 of 0.4 ng/ml 
(0.8 nM). This value was 15-fold lower than the IC50 for endothelial cell growth 
inhibition (6 ng/ml), suggesting a specific anti-angiogenic activity for the compound 
(117). Subsequent investigations of borrelidin’s effects also demonstrated that treatment 
with the compound reduced the occurrence of lung metastases in B16-BL6 mouse models 
of melanoma at concentrations known to inhibit angiogenesis (118). The fact that no 
alternative targets to TARS can be identified coupled with the threonine-dependent 
nature of some of the anti-angiogenic effects strongly implicates TARS as the mediator 
of these effects.  
In addition to the angiogenesis connections alluded to by borrelidin, TARS is the 
target of the PL-7 autoantibody in the polymyositis and dermatomyositis autoimmune 
disorders (119). In addition to TARS, auto-antibodies have been discovered against five 
other ARSs which lead to similar complications.  Etiological characterizations associated 
these conditions with auto-reactive T-cells in muscle tissue mediated through two major 
inflammatory pathways: NF-κB and TNFα signaling (120). Both of these signaling 
pathways share connections with inflammation and angiogenesis through regulation of 
downstream kinases or hypoxia inducible factor 1α stabilization (121,122). Of note, 
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Figure 4. Basic structural components of TARS. 
(A) The monomeric structure of TARS (PDB: 1QF6) with domains highlighted as follows: 
N1-domain (purple), N2/editing domain (yellow), linker helix (pink), aminoacylation 
domain (cyan), and anticodon-binding domain (blue). (B) Ribbon diagram of the TARS 
active site (PDB:1QF6) with specific features highlighted. AMP, A76 of the tRNAThr, and 
the conserved R442 are shown as stick models; the bound Zn2+ is shown as a grey sphere.  
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muscle biopsies from patients in the early phases of polymyositis and dermatomyositis 
have demonstrated increased expression of VEGF, possibly due to reduction in capillaries 
within the affected tissue (123). In addition, these disorders have been associated with an 
increased risk of several varieties of cancer (124). However, it is currently unclear as to 
whether or not the secretion of TARS in angiogenesis has any connection to these 
diseases or if these autoimmune disorders contribute to neovascularization in 
tumorigenesis. 
The ability of the TARS inhibitor, borrelidin, to disrupt angiogenesis and 
metastasis strongly implicated the compound as a possible cancer therapeutic. 
Additionally, the association of other ARSs with angiogenesis and the lack of any other 
targets for borrelidin suggested that TARS may possess secondary functions in 
aminoacylation. Despite the extensive literature on the topic angiogenesis remains a 
complicated process that is incompletely understood. Further investigation of TARS and 
its inhibitors will help clarify another aspect of angiogenesis and may open up new 
opportunities for pharmacological manipulation of vascular biology. The data presented 
herein provide evidence for a role of extracellular TARS in the stimulation of vessel 
migration and maturation in both in vitro and in vivo systems. Treatment with borrelidin 
or its derivatives are found to inhibit TARS’s angiogenic properties through the induction 
of conformational changes within the enzyme. Contrary to previous reports these effects 
are demonstrated to be separate from the toxicity exhibited by the compounds and 
rectifies incorrect assumptions of inhibitor mechanism. Together these data provide a 
foundation for future investigations TARS’s secondary function in angiogenesis and the 
mechanism of its inhibitor, borrelidin. 
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CHAPTER 2: CHARACTERIZING THE INHIBITION OF HUMAN 
THREONYL-tRNA SYNTHETASE BY BORRELIDIN AND DERIVATIVES 
 
2.1 Introduction 
Borrelidin is a polyketide, macrolide antibiotic that was first discovered in isolates 
from Streptomyces rocheii in 1949 and later identified in other Streptomyces species (1-
3). It was named for its potent anti-microbial effects against the fever-inducing 
spirochetes from the Borrelia genus. However, its functions have expanded greatly since 
it discovery. In addition to Borrelia, borrelidin was found to inhibit pathogenic 
spirochetes of genus Treponema, the malarial parasite Plasmodium falciparum, viral 
replication, and pathogenic fungi (4-7).  These effects have been linked to the molecule’s 
specific inhibition of TARS and, through it, the overall process of translation (8).  
TARS exhibits high sequence conservation between bacteria and eukaryotes. 
Consequently, borrelidin has been demonstrated to inhibit functions in a variety of 
organisms. Studies of borrelidin-resistant E. coli K12 strains and Chinese hamster ovary 
cells reveal modified or increased expression of ThrRS, the only known target of the 
compound (9,10). These observations support an interaction between TARS and 
borrelidin and suggests that this interaction is maintained through bacteria to mammals. 
Similarly, borrelidin-treatment was demonstrated to influence endothelial cell processes 
in both human umbilical vein endothelial cells (HUVECs) and mouse models, indirectly 
insinuating that borrelidin is capable of inhibiting several varieties of mammalian TARS 
(11,12). However, these hypotheses remain circumstantial without support from more 
direct approaches.  
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The interactions between borrelidin and several bacterial ThrRSs were confirmed 
in assays utilizing isolated enzymes from the representative bacterial sources E. coli, S. 
solfataricus, and Halobacterium sp. Calculated values of Ki were obtained for both E. 
coli and S. solfataricus and were found to be nearly identical at 3.7 nM and 4.5 nM 
respectively. Conversely, representative archaeal species, M. jannaschii and A. fulgidus, 
exhibited no significant inhibition by borrelidin, consistent with the observed low 
sequence conservation in archaeal TARS compared to the other domains of life (13). 
Despite this suggestive evidence that borrelidin is capable of inhibiting the mammalian 
TARS, direct proof of the enzyme-inhibitor interaction has not been reported.  
In addition to its inhibition of aminoacylation, borrelidin was found to disrupt 
angiogenesis in the mouse aortic ring fragment model (12). This feature led to subsequent 
investigations interested in the development of borrelidin as an anti-metastatic agent. 
Unfortunately, the potential therapeutic benefits of borrelidin are limited by its acute 
toxicity to living cells (14). Efforts have been made to improve the clinical usefulness of 
borrelidin by generating derivative molecules with a wider therapeutic index.  In order to 
synthesize these derivative molecules, the complete borrelidin biosynthetic operon from 
Streptomyces parvelus Tu4055 was cloned and sequenced.  By selective gene mutation 
and “priming” the biosynthesis of borrelidin with alternative dicarboxylic starter 
compounds novel variants of borrelidin were readily achieved. While this technique 
could theoretically be used to modify a variety of locations within the borrelidin 
molecule, modifications to the macrolide backbone and nitrile group completely 
eliminated the compound’s functionality. In contrast, modifications to the C17 pendent 
group produced derivative compounds with varying affinities and properties (15,16). 
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Therefore, all borrelidin derivatives used in recent studies vary exclusively at the C17 
site.  
 
Semisynthetic generation of borrelidin derivatives has produced a battery of 
compounds (Figure 5). The most promising of these molecules for use in anti-angiogenic 
treatments is BC194, which substitutes a cyclobutane carboxylic acid for the C17 
cyclopentane carboxylic acid group of borrelidin. Surprisingly, this seemingly minor 
modification has been demonstrated to reduce the toxicity of the compound by nearly 
1000-fold as determined by growth inhibition of human umbilical vein endothelial cells 
(HUVEC) (16). Despite this change in toxicity, however, BC194 retains potent anti-
 
Figure 5. Structures of macrolides used in this study. 
Structures of borrelidin (top left), BC194 (top right), BC196 (bottom left), and BC220 (bottom 
right). Carbons C1 and C17 for the macrolide component of each compound have been labeled.  
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angiogenic activity and will be discussed in greater detail within later chapters. 
Additionally, the derivatives BC196 and BC220, consisting of 2-methylbutanoic acid and 
cyclopentane carboxylic acid 3-ethyl piperidine ester C17 substitutions respectively, 
represent lower affinity derivatives and have been included in these studies as well. 
Originally, these derivatives were investigated for their high specificity against the 
malarial parasite Plasmodium falciparum relative to the human host, however, they are 
used here to draw structural comparisons between the other compounds (17).  
In this work we demonstrate that the C17 modification of BC194 does not 
significantly alter its affinity for human TARS from that of borrelidin in enzymatic 
assays. However, in accordance with recent crystallographic data, BC194 is found to be 
more susceptible than borrelidin to competition by threonine in biological assays. Taking 
these observations into consideration with the conformational changes presented by the 
structural data and the slow, tight-binding kinetics of the compound leads to the 
presentation of a two-step, induced-fit model of binding. This model justifies the apparent 
incongruence of the competitive structural data with the noncompetitive kinetics and will 
facilitate future understanding of borrelidin and its derivatives. Finally, point mutations 
are generated in human TARS in order to develop borrelidin-resistant mutants that can be 
used to investigate the TARS specificity for borrelidin-related functions in biology.  
 
2.2 Results and Discussion 
2.2.1 Discussion of borrelidin’s slow, tight-binding kinetics of enzymes 
Inhibitors are often described by an equilibrium dissociation constant (Ki) for the 
formation of the enzyme-inhibitor complex. The true Ki value accounts for the inhibitor’s 
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modality (ie. competitive, noncompetitive, etc.) and how this affinity is influenced by 
changes in substrate with respect to the reactions Km.  Therefore, this value is 
independent of the reaction conditions. However, in absence of detailed knowledge of 
inhibitor modality or kinetic constants an apparent Ki value (Ki
app) can used for relative 
comparisons of inhibitor affinity so long as nearly identical conditions are maintained.  
Commonly, calculations for Ki
app are based on reversible, steady-state 
measurements of initial velocity (v) and must satisfy several conditions. In particular, 
these methods assume that the formation and dissociation of the enzyme inhibitor 
complex (EI) is fast relative to the rate of enzymatic turnover and that the concentration 
of EI is negligible to the concentration of free inhibitor. However, early investigations of 
borrelidin binding modality with E. coli ThrRS using intrinsic tryptophan fluorescence 
exhibited kon and koff values of 5*10
6 s-1 and <0.1 s-1 respectively. From these data, the 
lower limit of the TARS-borrelidin complex half-life can be determined by using the 






By fitting koff at <0.1 s
-1, a half-life of at least 7 minutes is obtained, indicating that the 
rapid binding assumption is not met. As a notable consequence, the degree of inhibition 
for these slow-binding inhibitors appears to change over time as demonstrated in Figure 
6. In absence of inhibitor and at a concentration of 10 nM E. coli TARS (Ec ThrRS; 
ThrRS designates the prokaryotic enzyme), the steady-state aminoacylation reaction 
proceeds in a linear fashion until it has exhausted its available substrates. Similar 
isotherms would be predicted for rapid binding inhibitors except that the initial slopes 
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would be reduced as a function of inhibitor concentration. In contrast, reactions 
containing 20 nM borrelidin exhibit clearly visible time dependence for inhibition. In 
absence of pre-incubation, the reaction rates appear similar to the uninhibited reaction at 
earlier time points but level off within 10 minutes. Given that the substrate concentrations 
are identical in all reactions, this plateau is directly related to inhibitor binding and not 
the exhaustion of substrates. Conversely, pre-incubation of Ec ThrRS and borrelidin prior 
to the addition of substrates bypasses the slow-binding step and establishes a linear 
inhibition-isotherm. The fact that the rate of the pre-incubated reaction does not seem to 
increase over time suggests the rate of dissociation is so slow as to appear irreversible. 
Therefore, Ki values will be determined from initial velocity values of reactions pre-




Figure 6. Borrelidin exhibits slow-binding kinetics. 
The aminoacylation activity of Ec ThrRS treated with the DMSO vehicle (Uninhibited, blue) or 
borrelidin for either 30 minutes before (pre-incubation, green) or simultaneously with (No 
incubation, red) the canonical substrates. Activity was determined by the production of Thr-
tRNAThr per active site per minute; mean ± SD, n=3.  
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Initial investigations of borrelidin’s effects on Ec ThrRS revealed significant 
inhibition when ThrRS and borrelidin were present at similar concentrations, indicating 
that borrelidin is also a tight-binding inhibitor. This property, like slow-binding, is 
accompanied by its own set of complications that must be addressed for proper kinetic 
analysis. For Ec ThrRS, the Ki
app was calculated from the IC50 (the concentration of 
inhibitor that inhibits 50% of enzymatic activity under the given conditions) under the 
assumption of excess inhibitor and later adjusted for tight-binding character. Often the 
IC50 value of weak-binding inhibitors is a sufficient approximation for Ki
app. This value 
can be determined by plotting the fractional velocity (vi/v0, where vi and v0 are the initial 
velocities of the inhibited and uninhibited reactions respectively) against the total 
concentration of inhibitor in the reaction ([I]T) and fitting the resulting data to the 
















However, the derivation of this equation depends on the assumption that [I]T is in great 
excess of the total enzyme concentration ([E]T). That is to say [I]T >> [E]T. Therefore, the 
concentration of inhibitor in complex with enzyme is negligible compared to the free 
inhibitor concentration ([I]f) and [I]T can be used as a close approximation for [I]f (ie. [I]T 
≈ [I]f). In contrast, borrelidin significantly reduces Ec ThrRS activity at nearly equimolar 
concentrations to the enzyme, indicating that bound borrelidin represents a significant 
proportion of the total concentration. To address this concern, early borrelidin studies 
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converted IC50 into Ki
app values using an equation that accounts for borrelidin’s tight-
binding properties by associating IC50, Ki
app, and [E]T using the following equation 










While this method could also be used for the determination of Ki
app with human TARS, 
the work presented in this dissertation utilized the more robust Morrison quadratic 

















Unlike the IC50 method, the Morrison equation requires no assumptions related to the 
depletion of inhibitor concentration due to complex formation with the enzyme and can 
directly calculate Ki
app from a plot of fractional velocity versus inhibitor concentration.  
 
2.2.2 Inhibition of human threonyl-tRNA synthetase by borrelidin and derivatives 
 The ability of borrelidin and related-compounds to inhibit human TARS was 
investigated kinetically using in vitro enzymatic assays similar to the early methods used 
with prokaryotic versions of the enzyme. These procedures utilized human tRNAThr and 
TARS constructs recombinantly expressed in E. coli cells and monitored the production 
of Thr-tRNAThr as a measurement of aminoacylation activity. By plotting the relative 
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velocity of the inhibited reaction (vi/v0) versus the concentration of inhibitor, a curve is 
obtained from which Ki
app can be determined using the Morrison quadratic equation 
above. Care was taken to maintain conditions as close to those reported for E. coli ThrRS 
to keep comparisons between Ki
app values as accurate as possible. These procedures were 
repeated for the various derivatives of borrelidin as well. All data have been included in 
Table 2.             
 
 Recombinant human TARS was found to be active with a rate of 3.325 ± 0.2083 
min-1 (Figure 7A). Consistent with its high sequence conservation to Ec ThrRS, this 
TARS construct exhibited tight-binding interactions with borrelidin.  Likewise, a pre-
incubation step between the enzyme and inhibitor was used to account for the time 
dependence of the borrelidin-TARS interaction. Borrelidin inhibited TARS with a Ki
app 
of 5.44 nM (Figure 7B) nearly identical to the 3.7 nM value obtained for ThrRS. Despite 
its significantly reduced toxicity, BC194 also formed a comparably tight interaction with 
TARS, presenting with a Ki
app of 4.09 nM (Figure 7C). Conversely, the Ki
app values for 
BC196 (Figure 7D) and BC220 (Figure 7E) were significantly higher at 208.20 nM and 
>10 µM respectively.  
Taken together, the Ki
app values can provide some mechanistic insights on their 
own. The structural variability for all the tested compounds is limited to modifications in 
Table 2. Kiapp values of borrelidin derivatives on TARS constructs 
Construct Borrelidin BC194 BC196 BC220 
E. coli ThrRS 3.7a 0.006b -- -- 
Human TARS 5.44 4.09 208.2 >10,000 
L567V TARS -- 32.2 -- -- 
a data from Ruan et al. (13) 
b data from Anand Minajigi dissertation – Note these data have been difficult to 







Figure 7. Determination of Kiapp for borrelidin and related compounds against human 
TARS. 
 (A) Aminoacylation activity of purified TARS as determined by formation of Thr-tRNAThr per 
active site per minute; mean ± S.D.; n=3. (B-E) Plots showing the fractional initial velocity of 
TARS (10 nM) as a function of borrelidin (B), BC194 (C), BC196 (D), or BC220 (E) 




the pendant side chain, demonstrating the importance of this group to the binding each 
compound. Specifically, the two strongest binders, borrelidin and BC194, possess closed 
ring structures; whereas BC196, which resembles BC194 with an open carboxyl-
cyclobutyl ring, exhibits a significantly higher Ki
app.  Most likely, this difference is due to 
the higher degrees of freedom present in the open structure compared to the closed. 
Conversely, while BC220 possesses a closed cyclopentyl ring like borrelidin, the 
esterification of the carboxyl group severely reduces the compounds affinity for TARS. 
However, it is uncertain as to whether or not this modification reduces binding through 
steric interactions or through the loss of the negatively charged carboxyl group. In 
contrast, the macrolide backbone is identical for all compounds and is predicted to make 
the majority of the compounds’ contact with the enzyme. Therefore, the difference in 
affinity due to the C17 group may not be enough to counteract the strong contributions of 
the macrolide ring in borrelidin and BC194, explaining the nearly identical Ki
app values.  
Conversely, the variations in the BC196 and BC220 side chains may be disruptive 
enough to inhibit strong interactions with the enzyme. However, structural information 
must be considered to truly understand borrelidin’s binding mode.  
 
2.2.3 Determination of borrelidin’s mode of inhibition. 
 As the high resolution crystal structure of the borrelidin-Ec ThrRS complex was 
not reported until recently, early investigations of borrelidin’s binding mode were limited 
to kinetic and mutational data. Naturally occurring mutations that conferred borrelidin 
resistance were found to correspond to a hydrophobic pocket adjacent to the Ec ThrRS 
active site implicating this region as the likely borrelidin binding site (13). This was not 
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completely surprising as the non-polar macrolide ring would form higher affinity 
interactions with hydrophobic residues. Other studies also demonstrated that the binding 
of borrelidin induced a dose-dependent quenching of an intrinsically fluorescencent 
tryptophan residue (13). Previously, this fluorescence had been associated with Trp434 
and Trp478 in the E. coli ThrRS (Trp512 and H556 in humans) positioned near the active 
site and were quenched in response to conformational changes induced by the binding of 
ATP and threonine (24). Together these data would likewise suggest that borrelidin 
induces conformational changes in Ec ThrRS upon binding. More importantly, however, 
the phenomenon occurred in absence of the canonical substrates and eliminated the 
possibility of borrelidin binding using an uncompetitive mode. Furthermore, despite this 
location near the active site, borrelidin’s inhibitory properties were unaffected by the 
addition of threonine and ATP ranging in concentrations from 0.01 to 1 mM and 0.02 to 
10 mM respectively, suggesting that borrelidin does not possess a competitive or mixed-
type inhibition mode as well (13). Therefore, these early reports suggested that borrelidin 
must bind noncompetitively. However, the true modality of borrelidin is more 
complicated than originally predicated owing to recent crystallographic data of the 
TARS-borrelidin complex solved by our collaborator Min Guo (25). 
Recently, the structure of borrelidin co-crystallized with a fragment of human 
TARS (ΔN1N2-TARS) comprising the aminoacylation and anticodon-binding domains 
(residues 318-723) was solved to a resolution of 2.6 Å. The resulting structure challenges 
the conclusion of a noncompetitive binding mode suggested by the kinetic data. 
Consistent with the previous investigations, borrelidin was found to bind within the 
hydrophobic pocket of the aminoacylation domain active site of the protein. Specifically, 
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the macrolide component forms hydrophobic interactions with residues L567, S386, 
H388, Y540, D564, Q562, H590, Y392, H391, and F539 (human numbering; Figure 8A). 
The pendent side chain further contributes interactions with residues T560, R442, M411, 
 
 
Figure 8. TARS-borrelidin binding interactions. 
(A, B) Residues involved in the borrelidin-TARS interaction for the macrolide (A) and 
pendent group (B) components. The borrelidin structure is shown in yellow and binding 
resides are shown in magenta. Structure provided by Min Guo. 
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C413, Q460, and A592 (Figure 8B). This large number of contacts likely explains the 
tight-binding character of the compound. Establishing all of these interactions, however, 
requires structural changes within the enzyme as demonstrated by comparison of the 
borrelidin-TARS complex to other TARS structures. 
The borrelidin induced conformational changes can be easily observed when 
compared to the structures of earlier Ec ThrRS complexes. These Ec ThrRS structures are 
either empty (apo Ec ThrRS; PDB: 1EVK) or in complex with the threonyl-adenylate 
analog, threonyl sulfamoyl adenylate (PDB: 1NYQ), or AMP (PDB: 1QF6). Although 
the borrelidin-TARS complex described above refers to the human enzyme, the structure 
for the aminoacylation and anti-codon binding domains of the Ec ThrRS ortholog was 
also solved. Both structures superimpose with an r.m.s.d (root mean square distance) of 
0.644 Å.for all 279 Cα carbons, indicating that the overall folds are highly similar. 
Superposition of E. coli ΔN1N2-ThrRS with the various substrate bound structures 
revealed nearly identical conformations with the exception of one region adjacent to the 
aminoacylation active site (Figure 9A). As demonstrated by the threonine and AMP 
bound structures, substrate binding induces the closing of a specific helix and loop 
(residues 492-547 for humans and 415-469 in E. coli) into the active site as has been 
previously observed (26). By comparison, borrelidin binding extrudes this helix by 14° 
relative to the substrate bound conformations and opens the TARS active site even more 
than the apo structure. These structural changes are consistent with the earlier intrinsic 
tryptophan fluorescence data for both borrelidin and substrate binding mentioned above 
since Trp434 (Trp512 in humans) is located within this region. In addition to these 
conformational changes, superposition of the borrelidin-ThrRS structure with the other 
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complexes also revealed substantial overlap of borrelidin with all three substrate binding 
pockets, suggesting that borrelidin functions as a competitive inhibitor (Figure 9B, C). 
This result is surprising, since borrelidin has been previously reported as a non-
competitive inhibitor. Nonetheless, this observation can be explained. 
The structural evidence suggesting that borrelidin binds in a competitive fashion 
seems to contradict earlier kinetic data indicating a non-competitive binding mode (13). 
However, the misinterpretation of a competitive-binding mode as non-competitive is 
common with slow, tight-binding inhibitors. Several mechanisms can contribute to the 
slow-binding of a compound (reviewed in (18)). In the case of small molecule inhibitors, 
these scenarios typically fit one of three descriptions: 1) the binding of the compound is 
inherently slow; 2) the compound binds only one isomer of an enzyme that slowly 
isomerizes in solution; or 3) the compound forms a weak initial complex and 
subsequently induces a slow conformational change in the enzyme for full 
accommodation. The dose-dependent effect of borrelidin, ATP, or threonine on the 
intrinsic tryptophan fluorescence of E. coli ThrRS as well as the observed structural 
changes within TARS upon the binding of borrelidin or substrates clearly indicate that 
conformational changes are induced upon substrate or compound binding (13,24). 
Therefore, model three appears to be the most relevant.  
This model would suggest that borrelidin and related compounds only weakly 
associate with TARS upon first encounter. In this initial phase, binding occurs under 
rapid equilibrium conditions and is competitive with respect to substrates. Subsequently, 
the enzyme undergoes a slow isomerization into a final, tightly-bound complex. This new 
conformation precludes the binding of substrate molecules and would appear to behave 
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Figure 9. Borrelidin induces conformational changes in TARS and disrupts substrate 
binding. 
(A) Superposition of the ΔN1N2-ThrRS-borrelidin complex (yellow) with apo- (cyan; 
PDB:1EVK), threonine sulfamoyl adenylate (AMS-Thr; magenta; PDB: 1NYQ), and AMP 
(PDB:1QF6) Ec ThrRS structures with focus on the substrate binding helix and loop (residues 
492-547 for humans and 415-469 in E. coli). (B) Superposition of the ΔN1N2-TARS-borrelidin 
and Ec ThrRS-AMS-Thr (PDB: 1NYQ) complexes revealing steric clashing between borrelidin 
(green) and AMS-Thr (magenta). The true space occupancy of the borrelidin side chain is 
indicated by dots. (C) Superposition of the ΔN1N2-TARS-borrelidin and Ec ThrRS- A76-
tRNAThr (PDB: 1QF6) complexes revealing steric clashing between borrelidin (green) and A76-
of tRNAThr (magenta). Borrelidin’s true space occupancy is indicated by dots. 
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non-competitively (27). Owing to the pre-incubation step used in the Ki
app determination 
experiments described above and in previous reports, TARS-borrelidin complexes would 
be predominantly in the second binding phase at the start of these reactions. Effectively, 
once in this tightly-bound phase, borrelidin titrates away free TARS, resulting in an 
apparent reduction of [E]T (18). Kinetically, a decrease in [E]T manifests as a lower value 
for Vmax. However, [E]T is unrelated to substrate binding affinity and would not change 
the value of  Km for any of the substrates. Classically, inhibitors that reduce Vmax without 
affecting the Km would be characterized kinetically as non-competitive. Therefore, 
borrelidin appears to be a competitive inhibitor that exhibits non-competitive 
characteristics. 
 
2.2.4 Characterizing the differences in borrelidin and BC194 binding 
As mentioned above, the great toxicity of borrelidin to living cells led to the 
development of less toxic derivatives, the most successful of which appears to be BC194. 
Previous reports clearly indicate that BC194 exhibits significantly reduced toxicity when 
compared to borrelidin (16). The physiological cause of this toxicity is linked to the 
initiation of amino acid starvation responses in response to the compounds’ inhibition of 
TARS aminoacylation function and will be addressed in more detail in Chapter 3. 
Interestingly, borrelidin toxicity can be rescued by point mutations in the TARS enzyme, 
suggesting that the observed effects of the compounds are mediated exclusively through 
TARS (13). This suggests two different hypotheses to account for the differences in 
toxicity between borrelidin and BC194: 1) the two compounds induce distinct 
conformational changes, only one of which is associated with the toxic effects; or 2) the 
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compounds have altered interactions with TARS, allowing for varying degrees of 
competition with the canonical substrates. Crystallographic data would eventually 
confirm the second model.    
Recently the structure of the human ΔN1N2-TARS fragment was co-crystallized 
with BC194 and solved by out collaborator, Min Guo, to a resolution of 2.8 Å. 
Superposition of the borrelidin and BC194 TARS complexes reveals nearly identical 
structure (0.62 Å r.m.s.d.) over 402 Cα’s including the retention of all macrolide 
interactions (Figure 10A, B).  In a global structural sense, borrelidin and BC194 act to 
stabilize the same conformational state for TARS, which indicates that conformational 
changes are unlikely to be responsible for variance in toxicity between the two 
compounds. The loss of the methylene group from BC194’s C17 cyclobutane group 
lengthens the interaction between the C17 carboxylate and the amide nitrogen of Q460 by 
0.9 Å relative to the corresponding interaction in the borrelidin complex (Figure 10C). 
Likewise, the Van der Waals interactions between the pendant ring and A592 are 
completely lost in the BC194 structure. Interestingly, examination of the Ec ThrRS 
structure co-crystallized with threonine reveals that Q460 and A592 make key hydrogen-
bond and hydrophobic interactions with L-threonine (Figure 10D). The loss of these 
interactions in BC194 may render its interaction with TARS more susceptible to 
competition with threonine and permit translation to continue over wider range of 
concentrations. An important prediction of these structural studies is that borrelidin and 
BC194 should exhibit differential sensitivity with respect to the inhibition of overall 
translation. This hypothesis was tested by comparing the formation of luciferase in a cell 
free protein synthesis system at varying concentrations of borrelidin and BC194 and 
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determining the Ki
app (Figure 10E, F).  Borrelidin exhibited a Ki
app of 100 nM, which is 
more than half the value of 209 nM recorded with BC194. Therefore, BC194 appears to 
be more susceptible to competition with threonine, allowing for translation to occur over 
a broader range of the compound.  
The structural and biochemical differences between borrelidin and BC194 
discussed above appear to be in striking contrast to its nearly identical Ki
app obtained for 
both compounds in enzymatic assays (Section 2.2.2). However, the two-phase binding 
model described in Section 2.2.3 provides an explanation. Once again, the formation of 
the initial encounter-complex in the first phase of binding occurs under rapid equilibrium 
conditions and would be readily susceptible to competition by the canonical substrates 
(27). The C17 side-chain likely contributes to the formation of this initial complex and 
would be highly responsive to the structural differences between borreldin and BC194. 
This would also hold true with BC196 and BC220 as well since these molecules differ 
even further from borrelidin than BC194. Isomerization of the enzyme then occurs, 
creating a complex with an extremely low off rate that is substantially more resistant to 
substrate competition. This model also accounts for reported Ki
app values since TARS is 
pre-incubated with the inhibitors prior to initiating the reaction in these enzymatic assays 
and would be predominantly tied up in the stable, tight-binding mode (13,17,28). Since 
this tight-binding phase consists primarily of interactions with the macrolide backbone 
the affinities of borrelidin and BC194 would likely be identical at this stage. Conversely, 
pre-incubation is not practical in the more complex biological approaches, such as in 
vitro translation or cellular based assays, due to constant availability of substrates or 
translation of new TARS. Therefore, a significant population of TARS would remain in 
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Figure 10. Structure of TARS-BC194 complex. 
(A) Structure superimposition of TARS-BC194 and TARS-borrelidin complexes. The protein is 
shown in ribbon cartoon representation, and the bound BC194 and borrelidin are shown as pink 
and blue sticks, respectively. (B) Two-dimensional scheme of TARS-BC194 interactions. H-
bonding residues are shown as sticks. Hydrophobic interacting residues are shown in grey. (C) 
Close up view of BC194 and borrelidin binding site residues. The five shared H-bonds are 
shown as black dash lines.  The 2 borrelidin-specific interactions are shown as blue dash lines, 
while the corresponding distances in BC194 structure are indicated in pink. (D) Close up view 
of threonine binding interactions. Interactions are shown as dashed lines. (E, F) The effects of 
borrrelidin and BC194 treatment on a cell-free translation system. Rabbit reticulocyte lysate 
(RRL) was incubated with 0.02 mg/ml luciferase mRNA and translation of luciferase enzyme 
was quantified in a luminescence assay. Serial diluted BC194 (E) and borrelidin (F) (2.5 nM - 
25 µM) was added to inhibit the translation of luciferase mRNA; mean ± SEM, n=3. Data in 
parts (E) and (F) were kindly provided by Min Guo, Scripps, Fl. 
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the rapid-equilibrium phase and be subject to competition by threonine. Under these 
conditions, borrelidin’s greater affinity would facilitate the progression of the TARS-
borrelidin complexes to the tight-binding phase relative to the BC194-containing 
complexes. 
 
2.2.5 Development of a Borrelidin-resistant point mutation 
 Early studies of borrelidin inhibition identified several naturally occurring point 
mutations in E. coli ThrRS that conferred varying degrees of resistance to the compound 
(13). Since the majority of borrelidin-binding interactions are maintained from E. coli to 
humans it seems reasonable that similar resistance-conferring mutations could be 
generated in the human enzyme. Of particular interest, the successful generation of these 
mutations would be useful in subsequent investigations of borrelidin’s anti-angiogenic 
mechanism. At the beginning of this dissertation work TARS was not thought to have a 
role in angiogenesis; as such borrelidin’s anti-angiogenic properties were thought to be 
possibly mediated through secondary targets of the compound, namely the splicing 
associated factor FBP21 and the cyclin dependent kinase Cdc28/Cln2 (29-31). However, 
the effects for both compounds were observed in cells at low μM concentrations (0.5-5 
μM for FBP21 and about 10-50 μM for Cdc/Cln2), which is well above low nM toxicity 
threshold observed for the compound and seem to be unlikely candidates for the anti-
angiogenic effect of the compound (16). Therefore, if a point mutation in TARS were to 
confer resistance to borrelidin’s effects it would confirm the TARS dependent nature of 
the interaction.  
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In early efforts to identify mutations that confer borrelidin resistance, libraries of 
randomly mutagenized E. coli were generated and screened for colonies resistant to 
borrelidin treatment. Subsequent analyses revealed that the majority of these mutations 
were associated with L489M substitution in the Ec ThrRS gene (thrS). Similar 
substitutions were also generated using site-directed mutagenesis in order to further 
investigate the effects of mutations within the borrelidin binding site of TARS. Notably, 
the conversion of L489 to Trp conferred the greatest resistance to borrelidin, increasing 
the Ki value nearly 1500-fold relative to the wildtype enzyme. Using a combination of 
structural and sequence alignments L489 was found to be conserved as Leu567 in the 
human enzyme. Structural data indicate that this leucine residue forms Van der Waals 
contacts with the C12 nitrile of the borrelidin compound in both human and E. coli 
enzymes (Figure 11A), suggesting that mutations at this site should produce similar 
effects related to borrelidin binding (25). Therefore, site-directed mutagenesis was used 
to generate the equivalent L567W mutation as well as the more conservative L567V.  
 In order to verify the resistance provided by the point mutations, the Ki
app values 
were determined. Initial kinetic characterizations revealed that both mutations possessed 
aminoacylation activity, albeit at very different rates. L567V TARS turned over at a rate 
of 4.429 min-1, close to the 3.325 min-1 observed for the wildtype enzyme (Figure 11B). 
Using the same method as the wildtype TARS above, L567V TARS possessed a Ki
app of 
32.2 nM for BC194 (Figure 11C), approximately 8-fold higher than the 4.09 nM obtained 
for the wildtype enzyme (Table 2). Conversely, L567W TARS catalyzed aminoacylation 
at a rate of 0.2970 min-1. Owing to this much slower rate, L567W TARS activity data 
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were difficult to distinguish from background radioactivity counts after the addition of 




Figure 11. L567V TARS exhibits a Kiapp value greater than WT TARS. 
(A) Close up of the L567 and C12 nitrile interaction in the borrelidin (yellow)-human TARS 
complex. (B) Aminoacylation activity of purified WT TARS (blue), L567V TARS (red), and 
L567W TARS (green) as determined by formation of Thr-tRNAThr per active site per minute; 
mean ± S.D.; n=3. (C) Plots showing the fractional initial velocity of WT TARS (blue) and 




2.3 Experimental Procedures 
2.3.1 Threonyl-tRNA Synthetase Preparation 
 N-terminal His6-tagged human TARS was expressed and purified from E. coli 
RossettaTM 2(DE3)pLysS competent cells (EMD) transformed with the plasmid pET28a 
hctThrRS (provided by Dieter Söll, Yale). L567V TARS was generated using identical 
procedures following QuickChange (Stratagene) site-directed mutagenesis with olio-
deoxynucleotide primers from Operon. Transformant cultures were grown in terrific 
broth supplemented with 100 mg/ml kanamycin and 100 mg/ml chloramphenicol at 37°C 
to a cell density of A600 = 0.6. Expression of HsThrRS was induced with 1 mM isopropyl 
1-thio-β-D-galactoside overnight at 15°C. The bacterial pellet was lysed by sonication in 
sonication buffer (20 mM potassium phosphate buffer pH 8.0, 100 mM KCl, 35 mM 
imidazole, and 5 mM β-mercaptoethanol) and cleared by centrifugation at 17050 x g for 
30 minutes. Nucleic acids were precipitated by the addition of protamine sulfate to a final 
concentration of 0.3% followed be centrifugation. The supernatant was loaded onto a 
HisTrapTM FF column (GE Healthcare) equilibrated with sonication buffer and eluted by 
an imidazole gradient of 35-250 mM over 20 column volumes. TARS containing 
fractions were identified by SDS-PAGE and GelCodeTM Blue (Thermo Scientific), 
pooled, and dialyzed into hydroxyapatite binding buffer (100 mM potassium phosphate 
buffer pH 6.8 and 5 mM β-mercaptoethanol). The sample was loaded onto a CHT-
Tricorn hydroxyapatite column and eluted over 20 column volumes by using a gradient 
of hydroxyapatite binding buffer to 500 mM potassium phosphate pH 8.0 and 5 mM β-
mercaptoethanol. ThrRS containing fractions were determined by SDS-PAGE, dialyzed 
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into 20 mM HEPES pH 8.0, 100 mM KCl, 5 mM β-mercaptoethanol, and 40% glycerol, 
and stored at -20°C. The concentration of active sites was determined as previously 
described (32). 
 Full-length, N-terminal 6xHis-tagged E. coli ThrRS (Ec ThrRS) was expressed 
and purified from IBPC 6881 E. coli cells containing the pTetthrS plasmid through 
identical procedures to those used for human TARS with minor exceptions (33). 
Kanamycin and chloramphenicol were replaced by 10 μg/ml tetracycline. The protein 
was purified using only the HisTrapTM FF column (GE Healthcare). 
 For crystallization, the N-terminal His-tagged human ΔN1N2-TARS (residues 
322-723) was constructed in a PET28a vector. The protein was expressed in strain BL21 
(DE3) and induced with 0.2 mM IPTG for 20 h at 16 °C. The cell pellet (from 4-8 liters) 
was lysed in NTA-wash buffer (500 mM NaCl, 20 mM Tris-HCl pH 8.0, 30 mM 
imidazole), loaded onto a Ni-HiTrap column and washed with NTA-wash buffer. The 
protein was eluted with NTA-elution buffer (500 mM NaCl, 20 mM Tris-HCl pH 8.0, 
250 mM imidazole). The eluted protein was further purified by a QAE anion exchange 
column with NaCl gradient. The peak fractions of the protein were then concentrated for 
crystallization.  
 
2.3.2 tRNAThr Preparation 
E. coli XL-1 Blue (Stratagene) cells expressing the plasmid pUC18hcttRNAThr-TGT 
(provided by Dieter Söll, Yale), coding for human tRNAThr, were cultured in LB broth 
supplemented with 100 mg/ml ampicillin at 37°C to a cell density of A600 = 0.5. 
Expression of tRNAThr was induced with 1 mM isopropyl 1-thio-β-D-galactoside for 14 
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hours.  Bacterial pellets were resuspended in 20 mM Tris pH 7.5, 20 mM MgCl2, and 10 
mM β-mercaptoethanol and extracted with water saturated phenol (pH = 4.8). The 
aqueous fractions were ethanol precipitated, resuspended in 10 mM HEPES and 50% 
formamide, and resolved using 8M Urea/10% polyacrylamide gel electrophoresis. The 
tRNA was identified by UV shadowing, electroeluted, and ethanol precipitated. The 
tRNA pellet was resuspended in 10 mM HEPES and stored at -20°C. The active 
concentration of tRNAThr was determined by plateau charging assay (32).  
 
2.3.3 Slow-Tight Binding Assay 
For slow-tight binding assays reaction mixtures consisted of 1 mM ATP, 2 U/µl 
pyrophosphatase (New England Biosciences), 80 µM threonine, 20 µM [14C]-threonine, 
and 10 µM of human tRNAThr in Buffer A. In addition untreated reactions and non-
incubated borrelidin reactions contained DMSO or 10 μM borrelidin respectively, with 
the concentration of DMSO normalized to the amount present in borrelidin reactions 
(about 0.00001%). These reactions were initiated with the addition of 2.5 nM Ec ThrRS 
and run at 37°C.  For pre-incubated borrelidin reactions, 175 nM Ec ThrRS was 
incubated with 700 nM borrelidin for 30 minutes on ice. The reaction was then initiated 
by adding 1 μl sample of the Ec ThrRS-borrelidin to 69 μl of reaction buffer, resulting in 
a 70-fold dilution. Aliquots were taken at varying time points and spotted onto 
Whatmann 3MM paper filters pre-soaked in 5% trichloroacetic acid (TCA). Filters were 
washed 3 times in excess TCA, once in 95% ethanol, and dried under a heating lamp. The 
formation of Thr-tRNAThr was detected by scintillation counter and the activity 
determined by linear regression of threonyl-tRNAThr formed per active site per unit time.  
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2.3.4 Steady-State Aminoacylation Assay 
The aminoacylation activities of the various TARS constructs were determined using 
modifications to established steady state aminoacylation procedures (32). Briefly, 
reaction mixtures consisted of 2 mM ATP, 2 U/µl pyrophosphatase (New England 
Biosciences), 160 µM threonine, 40 µM [14C]-threonine, and 10 µM of human tRNAThr 
in Buffer A (20 mM HEPES pH 8.0, 100 mM KCl, 10 mM MgCl2, 5 mM β-
mercaptoethanol). Reactions were initiated with the addition of 100 nM TARS and run at 
37°C.  Aliquots were taken at varying time points and spotted onto Whatmann 3MM 
paper filters pre-soaked in 5% trichloroacetic acid (TCA). Filters were washed 3 times in 
excess TCA, once in 95% ethanol, and dried under a heating lamp. The formation of Thr-
tRNAThr was detected by scintillation counter and the activity determined by linear 
regression of threonyl-tRNAThr formed per active site per unit time. 
 
2.3.5 Kiapp Determination Assays 
For Ki
app determination, reaction mixtures consisting of 2 mM ATP, 10 µM tRNA, 10 nM 
TARS and various concentrations of BC194 (0 - 35 nM) in Buffer A were incubated for 3 
minutes at 37°C and initiated with the addition of radio-labeled threonine (20 µM [14C]-
threonine and 180 µM threonine). Data collection procedures were otherwise identical to 
those described for steady-state aminoacylation. Values for Ki
app were obtained by 
plotting fractional velocity as a function of BC194 concentration and fitting the data to 


















2.3.6 Crystallization and Structure Determination.  
Crystallization was done by the sitting drop method. To crystallize human 
TARS – BC194 complex, protein solution (10 mg/ mL) was pre-mixed with 2 mM 
BC194 and 5mM L-Thr at 4 °C. The protein was then crystallized by mixing 0.5 μL of 
protein solution with 0.5 μL of precipitant solution, containing 0.1 M Tris pH 8.0, and 
8% PEG8000. After incubation at 18 °C for 3-7 days, the crystals were flash-frozen in 
liquid nitrogen for data collection with a cryo solution consisting of 0.08M calcium 
acetate, 6.4% PEG4000, and 20% glycerol. Diffraction data were obtained from the Ls-
cat 21-ID-G beamline at the Advanced Photon Source (APS, Argonne, IL).  
A dataset was integrated and scaled with HKL2000 (34). The structures were 
determined by molecular replacement based on the human TARS structure (pdb: 4P3N) 
in program Molrep (35). After corrections for bulk solvent and overall B values, data 
were refined by iterative cycles of positional refinement and TLS refinement with 
PHENIX (36) and model building with COOT (37). All current models have good 
geometry and no residues are in the disallowed region of the Ramachandran plot. 
 
2.3.7 In Vitro Translation Assay 
 The effects of BC194 and borrelidin on cell-free protein translation were assayed 
in a rabbit reticulocyte lysate (RRL) according to the manufacturer’s instructions 
(Promega), with the exceptions that no extra amino acid mix was added and 0.02 mg/ml 
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firefly luciferase mRNA was used in the assays. Experiments were performed in triplicate 
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CHAPTER 3: SEPARATION OF THE TOXICITIY AND ANTI-ANGIOGENIC 
EFFECTS OF BORRELIDIN AND BC194 
 
3.1 Introduction 
Aminoacyl-tRNA synthetases (ARSs) attach amino acids to their corresponding 
tRNA adaptors with high specificity in an essential and early reaction of protein synthesis 
(1,2).  In addition to this canonical function, ARSs and ARS-related proteins exhibit 
diverse alternative activities including RNA splicing, translational regulation, immune 
system modulation, and angiogenesis (3-7).  Recent genetic evidence has served to link 
ARSs to a variety of human and murine diseases associated with the brain and the 
nervous system, including Charcot-Marie Tooth disease (8,9), Type III Usher Syndrome 
(10), and various encephalopathies (11,12).  In several cases, these associations appear to 
be linked to secondary ARS functions, potentially those most closely tied to signaling.  
One secondary function with particular significance for human physiology is 
angiogenesis, where multiple ARS play a variety of stimulatory and inhibitory modes.  
As indicated in Chapter 1, tyrosyl-tRNA and tryptophanyl-tRNA synthetase are secreted 
in response to the inflammatory cytokines TNF-α and interferon γ, respectively (6,13,14).  
Fragments or splice variants of these ARSs exert opposite effects, with the YARS 
fragment stimulating angiogenesis and WARS inhibiting angiogenesis.  While there is 
evidence to suggest that the angiostatic properties of WARS depend on direct interactions 
with VE-cadherin, a role for ARSs in well-established angiogenic signaling pathways, 
such as those associated with vascular endothelial growth factor (VEGF), has not been 
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defined. In zebrafish, a mutations in the SARS gene encoding seryl-tRNA synthetase are 
associated with altered vascular development (15,16).  
 The class II threonyl-tRNA synthetase (TARS) is the most recent ARS for 
whom an angiogenic function has been identified, and exhibits some features that are 
distinct from YARS and WARS.  TARS is secreted from endothelial cells in response to 
TNF-α and VEGF, and potently stimulates angiogenesis in the human umbilical vein 
endothelial cell (HUVEC) tube formation and chicken chorioallantoic membrane assays 
(17).  The recent report of a strong association between TARS expression and advancing 
stage of ovarian cancer provides evidence that the pro-angiogenic function of TARS in 
angiogenesis is significant, at least in a pathophysiological context (18).  An open 
question is whether this pro-angiogenic function is a directly linked to the canonical 
aminoacylation function, or is instead an as yet undetermined secondary function.  
Moreover, the role of TARS in normal vascular development in metazoans, if any, 
remains to be determined.  
Insights into the pro-angiogenic properties of TARS are provided by the 
characterization of its potent inhibitor borrelidin. Previously, several point mutations 
within the borrelidin binding site of TARS were shown to confer resistance to the 
compound, with the greatest difference resulting from the substitution of L489 (E. coli 
numbering) with a tryptophan (19). The crystallographic data presented in Chapter 2 
provide an explanation for this dramatic change in affinity as this modification would 
disrupt a key interaction with borrelidin’s essential nitrile group (20). L489 is conserved 
from E. coli to humans in the form of L567 indicating that similar mutations could be 
generated in the human enzyme (see Chapter 2, section 2.2.5). Interestingly, the 
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substitution of L567 with valine in the human TARS enzyme was found to block the 
angiogenesis inhibiting properties of BC194. These data provide strong evidence that 
borrelidin and related compounds inhibit angiogenesis specifically through interaction 
with TARS in in vitro assays (21). 
The anti-angiogenic properties of borrelidin provide an opportunity for its use as 
an anti-metastatic agent (22). However, borrelidin has yet to be exploited clinically, 
owing to its cytotoxicity to normal epithelial cells at nanomolar concentrations (23). 
Several derivatives of borrelidin have since been developed through the biosynthetic 
engineering of bor gene cluster in attempt to alleviate this toxicity (20). Of particular 
interest is the derivative BC194 (Figure 5, Chapter 2) which possesses equipotent 
inhibition of TARS relative to borrelidin in enzymatic assays (Ki of 4.09 nM for 
aminoacylation) and a nearly identical structure to borrelidin save for the elimination of a 
single methylene group in the C17 pendent chain (21). Despite its similar properties, 
BC194 exhibits greatly reduced toxicity relative to borrelidin while still maintaining 
function as an anti-angiogenic compound (20).  
Recent work has also demonstrated that the toxic effects are due to the induction 
of the general control nonderepressible 2 kinase (GCN2) based amino acid starvation and 
is mechanistically distinct from the anti-angiogenic effects (21).  The reduction of 
aminoacylation activity resulting from ARS inhibitors or amino acid deprivation 
increases the intracellular concentration of uncharged-tRNA. These molecules then 
associate with GCN2, stimulating its dimerization and auto-phosphorylation activity. 
Active GCN2 then phosphorylates the guanine nucleotide cycling protein, eukaryotic 
translational initiation factor 2α (eIF2α), locking it in its GDP-bound conformation 
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(GDP-eIF2α) (24). Similar phosphorylation of eIF2α is also observed following the 
activation of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) by ER 
stress and the unfolded protein response (25,26). GDP-eIF2α inhibits translation of 
mRNA by blocking Met-tRNA initiator tRNA with the exception of select transcripts 
involved in stress response pathways (27). Specifically, GDP-eIF2α encourages the 
translation of activating transcription factor 4 (ATF4), a transcription factor that up-
regulates the expression of cell survival genes, such as VEGFA, (C/EβP) homology 
protein (CHOP), and other autophagy associated genes (28-30).  
 The differences in toxicity between BC194 and borrelidin are shown to originate 
from their varying ability to elicit the amino acid starvation response, yet both 
compounds exhibit equal potency in blocking angiogenesis.  Characterization of the 
molecular basis of this difference opens the door to potential exploitation of these 
compounds in a clinical setting, such as in the therapeutic inhibition of angiogenesis. 
Here, we demonstrate that the differences in toxicity between BC194 and borrelidin are 
shown to originate from their varying ability to elicit the amino acid starvation response, 
while their inhibition of angiogenesis occurs through a yet undetermined mechanism.  
Finally, we compare the effects of borrelidin derivatives on vascular development in the 
zebrafish, and provide direct evidence for the role of TARS in angiogenesis in vivo. 
 
3.2 Results 
3.2.1 Borrelidin mediated amino acid starvation elicits cell cycle arrest  
Borrelidin and BC194 were previously shown to exhibit significant differences in 
their toxicity to endothelial cells (20).  However, the molecular basis for these effects has 
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not been established. To better understand the physiological consequences of borrelidin 
and BC194, we compared their effects on HUVEC cell-cycle progression using flow 
cytometry (Figure 12A, B).  Treatment with 10 nM borrelidin arrested cells at the G0 
boundary, delaying progression into G2/M up to 24 h.  In contrast, cells treated with 10 
nM BC194 did not significantly deviate from serum treated controls, and entered the 
 
 
Figure 12. Borrelidin elicits toxic responses related to cell cycle progression in 
endothelial cells at lower concentrations than BC194. 
(A) Cell-cycle analysis of synchronized HUVECs treated with serum containing borrelidin 
or BC194 using flow cytometry. (B) Percentage of cells in G2/M phase following treatment 
with borrelidin or BC194. HUVEC cells were treated with 10 nM borrelidin or BC194, 
harvested at 0, 8, 16, and 24 h, and stained with propidium iodide. The cells in G2/M were 
determined by gating using the 16h serum control; mean ± SEM, n=3, *p<0.05 (one-way 
ANOVA, Tukey Test). (C) The effects of borrelidin and BC194 on HUVEC proliferation. 
Cells were exposed to the indicated concentrations of compounds for 48 h and the relative 
proliferation measured using an alamarBlue® assay.  
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G2/M phase 16 h following serum exposure (Figure 12B). The effects of borrelidin and 
BC194 on HUVEC proliferation were subsequently investigated using an alamarBlue® 
based assay (Figure 12C). Reductions in cell proliferation were observed at 
concentrations as low as 10 nM for borrelidin, whereas a 10-fold higher concentration of 
BC194 was required for a comparable decrease in cell proliferation. These observations 
suggest that a major component of borrelidin’s toxicity is its ability to block progression 
through the cell cycle.  
The observed differences in the ability of two compounds to induce cell cycle 
arrest may arise from variations in their ability to induce amino acid starvation. The 
amino acid starvation (AAS) response is typically detected as increased phosphorylation 
of the translational initiation factor eIF2α, which results from activation of the GCN2 
translational control kinase (31). Previously, borrelidin treatment was demonstrated to de-
repress expression of amino acid biosynthetic genes in yeast, a signature of GCN2 
activity (32). Particularly when coupled to the unfolded protein response, amino acid 
starvation leads to cell cycle arrest and, in severe cases, the initiation of apoptosis 
(24,33,34). To confirm that the anti-proliferative effects of borrelidin are linked to AAS 
pathways in animal cells, cultured HUVECs were exposed to increasing amounts of 
borrelidin or BC194, and then lysates from these cultures were probed for the starvation 
and apoptosis markers phospo-eIF2α and cleaved-caspase 3, respectively (Figure 13A, 
D). The phosphorylation of eIF2α was induced at concentrations as low as 10 nM 
borrelidin (Figure 13B) but at least 10-fold higher concentrations of BC194 were required 
to generate an equivalent response (Figure 13E). Likewise, the appearance of cleaved-
caspase 3 at 100 nM borrelidin (Figure 13C) compared to 1000 nM for BC194 (Figure 
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13F) demonstrates the greater potency of borrelidin relative to BC194 in inducing 
apoptosis.  These experiments underscore the existence of a critical concentration in the 
range of 10-100 nM where borrelidin elicits AAS, and BC194 does not. 
 
 
Figure 13. The cytotoxicity of borrelidin is linked to the induction of the amino acid 
starvation response. 
(A-F) HUVEC cells grown in full serum media were exposed to the indicated concentrations 
of borrelidin (A-C) or BC194 (D-F). Western blots of cell extracts were analyzed using 
antibodies recognizing phospo-eIF2α and cleaved-caspase 3 with β-tubulin as a loading 
control. Quantification of phospho-eIF2α and cleaved-caspase 3 for borrelidin (B, C) and 
BC194 (E, F) relative to β-tubulin; mean ± SEM, n≥3, *p<0.05 relative to 0 nM (one-way 
ANOVA, Tukey Test). #, Owing to the high variance at 1000 nM borrelidin resulting from 
extensive apoptosis and cell death, the extent of eIF2α phosphorylation could not be reliably 
quantitated. (G, H) Quantification of eif2α amounts relative to β-tubulin for both borrelidin- 
and BC194-treated cells (100 nM) in the presence of various threonine concentrations (0-10 
mM); mean ± SEM, n≥3, *p<0.05 relative to 0 mM threonine (one-way ANOVA, Tukey 
Test), #p<0.01 between compounds at same threonine concentration (two-way ANOVA, 
Sidak Test).  
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An important prediction of the structural and cell free protein synthesis studies in 
Chapter 2, section 2.2.4, is that borrelidin and BC194 should exhibit differential 
sensitivity with respect to the ability of threonine to rescue compound-induced amino 
acid starvation. Significantly, when threonine was added at concentrations between 2.5-
10 mM to HUVECs treated with 100 nM BC194, the phosphorylation of eIF2α was 
decreased to untreated levels (Figure 13G, H). By contrast, cells treated with 100 nM 
borrelidin still exhibited substantial levels of phospho-eIF2α over this same range of 
threonine concentrations. Thus, the combined structural and biochemical analysis 
suggests that the reduced ability of BC194 to inhibit protein synthesis attenuates its 
induction of amino acid starvation in HUVECs, thereby reducing its toxicity in growth 
and proliferation assays.  
As an additional control to demonstrate that borrelidin induced amino acid 
starvation response is directly linked to TARS inhibition, HUVECs were incubated with 
a third compound, BC220, which is structurally distinguished from borrelidin by a 3-
ethyl piperidine group that is esterified to the cyclopentane carboxylic acid moiety 
(Chapter 2, section 2.2.2). The Ki for inhibition of TARS aminoacylation by BC220 is 
greater than 10 μM (35). HUVECs exposed to BC220 showed no induction of eIF2α 
phosphorylation or cleavage of caspase 3 (Figure 14A-C), indicating that the lack of 
physiological response is highly correlated with its failure to inhibit TARS. In summary, 
the combined results with all three compounds demonstrate that the cytotoxicity of 
borrelidin activation is linked to the activation of the amino acid starvation response and 




3.2.2 Borrelidin and BC194 exhibit comparable inhibition of angiogenesis at sub-
toxic levels. 
Previous studies indicate that borrelidin and BC194 are both potent inhibitors of 
angiogenesis (20,22,36). One potential explanation of the anti-angiogenic effect is that it 
is a direct consequence of the induction of the amino acid starvation response in 
endothelial cells, leading to their self-destruction through apoptosis. To test this 
hypothesis, we compared the ability of all three macrolides to inhibit HUVEC branching 
at sub-toxic concentrations in the endothelial tube formation assay (Figure 15A, B). 
Significant decreases in branch formation were observed for both borrelidin and BC194 
relative to uninhibited conditions at concentrations as low as 1 nM, which is 10- and 100- 
fold below the lowest borrelidin and BC194 concentrations demonstrated to induce eIF2α 
phosphorylation. In contrast, exposure to BC220 at these same concentrations had no 
effect on tube formation (Figure 15A). Borrelidin and BC194 thus exhibit comparable 
potencies in inhibiting angiogenesis, despite the fact that 10-100-fold higher 
 
Figure 14. BC220 does not induce amino acid starvation toxicity responses. 
(A-C) Western blots of cell extracts exposed to BC220 at the indicated concentrations using 
antibodies against phospho-eif2α and cleaved-caspase 3 (A). Thapsigargin (Th; 1 µg/ml) 
was used as a positive control for amino acid starvation. Protein values for phospho-eif2α 
(B) and cleaved-caspase 3 (C) were quantified relative to the β-tubulin loading control; 
mean ± SEM, n≥3, *p<0.0001 relative to 0 nM (one-way ANOVA, Tukey Test). 
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concentrations of BC194 are required to produce the levels of cellular toxicity seen with 




Figure 15. Borrelidin and BC194 exhibit comparable inhibition of angiogenesis at sub-
toxic levels in HUVEC tube formation assays. 
(A) Quantification of HUVEC branching at varying concentrations of borrelidin, BC194, and 
BC220. HUVECs were plated on Matrigel in full EGM-2 (2% FBS) media and exposed to the 
indicated concentrations of compounds. Cells were fixed after 4-8 h and stained with Oregon 
Green 488 Phalloidin. Numbers represent percentage of control (0 nM) samples, mean ± 
SEM, n=3 *p<0.05 relative to 0 nM (one-way ANOVA, Tukey Test for each compounds). 
(B) Representative images of HUVEC branches for section A. 
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We extended these results by using the chorioallantoic membrane (CAM) assay 
(Figure 16A, B), which monitors basal vessel formation in the fertilized chicken egg and 
thus more closely approximates in vivo angiogenesis, relative to the simple HUVEC tube 
formation assay. As shown in Figure 4A, recurring administration of borrelidin or BC194 
to CAMs at concentrations of 10 nM and 1 µM over a 72 h period inhibited basal vessel 
formation relative to the PBS control. Similar to the HUVEC tube formation assays, 
borrelidin and BC194 exhibited comparable potencies at concentrations in the range of 1-
10 nM.  At substantially higher concentrations (100 µM), necrosis was clearly evident in 
the borrelidin treated CAMs, but not those treated with BC194 (Figure 16B). These 
observations demonstrate that BC194 appears to retain all of the potency of borrelidin in 
the inhibition of angiogenesis, while exhibiting substantially less cytotoxicity. We 
 
Figure 16. Borrelidin and BC194 exhibit comparable inhibition of angiogenesis at sub-toxic 
levels in chorioallantoic membrane assays. 
(A) The effects of borrelidin (BN) and BC194 on in vivo angiogenesis in a CAM assay. Fertilized 
chicken embryos were cultured ex-ova for 10 days after which compounds at the indicated 
concentrations were applied to gelform sponges on the CAM. Images were taken daily over 72 h 
and quantified as the change in vascularity score over this entire period; mean ± SEM, n≥12, 
*p<0.05 relative to PBS (one-way ANOVA, Tukey Test). (B) Representative images of CAM 
over time for BN and BC194 at 100 µM. 
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conclude that the inhibition of angiogenesis by borrelidin is therefore not dependent on 
the induction of apoptosis in HUVECs, and is more likely to be linked to a TARS-
specific property that is distinct from induction of the AAS.    
 
 
Figure 17. Borrelidin and BC194 treatment influences cell migration and cell-cell contacts. 
(A) Representative images of HUVEC cells in the donut migration assay. Upper panels- Images 
of Hoechst 33342-labeled HUVEC cells 0, 5, and 24 h after removal of PDMS gasket. Lower 
panels - Images of cells outside the original PDMS gasket boundary after 5 and 24 h using cell 
subtraction. (B) Quantification of migrated cells exposed to 5 or 25 nM BC194 after 5 and 24 h 
in the donut assay. HUVEC monolayers were cultured overnight in a 2 mm diameter, circular 
gasket. The gasket was removed and the cells treated with media containing the indicated 
concentrations of compound. Images were taken after 5 and 24 h and the number of cells outside 
the original 2 mm diameter region were counted; mean ± SEM, n≥6, *p<0.01 relative to DMSO 
of same time point (one-way ANOVA, Tukey Test). (C) Image of cells at the leading edge of the 
migratory boundary after 24 h exposure to DMSO (left) or 25 nM BC194 (right).  
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In a previous study, exposure of HUVEC cultures to exogenous TARS in 
transwell migration assays was found to increase cell migration, an important component 
in angiogenesis (17).  These observations complemented an earlier study showing that 
borrelidin inhibits tumor cell migration (37). To explore this observation further, the 
effect of BC194 on cell migration was examined using a donut migration assay (Figure 
17A-C) (38). In this assay, endothelial cells are confined by a cloning ring on a 
fibronectin-coated dish, and then cells that migrate after ring removal are quantified by 
image subtraction (Figure 17A).  The number of migratory cells was significantly lower 
in cultures treated with 5 nM BC194 for 5 h and 25 nM BC194 for either 5 or 24 h, 
relative to untreated cells (Figure 17B). Interestingly, close inspection of the cells at the 
leading edge of each sample reveals a marked decrease in cell-cell contacts in samples 
exposed to DMSO relative to 25 nM BC194 (Figure 17C). These data suggest that the 
slow migration may be, in part, due to the retention of cell-cell adhesion molecules in 
BC194-treated cells. These observations demonstrate that for borrelidin and BC194, the 
inhibition of angiogenesis and the inhibition of migration are correlated to each other, but 
not to the ability to induce amino acid starvation and apoptosis.  
 
3.2.3 BC194 induces specific ectopic blood vessel formation in zebrafish without the 
developmental toxicity associated with borrelidin. 
Close inspection of the surface vessels proximal to the borrelidin or BC194 
applied to the CAM assay revealed several instances of abrupt directional changes during 
vessel migration (Figure 18A).  Moreover, these directional changes often came in sets of 
three, potentially corresponding to three cycles of compound addition and clearance over 
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the 72-hour period. An attractive hypothesis is that the macrolide compounds elicit their 
anti-angiogenic effects by confounding TARS-dependent vessel guidance signals, 
resulting in an irregular vascular architecture.  
In order to investigate the effects of anti-TARS macrolides on vessel development 
in a whole animal model, we exposed transgenic zebrafish embryos derived from the 
Tg(flk: eGFP) or Tg(flk: dsRed) lines at 13-15 h post fertilization (hpf) to a range of 
concentrations of borrelidin, BC194, and BC220. After 30 h of compound exposure (~48 
hpf), significant changes in gross morphology were observed in embryos exposed to 
borrelidin (left column) but not BC194 (middle column) or BC220 (right column) (Figure 
18B). A more quantitative assessment of treatment toxicity was obtained through 
measurements of body length (Figure 18C) and heart rate (Figure 18D). Significant intra-
group changes were observed for fish treated with either borrelidin or BC194, but not 
BC220. However, inter-group analyses revealed that reductions in heart rate and body 
length were more characteristic of borrelidin-treated than BC194-treated embryos.  
To assess the angiogenesis-related effects of these compounds, we screened for 
aberrancies in the development of trunk inter-segmental vessels (ISVs) by fluorescence 
microscopy following exposure to 5 µM concentrations of the macrolides (Figure 19A). 
Significant patterning defects were observed in response to either borrelidin or BC194 
treatment.  Ectopic branches were readily formed in the ISVs of embryos exposed to 5 
µM BC194 for 48 h (72 hpf), but not in those of borrelidin-treated embryos (Figure 19B). 
By contrast, the ISVs in borrelidin-exposed fish were often truncated or incomplete at 




Figure 18. Borrelidin and BC194 exhibit different effects on zebrafish toxicity. 
(A) Representative CAM images showing rapid changes in vessel directionality, indicated 
by black arrows, before and after 72 hour treatment with 1 µM borrelidin and BC194. (B) 
Whole body images of ~48 hpf zebrafish embryos treated with various concentrations of 
borrelidin, BC194, and BC220 for 24 h. The DMSO vehicle was standardized for each 
sample. (C, D) Histograms showing the effects of borrelidin, BC194, and BC220 exposure 
on zebrafish body length (C) and heart rate (D). Dechorionated embryos were incubated for 
24 hours in egg water containing the indicated compounds. Body length measurements 
were obtained by analysis of bright-field images using Spot v 5.1 software; mean ± SEM, 
n=11, *p<0.05 relative to 0 nM (one-way ANOVA, Tukey Test). Heart rates were 
determined using bright-field microscopy to count heart beats over 15 second intervals; 




Figure 19. Exposure to Borrelidin and BC194 results in vascular defects and mis-
patterning. 
(A) Representative confocal images (20x magnification) of zebrafish ISVs at 48 and 72 hpf. 
Zebrafish embryos were incubated in egg water at 25 °C until 8-12 somites of age. The 
embryos were then manually dechorionated and incubated in egg water containing the 
indicated compounds at 28.5°C until the images were taken. Calibration bar represents 100 
µm. (B, C) Quantification of ectopic branching (B) and aberrant patterning (C) of ISVs. 
Embryos were incubated with the indicated compounds (5 µM) or DMSO until images were 
taken by fluorescent microscopy at 48 and 72 hpf. Aberrant structures were then counted 
within a region encompassing 5 ISVs anterior and posterior from the end of the yolk 
extension; mean ± SEM, n≥8, #*p<0.0001 relative to DMSO at 48 and 72 hpf respectively 
(one-way ANOVA, Tukey Test). § Borrelidin-treated fish rarely survived to 72 hpf. 
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embryos were treated with either DMSO or BC220 (Figure 19A-C).   
One explanation for the diminished toxicity of BC194 relative to borrelidin is 
that, as seen with in animal cell culture, BC194 has a reduced ability to induce amino 
acid starvation in the context of a whole animal model. To test this hypothesis, 
quantitative real time PCR was performed on total RNA prepared from embryos treated 
with equivalent (5 µM) concentrations of borrelidin, BC194, and BC220, and the DMSO 
vehicle. The ATF4 target genes asns, gpt2, and eif4ebp1 served as AAS markers in this 
experiment (24). Consistent with our model, borrelidin caused a significant increase in 
the expression of the markers asns and gpt2 but not BC194 (Figure 20). This experiment 
demonstrates BC194’s induction of ectopic ISV formation in the zebrafish is not a direct 




Figure 20. The vascular defects and mis-patterning resulting from BC194 treatment 
is not due to the induction of amino acid starvation. 
RT-qPCR values for the expression amino acid starvation response genes asns, gpt2, and 
eif4ebp1. Dechorionated embryos (15 hpf) were incubated in egg water containing the 
indicated compounds for 24 hours. Total RNA was extracted by trizol/chloroform and the 
expression levels relative to actb were determined using the ΔΔCT method; mean ± SEM, 
n=3, ****p<0.0001 relative to DMSO (two-way ANOVA, Tukey Test).  
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In addition to faulty vessel patterning, a reduction in vessel lumen formation was 
also observed in embryos treated with either 5 µM borrelidin or BC194 for 24 h (48 hpf) 
and remained partially incomplete even at 72 hpf. This observation was confirmed by live 
videos of blood flow in trunk vessels of 72 hpf embryos treated with BC194 or DMSO. 
No restriction of blood flow was observed in ISVs of DMSO-treated fish (Video 1) 
consistent with fluorescent images showing well-defined lumens (Figure 21A). In 
contrast, several ISVs in embryos treated with 5 µM BC194 were non-functional in terms 
of blood flow (Video 2) and appeared to correspond to vessels associated with ectopic 




Figure 21. Treatment with BC194 inhibits blood-flow through zebrafish ISVs. 
(A, B) Still frame image from videos of trunk blood flow in 72 hpf zebrafish embryos (left) 
and fluorescence image of blood vessels (right) treated with DMSO (A) or 5 µM BC194 (B) 
for 48 h. Non-functioning lumens and ectopic branches are designated with black arrows and 
asterisks respectively. See also associated Videos 1 and 2. 
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3.2.4 The effects of borrelidin and derivatives on gene expression of endothelial cell 
migration associated genes.  
The results of the prior experiments argue that the faulty patterning and reduction 
in vessel lumen formation seen with BC194 in the zebrafish originate from a TARS 
function distinct from the canonical role in protein synthesis. To obtain further insights 
into the role of TARS in angiogenesis, we investigated the effects of borrelidin, BC194, 
and BC220 on the expression of tars, vegfaa, and the downstream Notch-reporter genes 
ephrinb2a and heyL, in the zebrafish that are either known to be or hypothesized to be 
 
 
Figure 22. Borrelidin and BC194 treatment affects gene expression. 
(A-D) RT-qPCR values for the expression of tars (A), vegfaa (B), ephrinb2a (C), and heyL 
(D) at 48 and 72 hpf. Dechorionated embryos (15 hpf) were incubated in egg water 
containing the indicated compounds. Total RNA was extracted by trizol/chloroform and the 
expression levels relative to actb were determined using the ΔΔCT method; mean ± SEM, 
n=3, #*p<0.05 relative to DMSO at 48 and 72 hpf respectively (one-way ANOVA, Tukey 
Test). § denotes that borrelidin-treated embryos rarely survived to 72 hpf and were not 
included in this figure.  
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related to vascular development and branching. Quantitative real time PCR (RT-qPCR) 
of total embryo RNA revealed significant increases in the expression of both tars and 
vegfaa (Figure 22A, B) mRNA after exposure for 24 hours with borrelidin (48 hpf) or 48 
hours with BC194 (72 hpf). No changes in gene expression were observed for embryos 
treated with either DMSO or BC220, consistent with our TARS-dependent nature of our 
current model for borrelidin and BC194 action. Interestingly, the notch reporter genes 
showed no change over any of the tested conditions (Figure 22C, D). 
 
3.3 Discussion 
Natural product and synthetic inhibitors have been identified for many ARSs, and 
readily exploited to generate anti-microbial infectives (39,40), immunosuppressive agents 
(24,41), and potential modulators of cancer metastasis (42).  However, many natural 
compounds that target ARSs have a very narrow therapeutic index, dramatically limiting 
their clinical usefulness. The toxicity seen in many cases may reflect the acute sensitivity 
of animal cells to the inhibition of protein synthesis, which can arrest the cell cycle and 
elicit apoptosis (24,33). 
 Borrelidin’s pleiotropic effects on mammalian cell physiology have been 
appreciated for decades, but the molecular basis of its action or that of related compounds 
has been poorly understood (20). Here, a chemical and structural biology approach was 
used to compare the effects of borrelidin and two different derivatives, and gain insights 
into their ability to inhibit angiogenesis. Significantly, the cytotoxicity of borrelidin was 
found to originate from its induction of amino acid starvation, which leads to cell cycle 
arrest and apoptosis. The ability of borrelidin to induce amino acid starvation in yeast 
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was reported earlier (32). In animal cells, amino acid starvation induces the expression of 
the CCAAT/enhancer binding protein homology binding protein (CHOP), a transcription 
factor that stimulates apoptosis after prolonged nutritional deprivation (43). Not 
surprisingly, borrelidin is a potent inducer of apoptosis in acute lymphoblastic leukemia 
cells (44).  These studies therefore support a strong linkage between the ability of a given 
aminoacyl-tRNA synthetase inhibitor to induce the amino acid starvation response and its 
potency with respect to apoptosis and cell killing. Conversely, the inhibition of 
angiogenesis was observed at sub-toxic concentrations for both borrelidin and BC194, 
suggesting that the compounds’ inhibition of angiogenesis is mediated through a 
mechanism distinct from the induction of amino acid starvation. 
  
3.3.1 The greater toxicity exhibited by borrelidin relative to BC194 is due to its 
decreased susceptibility to threonine competition. 
The major structural difference between the two TARS macrolide complexes is 
that significantly weaker interactions with critical residues constituting the threonine 
binding pocket (45,46) were observed in the BC194 complex (Chapter 2).  Despite this 
structural change, BC194’s potency as an inhibitor of angiogenesis is undiminished. One 
hypothesis is that the inhibition of angiogenesis depends on the ability of borrelidin and 
BC194 to stabilize a TARS conformation that is distinct from unliganded and substrate 
bound states (Chapter 2, Figure 9). Such a model would be consistent with the 
observation that the stimulation of angiogenesis depends on the structural integrity of the 
catalytic domain, and its potential to associate with additional protein partners (see 
Appendix I for investigations of TARS binding partners). Initially, however, this model 
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may appear contradictory, given that BC194’s weaker interaction with the TARS enzyme 
would also be expected to disrupt its ability to inhibit angiogenesis as well. The 
resistance conferred by L567V TARS against BC194’s anti-angiogenic effects in CAM 
assays argues against a second borrelidin binding site within the TARS enzyme (21). 
However, the two-part binding mechanism of borrelidin and its related compounds 
presented in Chapter 2 may provide an alternative explanation.  
Upon first encounter BC194 forms a weaker complex with TARS relative to 
borrelidin, accounting for its increased susceptibility to threonine competition (Figure 13 
G, H). However, as demonstrated by enzymatic assays (Chapter 2, section 2.2.2), the 
binding affinity for the second, tighter interaction between TARS and either inhibitor is 
nearly identical. As such, compound toxicity appears to be associated with the weak 
encounter complex while the anti-angiogenic effects are related to the tight-binding 
mode. Considering also that TARS appears to mediate angiogenesis extracellularly while 
performing aminoacylation within the cell, the concentrations of threonine must be 
considered in both compartments (21). Notably, intracellular concentrations of threonine 
are significantly higher than those outside the cell, indicating that competition between 
the amino acid and the compounds would be reduced in the regulation of angiogenesis in 
comparison to aminoacylation (47). As an alternative mechanism, full incorporation of 
borrelidin or BC194 into the TARS active site is characterized by a very slow off rate 
(19). Moreover, despite the increased susceptibility of BC194 to threonine competition 
relative to borrelidin in the compound’s initial encounter with TARS, borrelidin and 
BC194 exhibit nearly identical final values for Ki
app. Therefore, both inhibitors may 
eventually proceed to a tightly bound complex but the greater activation energy 
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associated with BC194 binding at equimolar concentrations of threonine will reduce its 
rate of complex formation relative to that of borrelidin (48). Under these circumstances, 
compensatory mechanisms, such as the synthesis of new TARS, may be able to rescue 
the cell from the toxicity associated with the slower-binding BC194 but not borrelidin. 
However, as both compounds eventually develop a full set of interactions with the TARS 
active site, they would still be able to induce the necessary changes to inhibit 
angiogenesis.  
 
3.3.2 Borrelidin compounds influence blood vessel maturation and migration in 
zebrafish. 
A major finding of this study is that the reduction of TARS activity via borrelidin 
or BC194 administration produced phenotypes associated with incomplete vessel 
development, increased ectopic branching, and decreased vessel lumens (Figure 19, 21 
Videos 1, 2).  This represents the first demonstration of a role for TARS as a pro-
angiogenic factor in a whole organism model. Yet treatment with BC194 also increased 
expression of TARS (Figure 22A), an observation reminiscent of the response of CHO 
cells to persistent exposure to borrelidin (49). In view of the relatively high macrolide 
concentrations employed (i.e. several orders of magnitude over the apparent Ki), the 
increased TARS protein levels resulting from BC194 administration might effectively be 
masked by the stoichiometric formation of TARS-BC194 complexes, which are 
characterized by very slow off rates (19). Alternatively, the disruption in TARS levels 
resulting from BC194 treatment could alter a TARS-dependent concentration gradient 
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that is necessary for proper guidance and patterning of the developing vasculature 
(17,50,51).  
Along these lines, endothelial cells treated with BC194 showed a higher degree of 
cell-cell contacts relative to controls, even at the leading edge of a migratory boundary 
(Figure 17C). Weakened cell-cell contacts have been proposed to be an important 
component of angiogenesis (52). Inhibition of tyrosine phosphorylation on VE-cadherin, 
which alters cell-cell interactions, decreases VEGF-mediated migration and angiogenesis 
in cell culture (53). Furthermore, certain models of lumenogenesis involve the strictly 
regulated disruption of contacts between endothelial cells of the developing vessel (54). 
Borrelidin and related macrolide compounds may act to disrupt TARS-mediated 
regulation of cell-adhesion proteins, thereby preventing both migration and proper 
vascular development (37). The availability of specific inhibitory compounds and TARS 
variants that ablate its angiogenic function should prove to be valuable tools to critically 
test this hypothesis. The actions of borrelidin and BC194 can be ablated by single residue 
substitutions in the E. coli ThrRS (19), and TARS active sites (17), respectively (17,19), 
arguing against the previous suggestion that borrelidin binding to other secondary targets 
is physiologically significant in the inhibition of angiogenesis (36). Structural analysis of 
the ThrRS-borrelidin complex (see Chapter 2, section 2.2.3) suggests that the inhibition 
mechanisms of borrelidin and BC194 involve occlusion of the binding sites for one or 
more of the canonical aminoacylation substrates (55). Borrelidin is a slow tight binding 
inhibitor that competes with amino acid substrate binding, accounting for the potent 
stimulation of amino acid starvation (19).  
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Unfortunately, the above observations do not provide a direct mechanism through 
which TARS and borrelidin-based compounds influence angiogenesis. Early reports 
suggested that apoptosis of endothelial cells could contribute to the reduction in 
angiogenesis (56). While the impact of this phenomenon cannot be completely ruled out, 
it is complicated by a lack of specificity to a single cell type (23,57). Furthermore, the 
above data clearly indicate that anti-angiogenic effects of the compounds are observable 
at concentrations that do not induce amino acid starvation, suggesting that another 
mechanism is required to explain the relationship between TARS and borrelidin in 
angiogenesis.  
 
3.4 Experimental Procedures 
3.4.1 Cell Culture and Reagents 
Human umbilical endothelial cells (HUVECs) were maintained in Clonetics 
EGM®-2 complete media (Lonza) and used between passages 5 to 8. Borrelidin and 
BC194 were obtained from Biotica (now Isomerase Therapeutics Ltd (Cambridge, UK)).  
 
3.4.2 Flow Cytometry 
HUVECs were plated onto 10 cm dishes and serum starved in 0.5% FBS EGM®-
2 media for 24 h.  Cells were pre-treated with 10 nM borrelidin or BC194 for 6 h. To 
assess the serum-induced cell cycle entry, full serum media (EGM®-2 complete media) 
was added at staggered times, such that all samples were collected simultaneously for the 
8 h, 16 h and 24 h time points.  Cells were trypsinized, washed and fixed in 80% ethanol, 
washed in 2% BSA and then incubated with a solution containing 10 μg/ml propidium 
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iodide (PI) and 250 μg/ml RNAse A for 16 h as in (58).  Analysis of the PI signal (620 
nm) was performed on an EPICS XL four-color analytical flow cytometer coupled with 
EXPO32 ADC software.   
 
3.4.3 Endothelial Cell Proliferation Assay 
  The MTT-based alamarBlue® (Invitrogen) reagent was used to assess cell 
proliferation (59). HUVECs were seeded in a 96-well dish (1x103 cells/well) and grown 
for 48 h in EGM®-2 media. Cells were incubated with borrelidin or BC194 (0.1-1000 
nM) as indicated; media alone served as the control. After 48 h in culture, 10 µl/well 
premixed alamarBlue® was added and after 3 h at 37ºC the amount of reduced 
alamarBlue® was quantified by fluorescence (excitation at 530 nm, emission at 590 nm) 
on a microplate reader (Synergy™ HT, BioTek). Values were graphed as % Control 
compared with media alone. 
 
3.4.4 Western Blotting 
 HUVEC cells were seeded into 6-well dishes and incubated at 37 °C in EGM-2 
media with 2% FBS. When cells had reached 95-100% confluence the media was 
exchanged and the cultures were incubated with various concentrations of borrelidin, 
BC194, BC220, and DMSO for 24 h. For threonine rescue experiments, 2.5 to 10 mM 
threonine was also added to the cultures. Cell monolayers were washed with PBS and 
harvested using CellLyticTM M cell lysis reagent (Sigma) supplemented with complete 
Mini protease inhibitor tablets (Roche) according to the manufacturer’s instructions. For 
the thapsigargin control, the media was exchanged at the same time as for the borrelidin 
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compounds, but 1 µg/ml thapsigargin (Sigma) was not added until 1 h before harvesting. 
Lysate protein concentrations were determined using Quick StartTM Bradford Reagent 
(Bio-Rad) and stored at -80 °C until used. Lysates were resolved by 10% SDS-PAGE and 
transferred to nitrocellulose membranes for Western blot analysis. Primary antibodies for 
phospo-eif2α, cleaved-caspase 3, and β-tubulin were purchased from Cell Signaling and 
used at 1:1000. The secondary antibody, HRP-goat-anti-rabbit IgG (Santa Cruz), was 
used at 1:5000. Bands were detected by X-ray film or the VersaDoc 4000 MP (BioRad) 
using Pierce ECL blotting substrate or Supersignal West Femto reagent (Pierce) as 
needed. Densitometric values were determined using ImageJ software lane analysis tools 
(http://imagej.nih.gov/ij/; W. Rasband, NIH).  
 
3.4.5 In vitro Tube Formation Assay 
 Tube formation assays were performed as previously described (17,60). Briefly 
HUVEC cells were cultured until 95-100% confluent and seeded in to 48-well plates 
coated with MatrigelTM (BD Biosciences). Cells were incubated at 37 °C in EGM®-2 
media (Lonza) with 2% FBS and various concentrations of borrelidin, BC194, or BC220 
for 4 to 8 h. Cells were fixed with 10% neutral buffered formalin, stained with Oregon 
Green 488 phalloidin (Molecular Probes), and imaged via fluorescence microscopy. Tube 
structures were quantified using the Simple Neurite Tracer plug-in on ImageJ software 
(NIH). 
 
3.4.6 Chick Chorioallantoic Membrane Assay 
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 CAM assays were performed as previously described (17). Briefly, embryos from 
fertilized chicken eggs (Sunrise Farms, Catskill, NY) were cultured ex-ova in 10 cm2 
tissue culture dishes at 37°C until developmental day 10.  Surgical sponges (Surgifoam) 
approximately 1 mm3 were then arranged within the outer third of the membrane 
avoiding major vessels. Compounds in 10 µl volumes were applied directly to the 
sponges at 24 h intervals over the course of 72 h. Images were taken daily using a Leica 
MZ6 stereomicroscope and scored using modified Intensity Scoring described previously 
(61).  
 
3.4.7 Cell Migration Assay 
 The donut cell migration assay was performed as previously described (38). 
Briefly, polydimethylsiloxane (PDMS) donut-shaped gaskets were placed on fibronectin 
(BD Biosciences) -coated glass coverslips to form a 2mm-diameter culture well into 
which 8x103 HUVECs were seeded and allowed to adhere overnight. After removal of 
the gaskets, the circular HUVEC monolayers were washed twice with complete media to 
remove non-adherent cells, nuclei were labeled by incubation with Hoechst 33342 for 15 
min, and the monolayers were re-fed with complete media containing vehicle (DMSO) or 
BC194 at the indicated concentrations. Images of the circular monolayers were acquired 
after re-feeding and at the indicated times and image pairs were analyzed using a custom 
ImageJ macro to calculate the number of cells at each time point that have migrated 
beyond the original monolayer. 
 
3.4.8 Zebrafish Handling and Treatments 
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 This project utilized the transgenic lines Tg(flk1:eGFP) and Tg(flk1:dsRed) in 
which eGFP and dsRed expression respectively are controlled by the flk1 promoter. The 
Tg(flk1:eGFP) or Tg(flk1:dsRed) fish lines exhibit endothelial specific fluorescence 
starting at 48 and 72 hpf respectively. Due to its earlier expression the Tg(flk1:eGFP) line 
was used for all 48 hpf fluorescence images; all other applications used the 
Tg(flk1:dsRed) line.  Zebrafish were bred and maintained in accordance with approved 
University of Vermont IACUC standards for vertebrate animals and staged as previously 
described (62). Fertilized embryos were transferred to glass dishes and allowed to 
develop at 25°C until 8 to 12 somites in age. The fish were manually dechorionated and 
transferred to 24 well dishes containing 1 ml of egg water treated with 0.003% 1-phenyl 
2-thiourea to inhibit pigment, and various concentrations of borrelidin, BC194, BC220, 
or DMSO (vehicle control) and incubated at 28.5 °C for downstream analyses. In all 
conditions DMSO was standardized to match the highest concentration for each 
compound. Dead and dying embryos were removed and the media exchanged for fresh 
egg water and compounds every 24 h.   
 
3.4.9 Quantitative Assessment of Toxicity 
 Heart rate and body length data were acquired after the first 24 h of compound 
exposure using the Tg(flk1:dsRed) line and bright field microscopy. Heart rates were 
counted over 15 sec and converted to beats per min. For body length, images were taken 
using a Spot camera attached to a Nikon SMZ800 dissecting microscope at a 3X 
objective and analyzed with Spot v 5.1 software. 
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3.4.10 Confocal Imaging 
 Embryos were live imaged with a 20x objective using step sizes of 2 µm after 
mounting in 0.5% low melt agarose on glass bottom dishes (Mat-Tek) on a Nikon Eclipse 
Ti inverted microscope. Stacks were subjected to a kalman stack filter in ImageJ and are 
presented as maximum intensity projections. Images were processed with Adobe 
Photoshop for brightness and contrast. For quantification of ISV ectopic branches, 
images were taken using an Olympus IX71 inverted fluorescence microscope. Abnormal 
branches and vessel defects associated with ISVs were counted within a region 
encompassing five ISVs anterior and posterior to the end of the yolk extension. 
 
3.4.11 Live-Imaging of Zebrafish Blood Flow 
 Zebrafish embryos (72 hpf) of the Tg(flk:dsRed) line were treated for 48 hours 
with DMSO or 5 µM BC194 as described above. Fluorescence images were acquired on 
a Nikon TE2000-PFS epifluorescence microscope through a 20X Plan-Fluor objective 
using wavelength-appropriate filters (Chroma Technologies) with a Clara CCD camera 
(Andor, Inc.). Acquisition was controlled using Nikon Elements software and images 
were adjusted for presentation using Elements or Fiji/ImageJ (http://imagej.nih.gov/ij/; 
W. Rasband, NIH). 
 
3.4.12 RNA Expression in Zebrafish 
 Following manual dechorionation embryos (~8 somites; Tg(flk:dsRed)) were 
incubated for 24 or 48 h in egg water containing varying concentrations of compounds at 
28.5 °C. The fish were subsequently transferred in minimum volume to 1.5 mL 
 116 
microfuge tubes and then total RNA was obtained using Trizol:chloroform (Invitrogen). 
First strand cDNA was synthesized using Superscript II RT-PCR technology (Invitrogen) 
according to manufacturer’s instructions. RT-qPCR was performed using an ABI prism 
7700 Sequence Detection System (Applied Biosystems) and TaqMan® Assay primer 
pairs (Applied Biosystems) for tars, vegfaa, heyL, ephrinb2a, and act1a. Relative mRNA 
expression was determined using a comparative CT (ΔΔCT) method with act1b as an 
endogenous control.   
 
3.4.13 Statistical Analysis 
  All experiments were repeated at least 3 times; n values are reported in the 
corresponding figure legend. Values are presented as means ± SEM. Data were analyzed 
by one- or two-way ANOVA and Tukey or Sidak test as indicated using GraphPad Prism 
v6 software. Significance was defined as P < 0.05.  
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CHAPTER 4: INVESTIGATING THE MECHANISMS OF THREONYL-tRNA 
SYNTHETASE’S ANGIOGENIC FUNCTIONS 
 
4.1. Introduction 
Angiogenesis is a multifaceted process critical to the formation and metastatic 
progression of many human cancers (1). Many of the most prominent angiogenic factors, 
such as vascular endothelial growth factor (VEGF), have been investigated as potential 
targets for anti-metastatic therapeutics with several drugs already approved for use (2,3). 
Unfortunately, the benefits of these therapies are often temporary owing to adaptive 
responses by the target tissue (4). Therefore, the identification of novel angiogenic factors 
and small molecule inhibitors would be beneficial for the development of new 
diagnostics and combinatorial cancer therapies.  
The pro-angiogenic functions of TARS were recently demonstrated through 
studies led by Tamara Williams in the lab of Karen Lounsbury for which we provided 
essential enzymes and compounds for testing (5). The addition of exogenous TARS was 
found to stimulate human umbilical vein endothelial cell (HUVEC) tube formation and 
vascular growth in chorioallantoic membrane (CAM) assays. As angiogenesis is 
associated with both proliferation and migration of endothelial cells, the effect of TARS 
on these two aspects were subsequently investigated.  Specifically, the addition of TARS 
to the lower chamber in a transwell migration assay enhanced the movement endothelial 
cells from the upper level relative to media alone; however, the enzyme had no effect on 
the proliferation of these cells as determined by an alamarBlue® assay. In all cases, the 
angiogenesis-associated responses were subject to inhibition by subtoxic doses of the 
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borrelidin derivative, BC194. Interestingly, the borrelidin-resistant TARS mutant, L567V 
TARS (See Chapter 2, 2.2.5) also exhibited comparable angiogenic activity to the 
wildtype enzyme but did not respond to BC194 inhibition, suggesting that the effects of 
BC194 were mediated directly through the compound’s interactions with TARS. In 
contrast, exposure of CAM assays to the control ARS, leucyl-tRNA synthetase (LARS), 
had no effect on vessel formation, which indicates that this secondary function is not 
shared by ARSs in general. Given that all of the above observations were in response to 
extracellular TARS, the ability of HUVEC cultures to secrete the ARS was also 
examined. Notably, the usually cytoplasmic TARS was identified in conditioned media 
from endothelial cells treated with TNFα or VEGF (5). This mechanism is reminiscent of 
the angiogenesis-associated ARSs tyrosyl- (YARS) and tryptophanyl- (WARS) tRNA 
synthetases, which are also secreted from the cell in response to apoptotic or interferon-γ 
signaling respectively (6,7). However, the exact mechanism through which extracellular 
TARS regulates this process remains unclear.  
Investigations of the angiogenesis-inhibitory effects of borrelidin provide some 
clues to the mechanism of TARS-mediated angiogenesis. Early reports attributed 
borrelidin’s inhibition of endothelial cells to the induction of apoptosis (8). However, 
similar mechanisms have also been proposed for the apparent anti-tumor activities of 
borrelidin observed in both breast cancer and leukemia cells (9,10).  Therefore, these 
apoptotic effects appear to be related to the general borrelidin toxicity responses 
demonstrated in Chapter 3. Alternatively, the anti-angiogenic properties could be 
specifically associated with defects in vessel patterning and maturation as demonstrated 
by the zebrafish studies. The observation that the L567V point mutation is able to confer 
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resistance to the compound in both aminoacylation (see Chapter 2, section 2.2.5) and 
angiogenesis procedures implicates TARS as the target for macrolide induced anti-
angiogenic responses (5). Therefore, better understanding of TARS’s specific effect on 
angiogenesis would provide opportunities for its use as a target of angiogenic based 
therapies.  
The data presented in Chapter 3 revealed that treatment of zebrafish with BC194 
induces defects in vessel patterning that are distinct from the toxicity responses 
associated with borrelidin exposure. The lack of alternative targets for borrelidin coupled 
with the resistance conferred by the L567V TARS mutation in in vitro assays suggests 
that the compounds mediate these effects through direct inhibition of TARS’s secondary 
function (5). Knockdown of TARS in zebrafish using a splice-altering morpholino 
produces similar vascular defects to borrelidin and BC194 inhibition, confirming a role 
for TARS in vessel guidance in the developing zebrafish embryo. However, the 
mechanisms that control these effects remain a mystery. Using various point and 
truncation mutations, TARS’s stimulation of angiogenesis is shown to be independent of 
its aminoacylation function but requires a full-length protein. Finally, mutations that 
mimic borrelidin-induced conformational changes are shown to eliminate TARS’s 
angiogenic potential and strongly implicate the importance of protein-protein interactions 
in this secondary function. 
 
4.2 Results 
4.2.1 Knockdown of threonyl-tRNA synthetase expression in zebrafish morphants 
produces a vascular phenotype 
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The zebrafish data from Chapter 3 clearly demonstrate distinct toxicity and anti-
angiogenic effects in response to borrelidin and BC194 treatment. Furthermore, the 
angiogenesis specific results appear to be related to the induction of abnormal vessel 
 
Figure 23. Depletion of TARS elicits intermediate toxicity relative to borrelidin and 
BC194 inhibtion. 
(A) RT-PCR to validate the reduction of TARS levels by morpholino injection. Whole fish 
mRNA (72 hpf) was trizol/chloroform extracted and mRNA sequences amplified by RT-PCR 
with gene specific primers. The TARS (338 bp) and EF1α  control amplicons were run on 
1.5% agarose to show differences in relative intensities between uninjected controls (UIC) 
and morphant fish. (B) Whole body images of UIC and TARS morphant fish at 48 and 72 
hpf. 
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patterning. However, the mechanism behind these patterning defects remains to be 
determined. Specifically, TARS has been shown to be the target of borrelidin in in vitro 
assays but has not been proven to be responsible for the effects in zebrafish (5). To 
confirm that the vessel patterning effects of borrelidin and BC194 in zebrafish in Chapter 
3 are a direct consequence of action on TARS, the levels of functional TARS were 
reduced using a splice altering, antisense morpholino oligonucleotide (MO) (Figure 23A). 
 
Figure 24. TARS is involved in vascular development in the zebrafish. 
(A) Representative confocal images (20x magnification) of control and TARS morphant 
zebrafish ISVs at 48 and 72 hpf. Embryos were injected with a TARS morpholino (1.5 
µM) at the one to four cell stage. Fish were manually dechorionated at 24 hpf and 
imaged at 48 and 72 hpf. Arrows and asterisks denote the location of ectopic branches 
and missing/incomplete vessels respectively. (B, C) Quantification of ectopic branching 
(B) and missing/incomplete ISVs (C) from control and morphant zebrafish within a 
region encompassing five ISVs anterior and posterior to the yolk extension ; mean ± 
SEM, n≥29, #*p<0.0001 relative to uninjected controls at 48 and 72 hpf respectively 
(one-way ANOVA, Tukey Test).    
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Consistent with the hypothesis that TARS was responsible for the vascular effects of the 
borrelidin compounds, morphant fish developed with significantly more ectopic branches 
and incomplete vessels than the uninjected controls (Figure 24A-C). The severe 
morphological defects associated with borrelidin toxicity (Figure 23B) were not seen in 
the TARS morphant fish, but their phenotypes exhibited characteristics that were 
intermediate with respect to borrelidin and BC194 treatments. These results demonstrate 
that vascular development in the zebrafish is highly sensitive to alterations in the activity 
of TARS, induced either as a result of chemical inhibition or altered gene expression. 
Additionally, these data provide strong evidence that the vascular effects of the borrelidin 
and BC194 are mediated specifically through the inhibition of TARS.  
 
4.2.2 Necessary components of threonyl-tRNA synthetase-mediated angiogenesis 
 Consistent with previous reports, Chapter 3 demonstrated a clear role of TARS 
in angiogenesis (5). This function was further characterized in investigations of borrelidin 
and its derivatives. Specifically, the fact that the L567V point mutation in TARS was 
found to confer resistance to these compounds coupled with the recapitulation of 
borrelidin and BC194 treatment effects in fish through knockdown of TARS indicates 
that the effects of these compounds on angiogenesis must occur through modification of 
TARS’s functions (5). Furthermore, these effects can be separated from amino acid 
starvation, and would suggest that TARS functions through a more direct mechanism. 




To better understand the features of TARS involved in its secondary function, the 
angiogenic potentials of various TARS constructs (Figure 25) were investigated using 
HUVEC tube-formation assays. Unless noted otherwise, the catalytic activity for all 
constructs were determined by the aminoacylation assay and the resulting rates reported 
in Tables 3 and 4. As a baseline the pro-angiogenic TARS and non-angiogenic LARS 
were tested (Figures 26A-C). Similar to earlier reports, WT TARS significantly increased 
 
 
Figure 25. Linear schematics of TARS protein constructs. 
Linear schematics showing the TARS domains as they appear in the various protein 
constructs, specifically TGS (N1) (Purple), Editing (N2) (Red), catalytic (green), and anti-
codon binding (ACBD) (Blue) domains. Amino acid numbers and point mutation locations 
are indicated in the figure. 
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tube-formation of endothelial cells relative to untreated cultures (Figure 26A). 
Surprisingly, the control ARS, LARS, exhibited a minor reduction of tube formation, 
although the cause of this effect remains unknown. It should also be noted that LARS 
activity was determined as the rate of adenylate formation (using AMP formation as the 
 
 
Figure 26. Characterizing the angiogenic potential of TARS and related protein 
constructs. 
(A) Quantification of HUVEC branching in response to WT TARS, R442A TARS, Ec ThrRS, 
N1-TARS, ΔN1N2-TARS, and LARS exposure. HUVECs were plated on Matrigel in 10% 
EGM-2 (0.2% FBS) media and exposed to 100 nM of the indicated constructs. Cells were fixed 
after 4-8 h and stained with Oregon Green 488 Phalloidin. Numbers represent percentage of 
control (0 nM) samples, mean ± SEM, n=3 *,**, and **** correspond to p<0.05, 0.01, and 
0.0001 respectively relative to the media control (one-way ANOVA, Tukey Test). (B-D) 
Activity data for WT TARS, Ec ThrRS, R442A TARS, LARS and buffer control. WT TARS 
(B, D), Ec ThrRS (B) and R442A TARS (C) were determined as formation of Thr-tRNAThr per 
active site per minute; LARS was determined as AMP per LARS per minute. WT TARS was 
included in both graphs for comparative purposes; mean ± S.D.; n=3 (n=1 for Ec ThrRS).  
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readout) due to the lack of a viable tRNALeu purification protocol. Effectively this 
reaction measures the rate of formation and subsequent breakdown of the leucyl-
adenylate intermediate, which occurs slowly in absence of tRNALeu. While the acquired 
rate data cannot be directly compared to the aminoacylation rate data of the other 
constructs they clearly demonstrate that the negative control enzyme used in the tube-
formation assays was active for aminoacylation, its primary function. 
  
 
4.2.3 TARS-mediated angiogenesis is independent of aminoacylation activity 
Chapter 3 demonstrated that the toxicity effects of borrelidin and related 
compounds were the result of amino acid starvation from loss of aminoacylation activity. 
Conversely, the effects of angiogenesis were observed at sub-toxic concentrations of the 
drug. Together these data appear to indicate that TARS’s angiogenesis function is not 
dependent on aminoacylation. However, there is still a possibility that angiogenesis is 
more sensitive to a reduction of aminoacylation or that aminoacylation is one of several 
contributing factors. To confirm that angiogenesis was separate from the aminoacylation 
function of TARS, HUVEC tube-formation assays were performed using the R442A 
TARS. Arginine 442 (R363 in E. coli) forms key stabilization interactions with the 
Table 3. Aminoacylation activity data for various protein constructs 
Construct Activity (min-1) % Activity* 
WT TARS 3.325 ± 0.2083 100 
R442A TARS Below detectable limit -- 
Ec ThrRS 55.30 ± 5.594 1663 
LARS‡ 0.1140 ± 0.007845 n/a 
    *Relative to WT TARS 
       ‡ LARS activity was measured as AMP formation and is not directly 
       comparable to aminoacylation data 
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threonyl-adenylate and its mutations would be predicted to eliminate all aspects of TARS 
aminoacylation function (11). Consistent with this hypothesis, R442A TARS exhibited 
no adenylate formation (data not shown) or aminoacylation activity (Figure 26D; Table 
3). Despite this lack of catalytic activity, treatment of HUVEC cells with R442A TARS 
was found to significantly increase tube formation relative to the buffer control (Figure 
26A). Moreover, these results were comparable to those received for WT TARS.  
The angiogenic potential of R442A TARS was further supported through 
investigations by Dr. Tamara Williams using the in vivo chorioallantoic membrane assay. 
The addition of 1 μM R442A TARS soaked sponges to the membrane surface of chicken 
embryos stimulated the growth of surface vessels towards the sponge significantly more 
than PBS controls, much like has been previously observed with WT TARS (Figure 27). 
Similar results were not obtained with LARS, again suggesting this effect was not a 
general function of ARSs. The retention of angiogenic activity in R442A TARS clearly 
demonstrates that TARS aminoacylation function is not required for angiogenesis. As a 
side note, co-treatment of cells with 1 μM R442A TARS and 1 μM BC194 (a non-toxic 
concentration in CAM assays) attenuated R442A TARS-mediated angiogenesis. These 
data further support the findings in Chapter 3 that indicate separate inhibitory 
mechanisms for borrelidin-derivatives against TARS aminoacylation and angiogenesis 
activities. Therefore, these findings implicate borrelidin-mediated conformational 
changes as the cause of its anti-angiogenic activity and will be further investigated in 




4.2.4 TARS-mediated angiogenesis requires full-length constructs 
 As indicated in Chapter 1, section 1.6.4, all other ARSs possessing angiogenic 
functions do so through mechanisms requiring an appended domain or sequence 
(reviewed in Chapter 1). While no specific domain has been directly associated with 
TARS, it does contain an N-terminal 82 amino acid extension predicted to be 
unstructured followed by an N-terminal ubiquitin like domain of unknown function, 
known as the TGS domain. The TGS domain structure is conserved from bacteria to 
humans despite very different sequences. Conversely, the amino acid extension appears 
to have originated during eukaryotic evolution and is not found in prokaryotic versions of 
the enzyme. As such, it may be possible that this N-terminal region, known as the N1-
 
Figure 27. Characterizing the angiogenic potential of TARS and related protein 
constructs in chorioallantoic membrane assays. 
The effects of 1 μM R442A TARS with and without 1 μM BC194 and LARS on in vivo 
angiogenesis in a CAM assay. Fertilized chicken embryos were cultured ex-ova for 10 days 
after which compounds at the indicated concentrations were applied to gelform sponges on 
the CAM. Images were taken daily over 72 h and quantified as the change in vascularity 
score over this entire period; mean ± SEM, n≥12, ****p<0.0001 relative to PBS (one-way 
ANOVA, Tukey Test). Data were kindly provided by Drs. Tamara Williams and Karen 
Lounsbury.  
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domain, is important for the TARS’s angiogenic function. Therefore, the importance of 
both domains was investigated using the HUVEC tube formation assay with the isolated 
N1-TARS (TGS domain and the 82 amino acid extension), the ΔN1N2-TARS (isolated 
aminoacylation and anti-codon binding domains), and the Ec ThrRS constructs.  
 As the N-terminal 82 amino acid extension in only found in eukaryotic versions 
of the enzyme, the necessity of this domain was investigated using Ec ThrRS. Like other 
constructs, Ec ThrRS’s aminoacylation activity was investigated (Figure 26B). 
Interestingly, treatment of HUVEC cultures with the E. coli enzyme exhibited 
comparable stimulation of angiogenesis to human TARS (Figure 26A), indicating that the 
N-terminal extension is not required for TARS-mediated angiogenesis (at least once 
extracellular). Conversely, exposure of HUVECS to N1-TARS had no significant effect 
on tube-formation relative to the negative, buffer control but was significantly lower in 
comparison to full-length TARS (Figure 26A). As such these data would suggest that the 
N1-domain alone is not capable of stimulating angiogenesis. This is not completely 
surprising as Chapter 1 clearly demonstrated that borrelidin interacts with the TARS 
catalytic domain likely implicating that this domain is essential for angiogenic function. 
Therefore, the ability of ΔN1N2-TARS, which only possesses the isolated catalytic and 
anticodon-binding domains, to induce angiogenesis was investigated. Interestingly, 
treatment with the ΔN1N2-TARS construct produced significantly less tube structures 
than both the negative control and full-length TARS (Figure 26A), suggesting that 
ΔN1N2-TARS may even be inhibitory towards angiogenesis. Together, these data 
suggest that the entire TARS protein is required for the extracellular stimulation of 
angiogenesis with the exception of the eukaryotic, N-terminal extension. 
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4.2.5 Mutants that mimic the borrelidin-bound conformation eliminate TARS-
angiogenic activity 
The clear separation of aminoacylation and angiogenesis functions in TARS by 
experiments in Chapter 3 and with R442A TARS above led to the hypothesis that the 
anti-angiogenic properties of borrelidin-related compounds are due to their ability to 
stabilize a non-permissive conformation of the enzyme. In support of this mechanism, 
intrinsic tryptophan fluorescence studies demonstrate that the binding of borrelidin 
induces conformational changes within the TARS structure (also shown in (12)) 
suggesting that the anti-angiogenic properties of the compound could function through 
the disruption of TARS-protein interactions. Additionally, our crystallographic data (see 
Chapter 2) show the extrusion of a surface helix in the TARS aminoacylation domain by 
14° in both the borrelidin and BC194 bound complexes and agrees with our tube 
formation and CAM data that suggest similar anti-angiogenic potential for both 
compounds. To confirm the importance of this helix for TARS-mediated angiogenesis, 
the point mutations Q566W TARS and A538W TARS were generated because they were 
predicted by molecular modeling programs to mimic the borrelidin-bound conformation 
(Figure 28A) (13). Initial activity investigations revealed that Q566W TARS possessed 
aminoacylation activity greater than WT TARS (Figure 28B; Table 4) while A538W 
TARS was inactive in active site titration assays and was not investigated for 
aminoacylation activity. Interestingly, neither mutant increased tube formation relative to 
the buffer control, suggesting that this conformational change alone is enough to inhibit 




Figure 28. The effects of borrelidin-conformation mimetic mutations on TARS-mediated 
angiogensis. 
(A)  Schematic of the borrelidin-induced conformational change in the TARS active site. 
Borrelidin (BN, orange) binding opens up a region at the edge of the aminoacylation active site 
consisting of residues 492-547 (designated by arrow). Similar conformational changes are 
observed with Q566W and A538W mutations (positions in active site cleft designated by blue 
lines). Inset is a superposition of the TARS-borrelidin structure (TARS-BN; TARS shown in 
teal and BN in orange) superimposed with a computational model of the Q566W TARS (blue) 
showing nearly identical structures. (B) Quantification of HUVEC branching in response to WT 
TARS, Q566W TARS, and A538W TARS. HUVECs were plated on Matrigel in 10% EGM-2 
(0.2% FBS) media and exposed to 100 nM of the indicated constructs. Cells were fixed after 4-
8 h and stained with Oregon Green 488 Phalloidin. Numbers represent percentage of control (0 
nM) samples, mean ± SEM, n=3 * p<0.05 and # p<0.01 relative to the buffer control and WT 
TARS respectively (one-way ANOVA, Tukey Test). (C) Aminoacylation activity data for WT 
TARS and Q566W TARS as determined by formation of Thr-tRNAThr per active site per 
minute; mean ± S.D.; n=3. Diagrams in (A) were adapted from images kindly provided by our 





4.3.1 Borrelidin regulates angiogenesis in zebrafish specifically though interactions 
with TARS 
Early reports suggested that apoptosis of endothelial cells could contribute to the 
reduction in angiogenesis (8). While the impact of this phenomenon cannot be 
completely ruled out, it is complicated by a lack of specificity to a single cell type (9,10). 
Furthermore, the data from Chapter 3 clearly indicate that anti-angiogenic effects are 
observable at sub-toxic levels suggesting that another mechanism is required to explain 
the relationship between TARS and borrelidin in angiogenesis. The actions of borrelidin 
and BC194 can be blocked by single residue substitutions in the E. coli ThrRS, and 
TARS active sites, respectively (5,12), arguing against the previous suggestion that 
borrelidin binding to other secondary targets is physiologically significant in the 
inhibition of angiogenesis (14). This observation was shown to extend into whole animal 
models as demonstrated by the similar phenotypes exhibited between BC194 and 
borrelidin exposure compared to the knockdown of TARS through treatment with a 
TARS-specific morpholino. As such, the effects of compound treatment on zebrafish in 
Chapter 3 can be attributed to the direct inhibition of TARS.  
Table 4. Activity data for borrelidin conformation mimetic mutations 
Construct Activity (min-1) % Activity* 
WT TARS 3.325 ± 0.2083 100 
Q566 TARS 9.151 ± 0.3729 275 
A538W TARS‡ Below detectable limit -- 
         * Relative to WT TARS 
               ‡ As A538W TARS showed no adenylate formation in active site assays 




4.3.2 Defining the TARS components required for the regulation of angiogenesis  
Structural analysis of the ThrRS-borrelidin complex suggests that the inhibition 
mechanisms of borrelidin and BC194 involve occlusion of the binding sites for one or 
more of the canonical aminoacylation substrates. Borrelidin is a slow tight binding 
inhibitor that competes with amino acid substrate binding, accounting for the potent 
stimulation of toxic responses related to amino acid starvation (12). This toxicity 
response, however, has been demonstrated to be completely separate from the angiogenic 
specific effects. Conversely, the angiogenic effects exhibited by the various TARS 
constructs help to characterize the mechanism of TARS-mediated angiogenesis. Since Ec 
ThrRS was capable of stimulating angiogenesis it would seem that the N-terminal ~82 
amino acid extension found only in higher organism is not required for angiogenesis. 
However, it’s important to note that the tube formation assay only looks at the effects of 
constructs outside of the cell and would not provide any evidence for intracellular events. 
As such, the N-terminal extension maybe serve an important regulatory role or function 
in the currently unknown TARS secretory mechanism that is unnecessary in E. coli. The 
lack of structure in this region suggests a potential role as a protein-protein interaction 
domain since intrinsically disordered regions allow for versatile interactions with 
interaction partners (15,16). However, the actual function of this domain, if any, remains 
to be established.  
The loss of angiogenesis activity by Q566W TARS and A538W TARS clearly 
demonstrates the importance of borrelidin’s conformational change to the mechanism of 
the compound. Since Q566W TARS retains its aminoacylation activity it seems unlikely 
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that this effect is due to large scale structural effects or local unfolding linked to the 
mutant substitution. Moreover, the fact that this conformational change does not affect 
the normal function of the protein raises the possibility that its inhibition of angiogenesis 
is though the disruption of some currently unknown protein-protein interaction. This 
concept is further supported by the R442A TARS tube formation assays since these data 
emphasize that TARS’s aminoacylation function is not required for angiogenesis. 
The TARS-mediated mechanism of angiogenesis can be further characterized by 
the data from the N1-domain and ΔN1N2-TARS constructs. Since neither of these 
constructs appear to stimulate angiogenesis, these data suggest that the full-length protein 
is required. The use of ΔN1N2-TARS for crystallization further indicates that this 
construct retains its three dimensional structure and has not lost its angiogenic activity 
owing to partial denaturation. Interestingly, the Q566 mutation and its associated 
conformational change are located within the aminoacylation domain, suggesting that this 
construct retains the ability to engage in the protein-protein interactions that we 
hypothesize borrelidin disrupts. Consistent with this interpretation ΔN1N2-TARS 
reduced the number of tube like structures that grew in HUVEC culture, suggesting that 
the truncated construct likely titrates potential interactions made by the full length 
protein. Moreover, the necessity of the full length protein indicates that a second 
interaction with the N-terminus is likely essential for TARS angiogenic function. As 
described above, the ability of Ec ThrRS to stimulate angiogenesis suggests that this 
interaction is not mediated by the N-terminal extension and is more likely to be 
associated with the N1 (TGS) and N2 (Editing) domains of the protein.  
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 Unlike the ΔN1N2-TARS construct, the N1 domain alone did not inhibit 
angiogenesis in the tube-formation assay. However, the data for this construct were 
associated with a high standard error of mean (Figure 26A), which may indicate that this 
domain has some influence in the assay and its involvement in angiogenesis should not 
be completely ruled out. As the N1-domain does not possess a known active site, its 
contribution, if any, would be limited to the formation of interactions between TARS and 
other molecules. In this model TARS would be able to bridge two molecules together 
through the formation of concurrent interactions (further developed in section 4.3.3). 
Conversely, the N2 domain contains the editing active site and could theoretically 
function in both the formation of interactions and non-canonical catalytic activities 
(alternative catalytic functions of TARS are discussed in Chapter 5) (17). However, 
unlike the other domains of TARS, the contributions of the isolated N2 domain on 
angiogenesis have yet to be investigated.  
One important caveat of these data is that neither the N1-domain nor the ΔN1N2-
TARS constructs contain the N2 editing domain. This apparent oversight is due to the 
fact that both constructs were designed with other purposes in mind: the N1-domain was 
designed for protein-protein interaction studies (see Appendix I) and the ΔN1N2-TARS 
was designed for crystallization. Given the proven importance of the aminoacylation 
domain to the angiogenic mechanism it would seem unlikely that a construct consisting 
of both the N1 and N2 domains would have any pro-angiogenic activity. Conversely, if 
the N2 domain is the site of the second interaction, then a ΔN1-TARS (containing only 
the editing, aminoacylation, and anti-codon binding domains) could possibly exhibit 
angiogenic activity. Due to technical difficulties in the creation of the ΔN1-TARS 
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construct, however, these studies have yet to be performed. Nonetheless, the conclusion 
that two interactions are necessary would become very important in directing future 
investigations of this mechanism.  
 
4.3.3 Models for TARS-mediated angiogenesis and their disruption by borrelidin 
derivatives 
Together, the zebrafish morpholino and TARS construct data support a 
mechanism in which TARS regulates angiogenesis by stimulating proper vessel 
patterning and migration independent of TARS’s aminoacylation function. This process 
appears to be based on the formation of two separate protein-protein interactions, one of 
which is located within the TARS catalytic domain. Possible identities for these 
interactions have been investigated using mass-spectrometry approaches and the results 
of these experiments can be observed in Appendix I. The methods used in those 
interaction experiments, however, focused primarily on intra-cellular partners and may 
not fully account for the apparent extracellular nature of TARS’s secondary function (5). 
In contrast, the models presented below will focus on possible extracellular binding 
partners for TARS.  
One possible explanation for this two-binding site model is that extra-cellular 
TARS establishes a spatially regulated gradient through interactions with the extra-
cellular matrix. The second site is then able to mediate a contact with a cell surface 
receptor involved in vessel migration and guidance. In support of this hypothesis, 
interactions between TARS and fibronectin 1 (FN1), a major component of endothelial 
cell ECM, have been reported in the literature. This possible mechanism of TARS-
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mediated angiogenesis is currently being investigated and will be discussed with more 
detail in Chapter 6. 
In this model, the conformational change of Q566W TARS or treatment with 
borrelidin would disrupt either TARS’s interaction with the ECM or the cellular receptor. 
In the case of the ECM interaction, the TARS gradient would become more diffuse and 
harder for vessels to follow. Likewise, disruption of the TARS-receptor interaction would 
inhibit the perception of TARS by cells within a growing vessel. In either event, the 
vessels would not receive the proper guidance cues, leading to the appearance of ectopic 
vessels. This may explain the directional confusion displayed by in vivo assays, such as 
the ISV patterning and CAM vessel formation, following borrelidin and BC194 treatment 
since the diffuse TARS gradient would not allow for proper polarization of endothelial 
cells. This explanation is also compatible with our cell-based assays since each has a 
matrix component associated with the system. Previously, other angiogenesis-associated 
factors, such as VEGF, may elicit different signaling depending on if they are free or 
bound to the ECM. Therefore, disruption of TARS-ECM or receptor interactions could 
have profound effects on the regulation and specifics of its signaling activity. Currently, 
attempts to identify TARS-responsive receptors and borrelidin-susceptible interactions 
are underway. 
While the substantial cross-talk between receptors linked to angiogenesis makes it 
difficult to verify a particular pathway, circumstantial evidence implicates the toll like 
receptors (TLR) of the innate immune system as possible effectors. As mentioned in 
Chapter 1, TARS is the second most common of six ARS associated with anti-synthetase 
syndrome, a rare autoimmune disorder that includes polymyositis and dermatomyositis 
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resulting from the production of the anti-ARS autoantibodies. Recently, the most 
common ARS involved in this disorder, histidyl-tRNA synthetase (HARS), was 
demonstrated to induce muscle inflammation in mice by a TLR2- and TLR4-dependent 
mechanism (18). Activation of the TLRs has been shown to contribute to the process of 
angiogenesis, in part, through MyD88-mediated activation of the NF-κB transcription 
factor (19). This pathway up-regulates the production of TNFα and, consequently, VEGF 
(20).  As indicated earlier, TNFα and VEGF signaling stimulate the secretion of TARS 
from endothelial cells (5). Furthermore, TLR-induced expression of IL-10 in 
macrophages has been associated with the activation of STAT3, which binds to a specific 
site within the promoter region of the tars gene (21). Taken together these observations 
would describe a scenario in which TARS-mediated stimulation of TLRs would initiate 
pro-angiogenic responses and propagate the signal through the expression and secretion 
of additional TARS.  
Other possible receptor identities include focal adhesion complexes and 
purinergic signaling. Focal adhesion complexes are dynamic, multi-protein structures that 
mediate contacts between a cell and the surrounding ECM and possess well documented 
roles in migration (22). Interactions with ECM components are established by integrins 
and can signal into the cell via complex associated kinases (23,24). The co-clustering of 
growth factor associated receptors with integrins have also been observed and may 
collaborate with integrin signaling by interacting with ECM bound ligands, in this case 
TARS. Alternatively, the purinergic system responds to extracellular nucleotides and 
became of interest upon the discovery of non-canonical, catalytic functions in TARS. The 
binding of nucleotides to these purinergic receptors has been demonstrated to elicit 
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functions associated with angiogenesis, including migration and proliferation of 
endothelial cells (25-27). The catalysis of these reactions by TARS and the possible 
involvement of this receptor system will be discussed thoroughly in the next chapter. 
 
4.4 Experimental Procedures 
4.4.1 Cell Culture and Reagents  
Human umbilical endothelial cells (HUVECs) were maintained in Clonetics 
EGM®-2 complete media (Lonza) and used between passages 5 to 8. Borrelidin and 
BC194 were obtained from Biotica (now Isomerase Therapeutics Ltd (Cambridge, UK)). 
The TARS morpholino was purchased from GeneTools.  
 
4.4.2 Protein Preparation  
Purification of human TARS, Ec TARS, and ΔN1N2-TARS was performed 
identical to the procedures described in Chapter 2, section 2.3.1. Single amino acid 
mutants were generated using identical procedures following QuickChange (Stratagene) 
site-directed mutagenesis with olio-deoxynucleotide primers from Operon. 
 Preparation of human cytoplasmic LARS was adapted from previously 
described methods (28,29). A plasmid encoding for N-terminal His6-tagged human 
cytoplasmic LARS in the pPROEX hTb expression vector were transformed into E. coli 
B21(DE3) codon plus competent cells (Stratagene) and cultured in terrific broth 
supplemented with 100 μg/ml ampicillin 37°C to a cell density of A600 = 0.6. Expression 
of LARS was induced with 1 mM isopropyl 1-thio-β-D-galactoside overnight at room 
temperature. The bacterial pellet was lysed by sonication in buffer A (20 mM potassium 
 146 
phosphate buffer pH 8.0, 150 mM KCl, and 5 mM β-mercaptoethanol) and cleared by 
centrifugation at 17050 x g for 30 minutes. Nucleic acids were precipitated by the 
addition of protamine sulfate to a final concentration of 0.2% followed by centrifugation. 
The supernatant was loaded onto a HisTrapTM FF column (GE Healthcare) in buffer A, 
washed in 15 mM imidazole, and eluted by an imidazole gradient from 15 to 500 mM 
over 20 column volumes. LARS containing fractions were identified by SDS-PAGE and 
GelCodeTM Blue (Thermo Scientific), pooled, and dialyzed into buffer B (20 mM HEPES 
pH 8.0, 50 mM KCl, 5 mM β-mercaptoethanol, and 10% glycerol). The sample was 
loaded onto a HiTrap Q FF column (Amersham Pharmacia Biotech) and eluted over 20 
column volumes by KCl gradient from 50 to 1000 mM. LARS containing fractions were 
determined by SDS-PAGE, dialyzed into storage buffer  (100 mM potassium phosphate 
pH 6.8, 10 mM β-mercaptoethanol, and 50% glycerol), and stored at -20°C.  
 
4.4.3 In Vitro Tube Formation Assay  
Tube formation assays were performed as previously described (5,30). Briefly 
HUVEC cells were cultured until 95-100% confluent and seeded in to 48-well plates 
coated with MatrigelTM (BD Biosciences). Cells were incubated at 37 °C in 10 % 
EGM®-2 media in EBM®-2 media (Lonza) (ie. 0.2% FBS and and 10% normal 
supplement concentrations of EGM®-2). Various protein constructs were then added for 
4 to 8 h. Cells were fixed with 10% neutral buffered formalin, stained with Oregon Green 
488 phalloidin (Molecular Probes), and imaged via fluorescence microscopy. Tube 




4.4.4 Chick Chorioallantoic Membrane Assay  
CAM assays were performed as described in Chapter 3, section 3.4.6.  
 
4.4.5 Zebrafish Handling and Treatments 
 This project utilized the transgenic line Tg(flk1:eGFP) in which eGFP is 
expressed in 48 hpf and controlled by the flk1 promoter. Zebrafish were bred and 
maintained in accordance with approved University of Vermont IACUC standards for 
vertebrate animals and staged as previously described (31). An anti-TARS  morpholino 
(5’-TAATTTAGCCACTAACCTGATCCCA-3’) was designed targeting the splice donor 
site within exon 3 of TARS mRNA. Blocking this site is predicted to join exon 2 to exon 
4, introducing a frameshift and producing a stop codon five codons into exon 4. TARS 
morpholinos (1.5 mM) were injected into the yolk sac of Tg(flk1:eGFP) embryos at the 
one to four cell stage and incubated for 24 hours at 28.5 °C. The embryos were then 
dechorionated, transferred to fish egg water containing 0.003% PTU, and replaced at 28.5 
°C. The successful knockdown of functional TARS was confirmed by RT-PCR using the 
following primers:  
Exon 2, Forward: 5’-CAAGAATGCTGCTGGAGATG-3’ 
Exon 4, Reverse: 5’-CTTGTGCCTCTTCATCGTCA-3’ 
Imaging and aberrant vessel quantification were performed at 48 and 72 hpf as described 
below. 
 
4.4.6 Whole Fish and Confocal Imaging 
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Whole body and confocal images were obtained using procedures identical to those 
described in Chapter 3, sections 3.4.10 and 3.4.11. 
 
4.4.7 Statistical Analysis 
All experiments were repeated at least 3 times; n values are reported in the 
corresponding figure legend. Values are presented as means ± SEM. Data were analyzed 
by one- or two-way ANOVA and Tukey or Sidak test as indicated using GraphPad Prism 
v6 software. Significance was defined as P < 0.05.  
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CHAPTER 5: CHARACTERIZING THE NON-CANONICAL, CATALYTIC 
FUNCTIONS OF HUMAN THREONYL-tRNA SYNTHETASE 
 
5.1 Introduction 
The canonical aminoacylation reaction proceeds through a two-step mechanism. 
First, the amino acid is activated through condensation with ATP, forming an aminoacyl-
adenylate intermediate. This is followed by the transfer of the activated amino acid to the 
2’ or 3’-OH of the tRNA to generate charged-tRNA and AMP.  Interestingly, several 
ARSs have developed alterations to this core mechanism for the formation of 
dinucleoside polyphosphates. Excluding glycyl-tRNA synthetase, the majority of these 
reactions progress normally through adenylate formation but deviate in the transfer of 
adenosine phosphate from the adenylate to a second nucleotide triphosphate (1-3). The 
identity of this second nucleotide determines the identity of the dinucleotides (ie ATP  
Ap4A; GTP  Ap4G) (4).  
 The first reported synthesis of Ap4A by an ARS was in 1966 during 
investigations with lysyl-tRNA synthetase (KARS) (5). The biological significance of 
this find was debated over the next several decades, with potential roles in cellular 
proliferation and signaling events. More specific to ARS secondary functions is the 
connection between Ap4A synthesis and a non-canonical function of KARS in the 
regulation of the micropthalmia transcription factor (MITF), an important transcription 
factor in mast cells, osteoclasts, and melanocytes. Normally, MITF’s transcription factor 
activity is inhibited by the suppressor protein Hint (previously known as protein kinase C 
interacting protein 1; PKCI) but can be restored by the binding of diadenosine 
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oligophosphates, including Ap4A (6). Immune activation of mast cells leads to the 
phosphorylation and translocation of KARS into the nucleus, which binds to MITF and 
begins local production of Ap4A. This increase in Ap4A releases Hint from MITF, 
thereby allowing for the transcription of MITF-associated genes (7). Although this 
function of Ap4A is not directly related to TARS, it does demonstrate that Ap4A 
generation by ARSs is more than an accidental side reaction.  
 While most well-known for its role in the non-canonical function of KARS there 
are reports that provide possible connections of Ap4A synthesis to secondary functions in 
TARS. An early report of Ap4A synthesis by TARS published in 1989 and revealed rates 
comparable, if not slightly faster, than those observed for KARS. Even more interesting, 
the phosphorylation of unidentified serine residues by cAMP-dependent kinase was 
shown to enhance the rate of this reaction by nearly 8-fold (1). The fact that this side 
reaction is influenced by a common regulatory mechanism like phosphorylation 
emphasizes the possibility that it may be involved in an important biological function.  
 Previously, extracellular TARS has been demonstrated to induce angiogenesis 
(8). However, the mechanism behind this process remains to be determined. Interestingly, 
extracellular nucleotides have been associated with angiogenesis through receptor-
mediated signaling cascades known as purinergic signaling. This raises the possibility 
that one component of the ability of TARS to stimulate angiogenesis is related to its 
ability to catalyze the interconversion of nucleotides outside of the cell, including the 
synthesis of Ap4A from ATP. While most extracellular nucleotides are able to elicit some 
form of purinergic signaling the actual responses are specific for each nucleotide. This 
specificity is achieved by the presence of numerous receptors with varying degrees of 
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affinity for different nucleotide species. For Ap4A, signaling events are primarily 
mediated by the P2X ligand-gated ion channel family. Activation of P2X leads to an 
influx of Na+ and Ca2+ and stimulates the arterial vasoconstriction (9). Alternatively, 
P2Y1 activation by ADP leads to the release of intracellular Ca2+ stores through IP3-
mediated pathways and stimulates the proliferation of vascular smooth muscles cells 
through ERK1/2 pathways (10). In endothelial cells, ADP has been demonstrated to 
induce proliferation and migration (11,12). Additionally, activation of P2Y receptors by 
ADP on platelets was found to stimulate the release of VEGF and endostatin, which 
suggests the possibility of synergistic effects between purinergic signaling in platelets 
and endothelial cells on endothelial cell migration in vivo (13). Interestingly, Ap4A 
exhibits antagonistic activities against platelet P2Y1, emphasizing a complex interplay 
between various purinergic ligands.  
Section 1.6.4 of Chapter 1 introduced the observation that, with the exception of 
TARS, all angiogenesis-related functions of ARSs were dependent in some way on an 
appended domain. However, there are domains of unknown function contained within the 
TARS protein. One in particular is an N-terminal, ubiquitin like domain that is conserved 
from bacteria to humans. The domain is called the TGS domain for its appearance in 
TARS, GTPase, and SpoT proteins (14). The recurrence of this domain in GTPases is 
particularly interesting, since proteins, such as elongation factors, often use the catalysis 
of GTP to GDP to cycle between “on” and “off” states (14-16). Additionally, the protein 
SpoT catalyzes the formation of guanosine 5’-(tri)diphosphate, 3’-diphosphate 
((p)ppGpp), which is involved in the regulation of some bacterial genes (17,18). 
Therefore, the identification of secondary guanine nucleotide activities in TARS might 
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lead to the discovery of a switch between the canonical and non-canonical functions or 
otherwise provide insights into their mechanisms. 
 The data in this chapter present several non-canonical, catalytic functions of 
TARS, some of which have not been reported elsewhere. These reactions include a 
cryptic GTPase function, conversion of ATP to ADP, and the formation of Ap4A. They 
have been included in this dissertation work because of possible connections to the TARS 
pro-angiogenic mechanism. The rates of these reactions have been investigated using 
various TARS constructs in the presence and absence of borrelidin derivatives in order to 
draw possible connections with TARS-mediated angiogenesis. These connections will be 
further validated by investigating the involvement of the ADP and Ap4A receptors P2Y1 
and P2X using specific inhibitors to these receptors. Together, the characterization of 
these various aspects of TARS non-canonical functions provides context and foundation 
for future investigations into their contribution to angiogenesis. 
 
5.2 Results 
5.2.1 TARS possesses GTPase activity 
The conversion of GTP to GDP by TARS was monitored over time using 
autoradiography and thin layer chromatography to resolve the products and substrates 
(Figure 29A). Rates are reported as molecules of GDP produced per active site (or per 
monomer in the case of R442A TARS) per minute, which results in units of min-1 (Table 
5). With GTP as the only substrate, the base rate of GTPase activity for WT TARS was 
calculated to be 0.3033 min-1 (Figure 29B). While this rate may appear slow, it should be 
noted that GTPases often possess inherently low catalytic rates in the absence of GTPase 
 156 
 
Figure 29. Kinetic characterization of TARS GTPase activity. 
(A)  Representative autoradiographic images of TARS GTPase reactions under untreated 
(left) and 2 mM ATP (right) conditions using [α32P]-labeled GTP as a tracer. Reaction 
components were separated by thin-layer chromatography on polyethyleneimine-cellulose 
in 750 mM potassium phosphate buffer, pH 3.5. (B-E) Rate of GDP formation by purified 
TARS constructs under various conditions. (B) GTPase activity of 5 μM WT TARS (blue), 
R442A TARS (red), or Ec ThrRS (green). (C) GTPase activity of WT TARS in the 
presence of 0 μM (blue), 1 μM (red), 5 μM (green), or 10 μM (purple) tRNAThr. (D) WT 
TARS GTPase activity untreated (blue), with 2 mM threonine (red), 2 mM ATP (green), 
both 2 mM threonine and 2 mM ATP (adenylation, purple), or adenylation with 10 μM 
tRNAThr (aminoacylation, orange).  (E) WT TARS GTPase activity uninhibited (blue), 10 
μM BC194 (red), or 10 μM borrelidin (green). All data are presented as mean ± S.D, n=3. 
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activating proteins (GAP). Notably, Ec ThrRS exhibited no significant GTPase activity 
(0.01576 min-1) suggesting that this effect is not found in bacteria. Moreover, the lack of 
activity in the Ec ThrRS construct demonstrates that the observed rates for GDP 
production in WT and R442A TARS were not simply the result of solution hydrolysis. 
 
 
Subsequently, the effects of the canonical substrates on the GTPase activity 
were investigated (Figure 29C, D). The addition of 2 mM threonine provided a minor 
enhancement to the rate, increasing it to 0.3825 min-1 (Figure 29C). In contrast, ATP in 
any combination with other canonical substrates, significantly decreased the GTPase 
activity: alone, 2 mM ATP dropped the rate to 0.07097 min-1, 2 mM ATP and 2 mM 
threonine (adenylation conditions) dropped the rate to 0.03080 min-1, and 2 mM ATP 
with 2 mM threonine and 10 μM tRNAThr (aminoacylation conditions) dropped the rate 
to 0.03434 min-1 (Figure 29D). In contrast to the other two substrates, tRNAThr had no 
effect when added alone at 1 μM, 5 μM, and 10 μM, corresponding to the rates 0.3485 
min-1, 0.3231 min-1, and 0.3284 min-1 (Table 6).  
Table 5. Rates of GTPase activity by various TARS constructs 
Construct Condition Activity (min-1) % Activity* 
WT TARS: Uninhibited 0.3033 ± 0.01541 100 
 2 mM Threonine 0.3825 ± 0.03592 126 
 2 mM ATP 0.07097 ± 0.01488 23 
 Adenylation 0.03080 ± 0.01268 10 
 Aminoacylation 0.03434 ± 0.01167 11 
 10 μM Borrelidin 0.3082 ± 0.02850 102 
 10 μM BC194 0.3067 ± 0.02155 101 
R442A TARS: Uninhibited 0.2137 ± 0.01704 70 
Ec ThrRS: Uninhibited 0.01576 ± 0.01062 5 




Owing to the potential connection between the GTPase function and TARS’s 
secondary activities in angiogenesis, the effects of borrelidin and BC194 were also tested 
(Figure 29E). Both compounds were added at concentrations of 10 μM, which would 
saturate the 5 μM enzyme concentration. Interestingly, neither borrelidin nor BC194 had 
any effect on the rate of the GTPase reaction, exhibiting rates of 0.3067 min-1 for 
borrelidin and 0.3083 min-1 for BC194 relative to 0.3033 min-1 for the uninhibited 
reaction. 
 
5.2.2 TARS-mediated catalysis of Diadenosine Tetraphospate (Ap4A) 
 Two mechanisms have been reported for the formation of Ap4A. Most 
commonly, the reaction progresses through the canonical adenylation step of 
aminoacylation, forming an aminoacyl-adenylate intermediate. However, instead of 
transferring the amino acid to an awaiting tRNA molecule, the adenosine moiety is 
transferred to a second nucleotide triphosphate instead, generating a dinucleotide 
tetraphosphate (Figure 30A). As such, this mechanism would require that the 
corresponding amino acid is present to proceed. Alternatively, glycyl-tRNA synthetase 
has been observed to form Ap4A through an amino acid independent method. In this 
mechanism an oxygen of the γ-phosphate of an ATP molecule initiates a nucleophilic 
Table 6. The effects of tRNAThr on the rates of WT TARS GTPase activity 
Construct Condition Activity (min-1) % Activity* 
WT TARS: 0 μM tRNAThr 0.3033 ± 0.01541 100 
 1 μM tRNAThr 0.3485 ± 0.02269 115 
 5 μM tRNAThr 0.3231 ± 0.01755 107 
 10 μM tRNAThr 0.3284 ± 0.01779 108 
   *Relative to WT TARS, uninhibited 
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attack on the α-phosphate of another nucleotide, producing Ap4A (Figure 30B). Most 
often the second nucleotide in these reactions is ATP, resulting in Ap4A; however, other 
combinations of nucleotides are also possible so long as at least one nucleotide is 
adenosine (ie. Ap4N, where N is any nucleotide) (4). Despite the previously reported 
observations of TARS Ap4A synthesis activity the mechanism through which this 
reaction proceeds has yet to be determined.  
 
 
In order to determine the mechanisms used by TARS to synthesize Ap4A, WT 
TARS Ap4A synthetase reactions were monitored in the presence and absence of 
threonine. The rate of Ap4A synthesis was determined using autoradiography of α-
labeled ATP tracers resolved by thin layer chromatography on PEI-cellulose (Figure 
 
Figure 30. Ap4A reaction schematics. 
(A) Threonine-dependent reaction schematic requiring the formation of a threonyl-
adenylate intermediated. (B) Threonine-independent reaction schematic with direct 




Figure 31. Kinetic characterization of TARS Ap4A synthesis activity. 
(A) Representative autoradiographic images used for quantifying TARS Ap4A synthesis 
under untreated or 10 μM BC194 conditions. Reactions were monitored using [α32P]-
labeled ATP as a tracer and each time point was spotted onto a polyethyleneimine-
cellulose thin-layer chromatography plate and resolved using 3M ammonium sulfate and 
2% EDTA. (B-E) Rate of Ap4A synthesis by purified TARS constructs under various 
conditions (B-E). (B) Ap4A formation by 5 μM WT TARS (blue), R442A TARS (red), Ec 
ThrRS (green), or WT TARS in absence of threonine (purple). (C) Ap4A synthesis by WT 
TARS in the presence of 0 μM (blue), 1 μM (red), 5 μM (green), or 10 μM (purple) 
tRNAThr. (D) WT TARS Ap4A formation uninhibited (blue), with 10 μM BC194 (red), or 
with 10 μM borrelidin (green). (E) Ap4A synthesis by WT TARS in the presence of 0 μM 
(blue), 1 μM (red), 5 μM (green), or 10 μM (purple) tRNAThr and 10 μM BC194. All data 
presented as mean ± SD, n=3. 
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31A). Rates are presented as the number of Ap4A molecules generated per enzyme per 
minute (Table 7). Where possible, the rates have been adjusted to represent the active 
concentration of enzyme. 
 The reactions without threonine did not deviate significantly from background, 
in contrast to the 0.1391 min-1 received for the threonine containing reactions (Figure 
31B). These data indicated that the reaction likely proceeded though an adenylate 
intermediate and that all subsequent reactions should be performed in the presence of 
threonine. To confirm that the threonine was not simply required for structural purposes 
threonine-containing reactions were investigated using the adenylation deficient R442A 
TARS mutant. Like the reactions lacking threonine, no significant activity was observed. 
Conversely, Ec ThrRS readily catalyzed the reaction at a rate of 0.5052 min-1, which is 
more than three times the rate observed for the human enzyme. 
 
 
In addition to threonine, the effect of the tRNAThr on the reaction rate was also 
investigated (Figure 31C; Table 8). The presence of uncharged tRNA would be expected 
to inhibit Ap4A synthesis through the adenylate intermediate mechanism by allowing for 
the resolution of the adenylate through the canonical transfer reaction and reducing its 
Table 7. Rates of Ap4A synthesis by various TARS constructs 
Construct Condition Activity (min-1) % Activity* 
WT TARS: Uninhibited 0.1391 ± 0.007845 100 
 10 μM Borrelidin 0.05652 ± 0.005461 40.6 
 10 μM BC194 0.09595 ± 0.002774 69 
 No Threonine 0.0008236 ± 0.0003371 0.5 
R442A TARS: Uninhibited 0.001343 ± 0.0001381 1 
Ec ThrRS: Uninhibited 0.5052 ± 0.04095 363 
   *Relative to WT TARS, uninhibited 
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availability for Ap4A formation. Due to low concentrations of tRNAThr used in the 
reactions (1 μM to 10 μM) relative to the enzyme concentration of 5 μM and the long 
reaction duration, the presence of tRNAThr was only expected to exert minor effects, if 
any, as most would be converted to aminoacylated product early in the reaction’s 
progression. Surprisingly, the addition of 1 μM, 5 μM, and 10 μM of tRNAThr produced a 
dose-responsive increase in Ap4A formation rates of 0.1690 min-1, 0.1793 min-1, and 
0.2528 min-1 (corresponding to 21%, 29%, and 82% increases) relative to 0.1391 min-1 
without tRNAThr. The reason for this increase, however, remains unknown. 
 
 
 Previous work has demonstrated that borrelidin mediates its anti-angiogenic 
effects through TARS. Since Ap4A-signaling represents a possible mechanism for 
TARS-mediated angiogenesis it was important to investigate the effects of borrelidin on 
rate of Ap4A synthesis. Like with the GTPase activity, borrelidin or BC194 were added 
at saturating conditions (10 μM compound compared to 5 μM enzyme) (Figure 31D). The 
presence of the two compounds reduced the rate of Ap4A formation to 40.5% (0.05652 
min-1) and 69% (0.09595 min-1) respectively. This was not surprising as borrelidin and 
BC194 are known to inhibit TARS adenylate formation (19). The effect of BC194 
Table 8. The effects of tRNAThr on the rates of WT TARS Ap4A synthesis 
Construct Condition Activity (min-1) % Activity* 
WT TARS: 0 μM tRNAThr 0.1391 ± 0.007845 100 
 1 μM tRNAThr 0.1690 ± 0.008302 121 
 5 μM tRNAThr 0.1793 ± 0.01076 129 
 10 μM tRNAThr 0.2528 ± 0.01468 182 
 0 μM tRNAThr; 10 μM BC194 0.09595 ± 0.002774 69 
 1 μM tRNAThr; 10 μM BC194 0.08143 ± 0.004001 59 
 5 μM tRNAThr; 10 μM BC194 0.1171 ± 0.01041 84 
 10 μM tRNAThr; 10 μM BC194 0.1206 ± 0.01165 87 
 *Relative to WT TARS, uninhibited. 
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inhibition on the tRNA stimulation effect was also tested (Figure 31E). Unlike with the 
uninhibited reaction, the addition of 1 μM, 5 μM, and 10 μM of tRNAThr had less of an 
effect on Ap4A formation with rates of 0.08143 min-1, 0.1171 min-1, 0.1206 min-1 
(corresponding to a 15% decrease at 1 μM tRNAThr and a 22% and 26% increase at 5 μM 
and 10 μM tRNAThr relative to the reaction treated with BC194 alone).  
 
 
In addition to Ap4A synthesis, TARS was also found to catalyze the formation 
of Ap4G. Ap4G formation was monitored using the same method as Ap4A except that α-
phosphate labeled GTP was used as a tracer and final calculated value was not cut in half 
because, unlike with Ap4A, only one labeled phosphate would be included per molecule 
(Table 9). WT TARS catalyzed the formation of Ap4G at a rate of 0.1639 min-1, nearly 
identical to the 0.1391 min-1 obtained for Ap4A formation (Figure 32A). As proof of the 
products identity as Ap4G and not Gp4G, the reaction was run in the absence of ATP and 
with the aminoacylation deficient R442A mutant, which yielded rates of 0.01278 min-1 
and 0.01062 min-1 respectively. Together these data indicated that Ap4G synthesis was 
dependent on the formation of the threonyl-adenylate before the adenosine moiety is 
transferred to the second GTP molecule. Consistent with Ap4A formation, treatment with 
Table 9. Rates of Ap4G synthesis by various TARS constructs 
Construct Condition Activity (min-1) % Activity* 
WT TARS: Uninhibited 0.1639 ± 0.01224 100 
 10 μM BC194 0.07065 ± 0.009176 43 
 No ATP 0.01278 ± 0.005864 8 
R442A TARS: Uninhibited 0.01062 ± 0.004659 6 
Ec ThrRS: Uninhibited 0.5612 ± 0.06121 342 
          *Relative to WT TARS, uninhibited 
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BC194 reduced the rate of Ap4G synthesis to 0.07065 min-1, 43% of the uninhibited 
reaction (Figure 32B).    
 
 
5.2.3 TARS Catalyzes the Formation of ADP from ATP 
The conversion of ATP to ADP by TARS was discovered accidently when a band 
corresponding to ADP was identified on a thin layer chromatography plate originally 
monitoring the formation of the threonyl-adenylate intermediated. While initially 
dismissed as a substrate contaminant, its formation appeared to increase over the course 
of the reaction, suggesting that it was a product of the reaction. Like with the GTPase and 
Ap4A activities above, this find was particularly interesting due to the recognized 
connection between extracellular nucleotides and the regulation of angiogenesis through 
purinergic signaling. Notably, extracellular ADP is well documented to regulate 
endothelial cell migration, much like TARS. Specifically, ADP activates the G-protein 
coupled receptor P2Y1, which is highly expressed within endothelial cells (20). 
 
Figure 32. TARS catalyzes the synthesis of the hybrid dinucleotide tetraphosphate Ap4G. 
(A) Ap4G formation by 5 μM WT TARS (blue), R442A TARS (red), Ec ThrRS (green), or WT 
TARS in absence of threonine (purple). (B) WT TARS Ap4G formation uninhibited (blue) or 
with 10 μM BC194 (red). All data are presented as mean ± SD,  n=3. 
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Stimulation of this receptor in endothelial cells leads to the phosphorylation and 
activation of several key mitogen-activated protein kinases involved in endothelial cell 
migration, including ERK1/2, JNK, and p38 MAPK (12). Additionally, activation of the 
P2Y1 receptor has been demonstrated to transactivate VEGFR2, providing an indirect 
method for the regulation of angiogenesis (21).  
 
 
 ADP formation was measured from same reaction samples used for Ap4A 
except that they were separated by TLC using a potassium phosphate buffer instead of the 
ammonium sulfate/EDTA mix (Figure 33A). As with Ap4A, the amount of ADP at each 
time point was determined as a fraction of the total nucleotides in the sample and 
compared to the initial concentration of ATP added to the reaction.  Rates are presented 
as the number of ADP molecules generated per active site (or total enzyme concentration 
for R442A) per minute (Table 10). Because the measurements of ADP were taken from 
Ap4A reactions retrospectively, they are limited by the conditions used for Ap4A 
synthesis. As such, nearly all measurements contain threonine.  
Full kinetic investigations have been performed on WT TARS, WT ThrRS, and 
the aminoacylation deficient R442A TARS (Figure 33B). Both WT and R442A TARS 
Table 10. Rates of ADP formation by various TARS constructs 
Construct Condition Activity (min-1) % Activity* 
WT TARS: Uninhibited 0.1417 ± 0.01409 100 
 10 μM Borrelidin 0.2777 ± 0.03141 182 
 10 μM BC194 0.2738 ± 0.02056 193 
 No Threonine 0.3925 ± 0.03888 277 
R442A TARS: Uninhibited 0.1059 ± 0.01121 75 
Ec ThrRS: Uninhibited 0.01330 ± 0.02283 9 





Figure 33. Kinetic characterization of TARS ADP formation. 
(A) Representative autoradiographic images used for quantifying TARS ADP formation under 
untreated or 10 μM BC194 conditions. Reactions were monitored using [α32P]-labeled ATP as 
a tracer and each time point was spotted onto a polyethyleneimine-cellulose thin-layer 
chromatography plate and resolved using 750 mM potassium phosphate, pH 3.5 buffer. (B-E) 
Rate of ADP formation by purified TARS constructs under various conditions. (B) ADP 
formation activity of 5 μM WT TARS (blue), R442A TARS (red), Ec ThrRS (green), or WT 
TARS in absence of threonine (purple). (C) ADP formation rates of WT TARS in the 
presence of 0 μM (blue), 1 μM (red), 5 μM (green), or 10 μM (purple) tRNAThr. (D) WT 
TARS ADP formation rates uninhibited (blue), 10 μM BC194 (red), or 10 μM borrelidin 
(green). (E) ADP formation rates of WT TARS in the presence of 0 μM (blue), 1 μM (red), 5 
μM (green), or 10 μM (purple) tRNAThr with 10 μM BC194.  All data are presented as mean ± 
SD, n=3. 
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formed ADP from ATP, with rates of 0.1417 min-1 and 0.1059 min-1 respectively. Since 
R442A TARS is unable to catalyze the first, adenylation step of aminoacylation, these 
data would suggest that ADP formation is separate from the canonical reaction of the 
enzyme. It may also be worthwhile to note that, due to loss of adenylation activity, the 
active concentration of R442A could not be determined before these assays requiring that 
the total protein concentration be used instead. Therefore, it is possible that the rates of 
WT and R442A TARS would be closer if R442A TARS could be adjusted for the active 
concentration. In contrast to the human constructs, Ec ThrRS exhibited no activity above 
background with a rate of 0.01330 min-1, about 9% of the activity observed with the 
human enzyme. Therefore, like GTPase activity, ADP formation appeared to be a human 
phenomenon (although it remains to be tested in other organisms). 
When the reaction was run in absence of threonine, WT TARS exhibited a rate of 
0.3925 min-1, about 2.77 fold higher than the reaction with threonine (Figure 33B). While 
this reaction was not completed in triplicate like the others (this reaction was not 
necessary for the Ap4A studies) it does indicate that the reaction does not require 
threonine and suggests that, while ADP formation is a separate reaction from 
aminoacylation, it may still respond to aminoacylation substrates. Surprisingly, while 
threonine appeared to negatively impact the rate of ADP formation, the opposite was true 
for tRNAThr additions to the reaction (Table 11). The addition of 1 μM, 5 μM, and 10 μM 
tRNAThr increased the reaction rate from 0.1417 min-1 to 0.2804 min-1, 0.4063 min-1, and 
0.6561 min-1 respectively, which correspond to increases of 98%, 187%, and 363% 
(Figure 33C).   
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The connection between the ADP and angiogenesis opened the possibility of 
this ADP reaction as a potential mechanism for TARS’s effects on endothelial cell 
migration. Like with Ap4A, this hypothesis would also suggest that borrelidin and related 
compounds would be able to inhibit angiogenesis by altering the rate of this reaction. 
Therefore, the effects of Borrelidin and BC194 on this reaction were subsequently 
investigated (Figure 33D). At saturating amounts (10 μM relative to the 5 μM TARS) 
both compounds appeared to enhance the rate of the reaction: borrelidin increased the 
rate by 82% (0.2578 min-1) and BC194 by 92% (0.2738 min-1). This is very different 
from the potent inhibitory effects exhibited by the compounds against the canonical 
aminoacylation reaction. The effect of tRNAThr on the BC194-treated reaction was also 
investigated to check if the activity increase by tRNAThr is lost, enhanced, or unaffected 
by BC194 (Figure 33E). At concentrations of 1 μM, 5 μM, and 10 μM tRNAThr the 
reactions increased to 0.3766 min-1, 0.4304 min-1, and 0.5859 min-1 respectively. This 
corresponds to enhancements of 38%, 57%, and 114% relative to the reaction treated 
with BC194 alone and 93%, 166%, and 313% relative to the untreated reaction. Given 
Table 11. The effects of tRNAThr on the rates of WT TARS ADP formation 
Construct Condition Activity (min-1) % Activity* 
WT TARS: 0 μM tRNAThr 0.1417 ± 0.01409 100 
 1 μM tRNAThr 0.2804 ± 0.008072 198 
 5 μM tRNAThr 0.3993 ± 0.03835 287 
 10 μM tRNAThr 0.6479 ± 0.04162 463 
 0 μM tRNAThr; 10 μM BC194 0.2738 ± 0.02056 193 
 1 μM tRNAThr; 10 μM BC194 0.3766 ± 0.03478 266 
 5 μM tRNAThr; 10 μM BC194 0.4463 ± 0.06611 304 
 10 μM tRNAThr; 10 μM BC194 0.5870 ± 0.04631 413 
    *Relative to WT TARS, uninhibited 
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the similarities in these values when compared to the untreated, WT TARS reaction, it 
appears that the rate increases by BC194 are masked by those provided by the tRNA. 
While kinetic rates for ADP formation have not be thoroughly investigated with 
the other TARS constructs used in this work, the ability of these enzymes to catalyze this 
reaction can be identified qualitatively from observations of other experiments. 
Specifically, the TLC plates used in the determination of active site concentrations can be 
used to assess for the absence or presence of ADP. However, due to the very different 
assay conditions, direct comparisons concerning rates cannot be made. Using this method 
ADP formation has been observed with the borrelidin-resistant L567V TARS, the 
angiogenesis but aminoacylation active Q566W TARS, and the angiogenesis and 
aminoacylation deficient A538W TARS (Data not shown).  
 
5.2.4 Effects of purinergic inhibitors on TARS-mediated angiogenesis 
 Previously ADP and Ap4A have been shown to regulate angiogenesis by 
stimulating the purinergic receptors P2Y1 and P2X respectively. Therefore, the effects of 
purinergic signaling by TARS-generated ADP and Ap4A on angiogenesis were 
investigated using an endothelial tube formation assay and inhibitors of the P2Y1 and 
P2X receptors (Figure 34A, B). As previously described, the presence of TARS at 100 
nM enhanced tube formation by around 50%. Interestingly, the inclusion of 10 μM of the 
P2Y1 receptor inhibitor MRS2179 completely inhibited TARS-mediated angiogenesis 
back to baseline levels (Figure 34A). Conversely, no significant inhibitory effects were 
observed for the P2X inhibitor Ip5I (Figure 34B). However, the Ip5I treated cultures 
appear to visually trend to a reduction in tube-formation and may warrant additional 
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replications to see if statistical significance can be obtained.  Neither MRS2179 nor Ip5I 
exhibited significant effects on baseline tube formation in absence of TARS. 
 
5.3 Discussion 
5.3.1 Correlations between non-canonical, catalytic reactions and TARS-mediated 
angiogenesis 
 The data presented above demonstrate that TARS is capable of catalyzing 
several different reactions in addition to its canonical role in aminoacylation. For 
comparative purposes the various constructs and their ability to perform canonical and 
 
Figure 34. The effects of purinergic receptor inhibitors MRS2179 and Ip5I on TARS-
mediated angiogenesis. 
(A, B) Quantification of HUVEC branching in control of 100 nM WT TARS-treated 
cultures with and without MRS2179 (A) or Ip5I (B). HUVECs were plated on Matrigel in 
10% EGM-2 (0.2% FBS) media and exposed to various combinations of buffer, 100 nM 
TARS, and 10 μM of MRS2179 or Ip5I. Cells were fixed after 4-8 h and stained with 
Oregon Green 488 Phalloidin. Numbers represent percentage of control (0 nM) samples, 
mean ± SEM, n=3, ** and **** correspond to p<0.01 and 0.0001 respectively relative to 
the TARS-treated sample (one-way ANOVA, Tukey Test). 
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non-canonical functions are listed in Table 12. Unfortunately, no simple conclusions can 
be drawn between the angiogenic potential of the various TARS constructs and their 
participation in non-canonical catalytic activities. Primarily, the difficulty arises with 
either R442A TARS or Ec ThrRS. Both of these constructs have been demonstrated to 
stimulate angiogenic responses in endothelial tube formation assays.  However, since Ec 
ThrRS lacks GTPase activity and ADP formation and R442A TARS is unable to 
synthesize Ap4A or Ap4G, none of these reactions can be clearly attributed to the 
initiation of angiogenesis. Nonetheless, some explanations can be developed.  
 
 
 The discovery of GTPase activity in TARS opened up the possibility that this 
reaction could function as a switch between TARS’s canonical and non-canonical 
functions. Since TARS is normally found in the cytoplasm, it seems likely that the 











WT TARS Human enzyme Yes Yes Yes Yes Yes 




No Yes Yes Yes No 
L567V TARS Borrelidin resistant Yes Yes Yes Yes Yes 
N1-Domain 
Most N-terminal 
domain; no known 
function 














No No Yes Likely* Unlikely# 
* When tested, all constructs with ATP to ADP or GTPase activity have exhibited the other as well. 
‡ ΔN1N2-TARS is capable of rescuing cells from loss of WT TARS, supporting aminoacylation function. 
# So far, all constructs able to perform aminoacylation appear capable of Ap4A and Ap4G synthesis. 
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GTPase would initiate this switch event intracellularly. However, TARS’s angiogenic 
function requires that the protein be secreted outside the cell. Since the test substances are 
added extracellularly during the tube formation assay, any potential importance of the 
GTPase function would have been bypassed and, thus, would not have affected Ec 
ThrRS’s ability to simulate angiogenesis.  
 Of the three non-canonical reactions (GTPase, Ap4A/Ap4G synthesis, and ADP 
formation) the formation of ADP appears to be the strongest candidate as a mechanism 
for TARS-mediated angiogenesis. First, ADP is already known to stimulate endothelial 
cell migration, a function that is also attributed to TARS, through the stimulation of the 
P2Y1 receptor. The fact that the P2Y1 specific inhibitor, MRS2179, appears to attenuate 
TARS-mediated angiogenesis suggests that ADP purinergic signaling is important for 
this process as well. Furthermore, while Ec ThrRS is unable to generate ADP, it does 
catalyze the formation of Ap4A at a faster rate than human TARS. Since Ip5I did not 
seem to affect TARS-mediated angiogenesis, it seems unlikely that Ap4A is instigating 
its own purinergic signaling through the P2X receptor. However, Ap4A can be broken 
down into two ADP molecules by extracellular proteins, providing an alternative method 
of synthesizing ADP. Therefore, all angiogenic constructs appear to possess the ability to 
synthesize ADP to some degree. Furthermore, the rate of this hydrolysis appears to be 
slower than the breakdown of other extracellular adenosine phosphate nucleotides to 
adenosine, suggesting that Ap4A may also serve to prolong the purinergic response (22). 
This model, however, does not provide a clear mechanism for borrelidin and BC194’s 
inhibition of angiogenesis.  
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 Treatment of TARS with borrelidin and BC194 appears to stimulate the 
production of ADP instead of inhibiting it. One possible explanation for this may be 
connected to the assay conditions used in the measurement of ADP formation. Because 
ADP formation was measured retrospectively using time points from the Ap4A assays, 
most of the reactions contained threonine. Interestingly, the one reaction that did not 
contain threonine exhibited the fastest measured rate of ADP formation. While threonine 
did not fully block the reaction it may have stabilized a less efficient conformation of the 
TARS active site and slowed the reaction rate. This observation suggests that the rate 
enhancement exhibited by borrelidin and BC194 may be due to their competition with 
threonine in the reaction, a hypothesis that would be easily confirmed by investigating the 
effects of borrelidin and BC194 on ADP formation in absence of threonine. Therefore, it 
seems unlikely that borrelidin and BC194 would influence the ADP-mediated 
angiogenesis through modification of the ADP formation rate.  
 Since borrelidin and BC194 do not actually appear to affect the rate of ADP 
formation, they would have to inhibit ADP-mediated angiogenesis through a different 
mechanism. Previously, the borrelidin and BC194 induced conformational changes have 
been demonstrated to be important for inhibiting TARS-mediated angiogenesis as 
demonstrated by the conformational mimetic mutations Q566W TARS and A538W 
TARS (Chapter 4, section 4.2.6). Interestingly, both of these constructs possess the 
ability to catalyze the conversion of ATP to ADP, providing further evidence that 
inhibition of ADP formation cannot be responsible for borrelidin and BC194’s inhibition 
of angiogenesis. As an alternative it may be that, as part of its angiogenic mechanism, 
secreted TARS forms protein complexes that help localize it to specific extracellular 
 174 
regions. This spatial arrangement may bring it close to the P2Y1 receptor and, thus, 
would enhance its activation. In this model, borrelidin and BC194 would then induce 
conformational changes in TARS and disrupt its interaction with the protein complexes. 
It is important to note, however, that this discussion of how TARS can stimulate 
angiogenesis through ADP formation and its disruption by borrelidin and BC194 is only 
to establish it as a possible model. Therefore, while all the acquired data would support 
ADP as a possible mechanism for TARS-mediated angiogenesis, more data are needed to 
affirm it.  
 
5.3.2 Nucleotide preference in non-canonical, catalytic reactions 
One trend that can be observed in Table 12 is that all enzymes that possess 
GTPase activity also possess the ability to convert ATP to ADP. Furthermore, the 
addition of ATP clearly inhibits the GTPase activity in all conditions. Therefore, it may 
be possible that both functions compete for the same active site and, based on the rate 
data, there is a preference for adenosine nucleotides. Without further data it is difficult to 
say if the use of GTP in this reaction is an unintended side reaction or if it has a specific 
purpose. Phosphorylation has been previously shown to enhance the rate of Ap4A 
synthesis in TARS, therefore, it may be that some similar regulatory event might be able 
to increase the sites affinity for GTP over ATP. Alternatively, it may be that this GTPase 
activity functions as a switch between the canonical and non-canonical functions of the 
TARS proteins.  
While the conversion of nucleotide triphosphates to nucleotide diphosphates by 
TARS appears to prefer adenosine-based molecules over those with guanosine, the 
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opposite appears to be true for the synthesis of dinucleotide tetraphosphates. The 
synthesis of both Ap4A and Ap4G required that ATP be present for the formation of the 
threonyl-adenylate intermediated. As such, the synthesis of Ap4G should be in 
competition with that of Ap4A, assuming that both reactions are occurring in the same 
active site (which is reasonable given the dependence on the threonyl-adenylate). Under 
these conditions the rate of Ap4G would be expected to be slower than Ap4A due to this 
competition. However, Ap4G formed at rates comparable to Ap4A when ATP was the 
only nucleotide present. Therefore, it appears as if the formation of Ap4G is preferred 
over Ap4A. The affinity of other nucleotides for this reaction remain to be determined.  
 
5.3.3 ADP-formation and GTPase activity as nutrient and energy sensors 
As presented in Chapter 1, sections 1.2.1 and 1.6.1 a growing body of evidence 
implicates the ARSs as cellular nutrient and energy sensors. As the rates of ADP 
formation and GTPase activity in TARS are influenced by the levels of threonine and 
ATP respectively, these reaction may also serve a similar function.  In absence of 
threonine, the rate of ADP generation increased 277%. The elevated levels of ADP 
associated with these rates could then improve TARS’s stimulation of angiogenesis 
through the P2Y1 receptor or by activating some other, yet unknown response (11,12). 
Moreover, the extracellular concentrations of threonine are thought to be lower than those 
inside the cell, which would further enhance ADP production following TARS secretion 
(23). In contrast to ADP formation, the presence of ATP almost completely inhibits 
TARS’s GTPase activity. As such, this activity would be limited to conditions of low 
energy within the cell. Since GTPase activities in other proteins have been demonstrated 
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to modify their functions, this property could serve to switch TARS between its canonical 
and non-canonical functions in response to cellular energetic levels (15).  However, it 
remains to be determined if ADP, which would be abundant under low energy conditions, 
has any influence on the rate of GTPase activity as well.  
 
5.3.4 The effect of tRNAThr on ADP formation and Ap4A  
The observation that tRNAThr stimulates both ADP and Ap4A formation is 
interesting but its function and mechanism remain unknown. In both these reactions 
threonine and ATP are present in great excess, suggesting that any tRNAThr present 
should be fully charged by the first time point (this seems to be a safe assumption as 
TARS is present at 5 μM and would only require two turnovers in 30 minutes to 
aminoacylate 10 μM tRNAThr, the highest concentration used in any of the reactions).  
Curiously, the stimulatory effect of tRNAThr on ADP formation is unaffected by the 
presence of BC194 while it is reduced in Ap4A synthesis. However, this difference may 
be due to BC194’s inhibition of the adenylation reaction, which would disrupt Ap4A 
synthesis and compete with the positive effects of tRNAThr. Conversely, ADP formation 
appears independent of aminoacylation and would be unaffected.  
As a possible explanation for the positive effects of tRNAThr on ADP-formation, 
the accumulation of charged-tRNAThr in the reaction may block the canonical 
aminoacylation reaction through product inhibition. As the GTPase reactions above did 
not include threonine, no Thr-tRNAThr was generated, consistent with the lack of tRNA-
induced kinetic effects.  Conversely, since threonine was demonstrated to reduce ADP 
formation, product inhibition by Thr-tRNAThr may enhance ADP formation by blocking 
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threonine binding to its original substrate pocket. Likewise, BC194 also blocks threonine 
binding (Chapter 2, section 2.2.3) and may explain its enhancement to ADP-formation 
rates as well. Because the binding of tRNAThr and BC194 are mutually exclusive and 
would both depend on the exclusion of threonine to induce rate enhancements in this 
model, synergistic effects would not be expected, consistent with the above results.  
However, since the rate of ADP generation in absence of threonine (0.3925 min-1) is less 
than that observed at 10 μM tRNAThr with or without BC194 (0.6479 and 0.5870 min-1) it 
seems likely that threonine exclusion may not be the only effect.  
As an alternative or complementary mechanism, the binding of Thr-tRNAThr to 
one active site of a TARS dimer may alter the non-canonical activities within the same or 
other monomer. Previously, pre-steady state kinetics have demonstrated that the presence 
of tRNA reduces the rate of amino acid activation by Ec ThrRS (24). For another dimeric 
ARS, E. coli Histidyl-tRNA synthetase (HisRS), the adenylation reaction appears to 
proceed asymmetrically between the two monomers in absence of tRNA. Specifically, 
these investigations reveal that the second site is able to bind ATP and amino acid only 
after the first generates a bound adenylate intermediate. Even at this point, however, the 
generation of the adenylate intermediate in the second site appears to occur at a much 
slower rate (25). Interestingly, the addition of uncharged-tRNA appears to equalize the 
rates of both sites, which suggests that tRNA may be important for coupling the reactions 
in both sites (26). Therefore, it may be that product inhibition by charged-tRNA also 
alters the individual activity or coupling of the active site monomers, albeit in favor of 
non-canonical reactions. For ADP, the binding of charged-tRNA may induce 
conformational changes within either active site that facilitates ADP-formation. In the 
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case of Ap4A, the binding of charged tRNA in one site may encourage adenylate 
formation in the other, which, without free-tRNA to continue with aminoacylation, is 
resolved through the formation of Ap4A.  
  
5.4 Experimental Procedures 
5.4.1 Preparation of TARS Constructs and tRNAThr 
 The preparation of TARS constructs and tRNAThr was performed using 
procedures identical to those described in Chapter 2, sections 2.3.1 and 2.3.2.   
  
5.4.2 Ap4A, AMP, and ADP Formation assays 
Ap4A synthesis was investigated using adaptations of previously reported 
methods (3). Reaction mixtures consisted of 20 mM HEPES, pH 8.0, 100 mM KCl, 10 
mM MgCl2, 5 mM β-mercaptoethanol, 5 mM threonine (unless otherwise noted), 2.5 U 
pyrophosphatase (Roche), and 2.5, 5, or 20 µM E. coli ThrRS, wildtype human TARS, or 
R442A TARS respectively. Where necessary, reactions were pre-incubated with 10 μM 
BC194 or Borrelidin in DMSO or a comparable amount (0.05% V/V) of DMSO vehicle 
for 15 minutes on ice prior to initiation. Reactions were then incubated at 37 °C for 3 
minutes and initiated with the addition of 2 mM ATP. Aliquots were taken at varying 
time points and quenched in 3 volumes of 400 mM sodium acetate, pH 4.5, and 0.1% 
sodium dodecyl sulfate. Products were resolved by polyethyleneimine-cellulose TLC 
plates with 3M (NH4)2SO4 and 2% EDTA as mobile phase and quantified by 
phosphorimaging. The identity of Ap4A was confirmed by UV shadowing of an un-
labeled standard. Ap4A production was calculated as a percentage of total counts and 
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compared to the original amount of ATP present in the reaction. To account for the 
incorporation of two ATP molecules per Ap4A product the final values were multiplied 
by 0.5. ADP was measured using identical reactions except that products were resolved 
using TLC with 750 mM potassium phosphate buffer, pH 3.5. 
 
5.4.3 Ap4G synthesis and GTPase Assays 
Ap4G and GTPase assays were performed as Ap4A synthesis above with the 
following exceptions. Ap4G reactions always included 2 mM ATP and 2 mM threonine 
and 10 µM BC194 where indicated in Figure 32B. For GTPase assays ATP and threonine 
were not present in all reactions but were included in combination with 10 µM tRNAThr, 
10 µM BC194, and 10 µM borrelidin according to Figure 29 C and D. Adenylation 
conditions consisted of 2 mM ATP and 2 mM threonine and aminoacylation conditions 
further included 10 μM tRNAThr. Reactions were initiated using 2 mM GTP with trace 
amounts of [α-32P]-GTP. The components were resolved by TLC using the mobile phases 
750 mM KH2PO4, pH 3.5 for GTPase data and 3 M (NH4)2SO4 and 2% EDTA for Ap4G. 
Unlike with Ap4A, Ap4G involves only the incorporation of one labeled nucleotide and 
does not require the 0.5 correction factor. 
 
5.4.4 Cell Culture and Reagents 
Human umbilical endothelial cells (HUVECS) were maintained in Clonetics EGM-2 
complete media (Lonza) and used between passages 5 to 8. MRS2179 and Ip5I were 
obtained from Abcam® and Sigma-Aldich® respectively.   
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5.4.5 Tube Formation Assay with MRS2179 and Ip5I 
Tube formation assays were performed as previously described (8,27). Briefly 
HUVEC cells were cultured on 0.1% gelatin coated plates until 95-100% confluent and 
then seeded in to 48-well plates coated with MatrigelTM (BD biosciences). Cells were 
incubated at 37 °C in EGM®-2 media with 2% FBS and 10 μM MRS2179 or Ip5I where 
necessary for 4 to 8 h. Cellular structures were fixed with 10% neutral buffered formalin, 
stained with Oregon Green 488 phalloidin (Molecular Probes), and imaged via 
fluorescence microscopy. Tube structures were quantified using the Simple Neurite 
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CHAPTER 6: DISCUSSION AND FUTURE PERSPECTIVES 
 
6.1 Mechanisms of TARS-mediated angiogenesis 
6.1.1 Borrelidin’s inhibition of angiogenesis is mediated through direct interactions 
with TARS 
 Initial connections between TARS and angiogenesis were based on the anti-
angiogenic properties of its potent inhibitor borrelidin. The fact that TARS is the only 
known target of borrelidin with a Ki value in the low nM range coupled with the 
observation of angiogenesis-related activities in other ARSs opens the possibility that 
TARS may possess its own secondary functions in vascular biology. This relationship 
was subsequently confirmed when extracellular TARS was found to stimulate vessel 
formation and endothelial cell migration in several in vitro assays but was susceptible to 
inhibition by the borrelidin-derivative BC194. Moreover, BC194’s inhibition of TARS-
mediated angiogenesis could be attenuated through a single TARS point mutation, 
L567V, which indicates that the compound functions directly through TARS.  
Further investigations of borrelidin and BC194 revealed that their inhibition of 
angiogenesis could be separated from toxic effects on cells and more related to their 
association with TARS’s function in vessel patterning and maturation. Specifically, 
treatment of zebrafish with BC194 or knockdown of TARS expression with an anti-
TARS morpholino was shown to induce ectopic vessel growth and poor lumen 
development. The similar responses exhibited by both the inhibitors and the knockdown 
of TARS expression further supports TARS as the only target of borrelidin inhibition. 
Furthermore, these experiments represent the first time that TARS’s secondary function 
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in angiogenesis has been investigated in the context of a whole animal model. This 
connection between TARS and vessel guidance indicated that TARS is likely to form a 
regulated gradient that is followed by the migrating endothelial cells. Based on these 
observations a model for the induction of angiogenesis by extracellular-TARS was 
generated (Figure 35).  
 
6.1.2 Investigating the angiogenic potential of various TARS constructs in the 
zebrafish model 
 The investigations of TARS and its inhibitors on zebrafish vascular biology 
provide critical insights into the mechanisms of TARS-mediated angiogenesis. Moreover, 
the successful knockdown of TARS expression by the anti-TARS morpholino offers an 
opportunity to investigate the effects of the various TARS constructs on vessel patterning 
in the context of a whole organism model. Following morpholino treatment capped-
mRNA corresponding to the various TARS constructs characterized in Chapter 4 can be 
injected into developing zebrafish embryos to complement the reduction of endogenous 
TARS. Of particular interest, L567V TARS can be used to investigate the ability of this 
construct to resist the effects of borrelidin treatment and provide additional confirmation 
to the TARS-specific nature of these observations. Alternatively, Q566W TARS can be 
injected to investigate the effect of the borrelidin-conformation mimic on zebrafish vessel 
development. Since Q566W TARS retains aminoacylation function, this 
complementation would be expected to produce the ectopic branching associated with the 
angiogenesis specific effects of TARS without the toxicity associated with amino acid 
starvation. Finally, the ΔN1N2-TARS construct can be investigated since it still possesses 
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aminoacylation activity (although not trans-editing function) but lacks the ability to 
stimulate angiogenesis in tube-formation assays. Therefore, the two binding site model 
could be investigated in the context of a whole organism.   
 
 
Figure 35. Proposed models for TARS-stimulation and borrelidin-inhibition of 
angiogenesis. 
 (Left) Step by step proposal for stimulation of angiogenesis by TARS: 1) Activation of 
immune cells and hypoxic responses in cancer cells stimulate the secretion of TNFα and 
VEGF respectively. 2) TNFα and VEGF bind to receptors on the surface of endothelial cells. 
3) Activation of unknown signaling pathways stimulates the secretion of TARS from 
endothelial cells. 4) Stimulation of hypoxic cancer cells with TNFα also stimulates secretion 
of TARS (1). 5) Extra-cellular TARS forms a free or ECM-bound gradient that guides the 
migration of nascent vessels. (Right) Proposed mechanisms of borrelidin’s inhibition of 
angiogenesis. Mechanism 1 – binding of Bor elicits a conformational change in TARS that 
precludes its binding to an unknown receptor. Mechanism 2 – A borrelidin-mediated 
conformational change disrupts spatial regulation of secreted TARS by blocking interactions 
with the extra-cellular matrix. Mechanism 3 – Inhibition of TARS aminoacylation activity by 
borrelidin results in the accumulation of uncharged-tRNA which activates GCN2-mediated 
amino acid starvation responses.  
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6.1.3 TARS interacts with endothelial cell-derived extracellular matrices 
The observation of an angiogenic factor mediating two simultaneous 
interactions is not uncommon. Many of these molecules, notably platelet-derived growth 
factor (PDGF) and vascular endothelial growth factor (VEGF), associate with both a cell 
surface receptor as well as components of the extracellular matrix (2-4). This mechanism 
allows for the establishment of a spatially regulated gradient that assists in proper 
signaling to growing blood vessels. Disruption of the gradient’s spatial arrangement or its 
ability to interact with cellular receptors would, therefore, influence the navigation ability 
of migrating cells and produce defects in vessel patterning. 
PDGF released from vessels is important for guiding the migration of pericytes, 
blood vessel support cells, to newly formed vasculature. The targeting of the pericytes to 
these vessels is dependent on the binding of PDGF to the ECM adjacent to the 
endothelial cells. Loss of ECM binding by PDGF results in the accumulation of pericytes 
away from existing vessels as PDGF diffuses into the extracellular space (2). 
Alternatively, remodeling of the ECM by matrix-metalloproteases (MMPs) during 
angiogenesis can expose trapped soluble factors concealed within the matrix. For 
instance, MMP cleavage can separate the receptor binding portion of VEGFA from the 
ECM interaction domain, effectively generating a soluble VEGFA population. While 
both ECM-bound and soluble VEGFA appear to be bioactive, the two forms elicit 
differential effects on endothelial cells. Specifically, soluble VEGFA initiates more 
proliferative functions while bound isoforms induce a more migratory state (5,6). The 
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cause of this differential signaling is the direct association of the VEGFA receptor 
(VEGFR2) and a class of ECM-recognizing receptors known as integrins.  
Endothelial cells are sensitive to the condition of the ECM through the 
heterodimeric integrins which are activated by interactions with matrix proteins like 
fibronectin and vitronectin (7). Even when anchored to the ECM, VEGF remains 
bioactive and induces responses distinct from soluble VEGF (4). Specifically, bound 
VEGF appears to stimulate a population of VEGFR2 in complex with β1 integrin, which 
subsequently relocates to multimeric focal adhesion complexes involved in endothelial 
cell migration. In comparison to soluble VEGF, the cooperation between integrin and 
VEGF receptors exhibits greater activation of the pro-migratory p38-mitogen-activated 
protein kinase (p38-MAPK) (4). Moreover, other receptor tyrosine kinases (RTKs) than 
VEGFR2 have been demonstrated to interact with integrins and underlie a complex 
interaction between angiogenic signaling and the ECM that is too extensive to be 
explained here in full detail (8).  However, these observations do emphasize the potential 
importance of TARS-ECM interactions for the mechanism of the ARS’s function in 
angiogenesis.  
 Similar to VEGF and PDGF, observations in Chapter 4 suggest that TARS 
forms two separate interactions in the process of stimulating angiogenesis. Combining the 
various TARS constructs with the HUVEC tube formation assay (Chapter 4) allowed the 
structural components and activities important for TARS-mediated angiogenesis to be 
determined. The lack of angiogenic activity associated with the ΔN1N2-TARS truncation 
(containing only the catalytic and anti-codon binding domains) demonstrates that the full-
length protein is necessary for TARS’s vascular functions. Moreover, the addition of this 
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construct appeared to inhibit tube formation, suggesting that it might titrate away and 
interaction between the full-length protein and its target. When considered with the loss 
of secondary activity observed with the borrelidin-conformation mimic mutation Q566W 
TARS, these data suggest that two simultaneous protein-protein interactions are required 
for TARS-mediated angiogenesis. This hypothesis is also supported by the lack of 
angiogenesis exhibited by the N1-domain alone as well. However, this experiment should 
be reinvestigated using a fragment consisting of both the N1 and N2 domains so that all 
domains of TARS can be fully investigated.  
In this model, the first interaction, putatively between TARS and the ECM, 
establishes a gradient for nascent blood vessels essential for proper patterning. The bound 
TARS then makes a second interaction with a cellular surface receptor or related protein 
complex to mediate the necessary intracellular signaling pathways for migration. 
Borrelidin would be able to disrupt either the formation of the TARS gradient by 
inhibiting the TARS-ECM interaction or the intracellular signaling by blocking the 
TARS-receptor interaction. Recent preliminary data by Hannah Poulette and Karen 
Lounsbury provide some support for this model. Immunofluorescence experiments reveal 
that extracellular TARS readily binds to HUVEC-derived extracellular matrix (Figure 
36A, B). Treatment with BC194, however, has no noticeable effect on TARS binding 
(Figure 36B). Similar to in vitro angiogenesis assays, equivalent interactions are not 
observed with the non-specific ARS control leucyl-tRNA synthetase (LARS) (Figure 






Figure 36. TARS interacts with endothelial cell derived fibronectin. 
Endothelial cells (HUVECs) were plated on gelatin and incubated for five days to allow for 
the accumulation of extracellular matrix (ECM). In some cases (B) cells were lysed using 20 
mM NH4OH and 0.5% Triton-X in PBS, which leaves the ECM intact. The cultures were then 
treated for one hour under the indicated conditions and LARS, TARS, fibronectin (FN1), 
nuclei (DAPI) detected by immunofluorescence. (A) Images of HUVEC-derived matrix with 
intact cells treated with 100 nM TARS showing FN1 (left), TARS (middle), and merged with 
DAPI (right). (B) Merged images of HUVEC-derived ECM with lysed cells treated with PBS 
(Control) or as indicated in the figure. Data were kindly provided by Hannah Poulette and 
Karen Lounsbury.  
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The above observations are not the first evidence of TARS interaction with the 
ECM. Affinity-purification mass spectrometry experiments interested in focal adhesion 
complexes have reported interactions by TARS with fibronectin 1 (FN1) and integrins 
(10). As mentioned above, the connection between focal adhesions complexes and 
endothelial cell migration has been well established and is very important to the process 
of angiogenesis. The interaction between integrin receptors and FN1 is strongly 
dependent on an RGDS amino acid sequence and can disrupted through exposure to the 
equivalent peptide (11,12). Interestingly, treatment with the RGDS-peptide appears to 
disrupt the TARS-ECM interaction as determined by immunofluorescence experiments 
(Figure 35B). However, the effect is specific to regions that appear to have been directly 
beneath or adjacent to cells prior to dissolution and ineffective against TARS bound to 
more distantly deposited FN1. A possible explanation for this difference is the status of 
the fibronectin matrix itself. Soluble FN1 is typically found in a dimeric structure. 
However, in a cell and integrin-dependent process these FN1 dimers can be reorganized 
into multimeric, fibrillar networks through fibrillogenesis. Interestingly, the process of 
generating matrix FN1 can also expose new interaction sites in the FN1 molecules 
(13,14). Since the formation of the fibrillar form is dependent on cellular-based integrins, 
the RGDS peptide may disrupt normal fibrillogenesis and negatively impact the binding 
of TARS to these sites (15). Therefore, TARS-mediated angiogenesis may be dependent 
on specific structure attributes of the FN1 matrix. However, the exact mechanistic details 
of how these various forms of FN1 affect this process remain to be determined.   
 
6.1.4 Identification of extracellular TARS binding partners 
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 Chapter 4 revealed that the angiogenesis-inhibitory properties of borrelidin and 
BC194 are mediated through a specific conformational change within the TARS 
aminoacylation domain.  This observation suggests that TARS protein-protein 
interactions are important for the ARS’s angiogenic function. As described in Appendix 
I, affinity purification of TARS followed by mass spectrometry analysis revealed the 
major cellular interaction partners of TARS. However, these experiments focused on 
interactions within cellular lysates despite the fact that TARS appears to stimulate 
angiogenesis extracellularly. As such, future experiments would benefit from interaction 
studies focusing on extracellular and cellular surface interactions. Specifically, 
fluorescently labeled TARS constructs can be used to determine if the enzyme interacts 
with the cell surface and the specific domains involved. Furthermore, putative receptors 
or extracellular interaction partners could be isolated by affinity purification of TARS-
associated membrane complexes and identified by mass-spectrometry using 
modifications to established procedures (10). The successful identification of these 
interactions partners would allow for the better understanding of TARS-mediated 
angiogenesis and would facilitate subsequent investigations of downstream signaling 
pathways.  
 
6.1.5 Identification of downstream signaling 
 In addition to establishing a gradient through associations with the ECM, the 
two interaction model assumes that a second interaction mediates endothelial cell 
migration through the activation of downstream signaling pathways. Several common 
pathways involved in this process have already been investigated in the lab of Karen 
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Lounsbury, including ERK1/2, p38-MAPK, and NF-κB (data not shown). Unfortunately, 
the results so far have been inconclusive. Treatment of HUVECs with 100 nM TARS or 
10 nM BC194 have exhibited no effects on the phosphorylation of p38-MAPK and NF-
κB. Conversely, both treatments have been observed to induce phosphorylation of 
ERK1/2 within five minutes. However, this result is often inconsistent. Therefore, other 
pathways should be investigated. 
 Several RTKs are involved in the regulation of angiogenesis. As mentioned in 
Chapter 4, section 4.3.3, TLR 2 and 4 exhibit interesting characteristics that implicate 
these proteins as possible TARS receptors. While these receptors often activate NF-κB, 
which does not appear to be related to TARS-mediated angiogenesis, reported 
associations between TLRs and integrins can alter the TLR-signaling, much like ECM-
bound VEGF (4,16,17).  Furthermore, connections between TLR-signaling and activation 
of signal transducer and activator of transcription 3 (STAT3) signaling have been 
observed (18). STAT3 is activated through phosphorylation, which allows for the 
protein’s homodimerization, nuclear translocation, and subsequent upregulation of target 
genes though interactions with STAT binding elements (SBE) in the DNA. Interestingly, 
SBEs have been identified upstream of both VEGF and TARS (TARS site identified by 
DECODE, Decipherment of DNA elements database; SABiosciences), allowing for the 
induction of angiogenesis as well as a potential positive feedback mechanism (19). This 
potential connection between TARS and STAT3 signaling can be easily investigated 
through Western blot analysis against phospho-STAT3. Nonetheless, no direct evidence 
exists for TLRs as the putative TARS receptor, indicating that other targets should also 
be considered. 
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The connection between growth factor receptors and angiogenesis has been well-
established in the literature. The most important of these, of course, is the activation of 
VEGFR2 by VEGFA. However, EGFR, PDGFR, and FGFR can strongly influence this 
process in response to other ligands as well (20). Furthermore, many of these receptors 
have reported interactions with integrins, which can alter ligand-mediated signaling or 
initial ligand-independent activation (21).  Despite the varying affinities of these 
receptors to different ligands the down-stream signaling cascades often overlap.  The 
connections between several of these common factors to TARS-mediated angiogenesis, 
such as ERK1/2 and p38-MAPK, have already been investigated without clear results. 
However, the zebrafish data presented in Chapters 3 and 4 implicate that TARS is likely 
involved in the regulation of endothelial cell migratory mechanism.  One potential 
candidate for further investigation is Src kinase, which is can be activated through 
phosphorylation by growth factor or integrin receptor stimulation (22,23). 
Phosphorylated Src is able to activate focal adhesion kinase (FAK) which can 
subsequently activate a variety of responses connected to migration, invasion, survival, 
and growth (24). Furthermore, Src signaling has been demonstrated to activate STAT3 
(25,26). As with STAT3 above, the connection between Src and TARS-mediated 
angiogenesis can be easily investigated by Western blot against phosphorylated Src. 
 
6.2 The nucleo-cytoplasmic distribution of TARS 
6.2.1 TARS possesses an N-terminal region of unknown function 
 In addition to TARS four other ARSs have been associated with effects on 
angiogenesis (described in Chapter 1). The secondary functions of each of these is 
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dependent on domains acquired over the course of evolution not associated with 
aminoacylation. While no appended domain has been directly connected to TARS’s 
secondary function, the N-terminal region of TARS consists of the ubiquitin-like TGS 
domain  (residues 83-144) and an unstructured 82 amino acid extension (residues 1-82) 
of unknown function. The N-terminal extension appears to have arisen in eukaryotic cells 
and can be observed in even the most ancient of protists, such as Giardia lamblia. 
Conversely, the TGS domain is retained from bacteria to humans. As indicated in 
Chapter 4, E. coli TARS is capable of stimulating angiogenesis in tube formation assays, 
suggesting that the N-terminal extension is dispensable for TARS-mediated angiogenesis 
once TARS is extracellular (the possibility of intracellular regulation for TARS’s 
angiogenic function by this extension remains to be determined). Moreover, since the 
ΔN1N2-TARS fragment (consisting of the catalytic and anticodon-binding domains) was 
unable to induce angiogenesis, the TGS domain may be essential for mediating a second 
extracellular interaction important for angiogenesis. However, additional investigations 
with the N2 editing domain are required to confirm this. The possible roles for the N-
terminal extension, if any, have yet to be investigated.  
Structural data and sequence alignments demonstrate that prokaryotic TARS 
begins at the ubiquitin-like TGS domain while the eukaryotic homologs possess an N-
terminal extension that varies between species. In humans this extension consists of 82 
amino acids not visible by crystallography or NMR. Additionally, analysis of this region 
using Prediction of Order and Disorder by machine LEarning (POODLE) software 
confirms that the first 52 amino acids of the protein are disordered (27). Regions of 
intrinsic disorder are often sites of protein-protein interactions and are covered in greater 
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detail in Appendix I. Therefore, it is possible that the N-terminal extensions of eukaryotic 
TARS mediate interactions required for the regulation of the protein’s secondary 
functions.  
 
6.2.2 TARS’s N-terminal region possess a possible nuclear localization signal 
Alignments of eukaryotic N-terminal regions reveal that the sequences of these 
extensions can vary greatly among different organisms. This is not surprising, however, 
as mutations in obligate disordered regions are common owing to the fact that sequence 
conservation is not as critical to maintaining disordered regions as it is with ordered ones 
(28). Despite this sequence variance, however, some features appear to be maintained. 
Notably, animals and other eukaryotes, such as Saccharomyces cerevisiae, possess a 
KKXK sequence (KKKNK in humans) which is similar to other sequences demonstrated 
to function as nuclear localization signals (NLSs) in other proteins (29). Of particular 
interest, an NLS is essential for SARS’s control of angiogenesis through the regulation of 
VEGF expression (30). As shown in Chapter 3, pharmacological inhibition of TARS can 
also regulate VEGF expression, however, there are currently no reports that the KKKNK 
sequence functions as an NLS, let alone is involved in the regulation of VEGF 
expression.  
 In support of TARS’s putative NLS, preliminary data demonstrate that TARS 
possesses a variable nucleo-cytoplasmic distribution. Immunofluorescence studies reveal 
the presence of punctate TARS containing structures within the nucleus in both human 
umbilical vein endothelial cells (HUVEC) (Figure 37; data by Hannah Naughton) and 
SKOV3 ovarian carcinoma cells (SKOV) (Karen Lounsbury and Jessica Cassavaugh, 
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unpublished data). Exposure of HUVEC cell cultures to 50 ng/μl VEGF further increased 
this nuclear population of TARS (Figure 37, right panels). In contrast, treatment with 10 
nM BC194 induced a clear peri-nuclear localization as demonstrated by the appearance 
of a halo-like appearance of TARS immediately around the nucleus (Figure 37, left 
panels). In combination, the VEGF and BC194 treatments increased both the nuclear and 
peri-nuclear distribution of TARS. As a possible explanation for the peri-nuclear 
distribution, the induction of amino acid starvation by BC194-inhibition of TARS may 
induce endoplasmic reticulum-associated degradation pathways by activating responses 
similar to the unfolded protein response (9,31,32).  This nuclear distribution is partially 
corroborated by Western blots comparing the presence of TARS in the cytoplasm and 
nucleus.  
To further investigate the subcellular distribution of TARS in endothelial cells, 
nuclear and cytoplasmic fractions from cultures treated with BC194 and VEGF were 
obtained and the presence of TARS determined by Western blot (Figure 38A, B). While 
full-length TARS was not observed in endothelial cell nuclear extracts treated with 
control, BC194, VEGF, or BC194/VEGF combination conditions, a band corresponding 
to a ~35 kDa fragment was observed under all conditions and appeared to increase in 
BC194 and VEGF treated samples. Furthermore, the effects of BC194 and VEGF on the 
appearance of the band were additive as the greatest intensity was observed in cultures 
treated with both.  Of particular interest, this band is the same size as would be expect for 
the combined N-terminal extension, TGS-domain, and N2 editing domain (N1N2) 
(Figure 38A). The TARS antibody that was used in these Western blot experiments 
targets amino acids 1-98, which would fall in this region. Conversely, the antibody used 
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Figure 37. BC194 and VEGF treatments influence the cellular distribution of TARS. 
Immunofluorescence images of TARS (red) with DAPI nuclear stain (blue) following treatment 
with DMSO vehicle control (top left), 10 nM BC194 (bottom left), 50 ng/μl VEGF (top right), 
and 10 nM BC194 and 50 ng/μl VEGF (bottom right). HUVEC cell cultures were grown to near 
confluency in full EGM-2 media (2% FBS) and then treated as indicated for 24 hours in 10% 
EGM-2 media (0.2%). Images are shown in duplicates with and without DAPI stain for better 
visualization of nuclear TARS. Areas occupied by the nucleus are outlined by dotted lines. 
Images kindly provided by Hannah Naughton.  
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in the immunofluorescence experiments targets the catalytic domain. Since target size is 
undeterminable with immunofluorescence the exact form of TARS in the different 
locations remain unknown, which makes it difficult to fully consolidate these data with 
those acquired by Western blot. Nonetheless, cleavage of the TARS N-terminal domains 
may be important for the enzyme’s nuclear localization and warrants further 
investigation. Another similar N-terminal fragment has been previously observed in 
nuclear fractions from the PC-3 prostate carcinoma cell line following treatment with 10 
ng/μl TNFα (Figure 38C). Titration of the BC194 compound demonstrated a visual 
increase in the appearance of a band corresponding to ~25-37 kDa within the nuclear 
fraction, which is the approximate location expected for the N1N2 fragment, however, 
difficulties visualizing the lamin loading control prevented accurate quantification of the 
nuclear fraction. Full-length TARS was also observed in these fractions as well, but its 
appearance did not correlate with treatment. A caveat of nuclear fractionation is that 
components of the peri-nuclear region may also remain associated with the nucleus. As 
such, it may be that some of the observed full-length TARS is an artifact of the 
fractionation process.  
The possible redistribution of an N-terminal TARS fragment is of particular 
interest due to its interactions with the von Hippel-Lindau tumor suppressor, a master 
regulator of the pro-angiogenic transcription factor 1α (HIF1α) (see Appendix I for more 
information) (33). The interaction with VHL appeared to be greater with N1-TARS 
relative to the full-length protein, suggesting that liberation of the N1-domain could have 
downstream biological functions through modification of normal VHL function. 




Figure 38. Effects of BC194, TNFα, and VEGFA on the nucleo-cytoplasmic 
distribution of TARS. 
(A, B) Nuclear (A) and cytoplasmic (B) fractions from HUVECs blotted for TARS and 
loading controls lamin A/C (nuclear fractions) and β-tubulin (cytoplasmic fractions). Please 
note the differences in molecular weights for nuclear and cytoplasmic TARS. (C) Nuclear 
and cytoplasmic fractions of PC-3 prostate carcinoma cells blotted for TARS in the presence 
or absence of 10 ng/μl TNFα. Full length TARS and the putative TARS truncation are 
indicated. (D, E) Western blots against HA-tag (TARS), HIF1α, and β-tubulin in nuclear 
and cytoplasmic lysates from HEK293 cells transfected with over-expression plasmids 
encoding WT TARS (D) or L567V TARS (E) exposed to the indicated concentrations of 
BC194. * indicates that the corresponding nuclear loading control (Histone 3) did not yield 
an interpretable blot. Data in parts A and B were kindly provided by Hannah Naughton. 
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regulation of its functions (34-36). When over-expressed in HEK293 cells, full-length 
WT TARS was found to redistribute to the nucleus in a BC194 dose-dependent response 
(Figure 38D). Unexpectedly, L567V TARS was also found to relocate to the nucleus 
upon treatment with BC194  (Figure 38E) despite its resistance to the compound’s effects 
in angiogenesis based assays (9). Possibly, this relocation may be due to a BC194-
activated stress response whose activation is normally involved in the nucleo-cytoplasmic 
distribution of TARS or is simply an artifact associated with the over-expression system. 
Interestingly, HIF1α protein levels appeared to stabilize at higher concentrations of 
BC194. However, other experiments demonstrate a reduction in HIF1α levels following 
BC194 treatment (see Figure 40 in Appendix I), suggesting a complex relationship 
between TARS and HIF1α that warrants further investigation. 
Altogether the above findings suggest that subsequent investigations related to 
TARS’s nucleo-cytoplasmic distribution and intracellular fragmentation may be 
beneficial for complete understanding of the ARS’s angiogenic functions. The 
importance of the KKKNK sequence for angiogenic and other biological functions can be 
investigated by generating mRNA for human TARS containing a deletion of this 
sequence. This mRNA can then be injected into zebrafish embryos along with an anti-
TARS MO to see if any vascular or morphological defects occur. Furthermore, the 
identity of the putative N-terminal TARS fragment found in the nuclear fractions should 
be verified. This could be accomplished using affinity purification of TARS from 
HUVEC cell cultures with an N-terminal biotin tag followed by SDS-PAGE separation 
and mass-spectrometry identification of the resulting peptides.  
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6.3 TARS secretion by exosomes 
 One of the most important questions that remains for the extracellularly acting 
ARSs in angiogenesis, YARS, WARS, and TARS, is the mechanism through which these 
proteins are secreted. The identification of these pathways will likely be critical to the 
understanding the regulation of these secondary functions. For each of the three ARSs, 
secretion is induced by specific signaling molecules, such as interferon γ, TNFα, or 
VEGF, in cell culture experiments (9,37,38). Additionally, in all cases the cells appear to 
be remain intact throughout the secretory process, indicating that secretion is not simply 
the release of cellular components from dying cells. More in depth investigations of 
WARS eliminated the classical golgi and Ca2+-dependent secretory pathways (39).  
While this observation does not eliminate these canonical pathways as secretion 
mechanisms for YARS and TARS it does indicate that other mechanisms exist that are 
capable of secreting entire ARS molecules. As an alternative secretory mechanism, 
TARS has been identified in exosomes, protein and RNA rich vesicles ranging in 20 to 
100 nm in diameter (Figure 39) ((40,41) and David Lyden direct communication).  
Exosomes form by budding into the endosomal compartment, forming multi-
vesicular bodies and acquiring portions of the cytoplasm during the process. Fusion of the 
multi-vesicular bodies with the plasma membrane releases the exosomes and their cargo 
into the extracellular space. Of particular interest for TARS’s secondary function, 
exosomes are associated with the establishment of the pre-metastatic niche of melanoma 
to bone marrow progenitor cells (42). Similarly, TARS is associated with cancer 
progression and its inhibition by borrelidin has been shown to inhibit the progression of 
melanoma metastases (1,43). However, one potential caveat with the exosomal secretion 
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model concerns the release of the components contained within the vesicles once outside 
the cell. Interestingly, activation of P2X purinergic receptors have been shown to 
stimulate the release of exosomes from dendritic cells. While not directly related to 
endothelial cells, this observation reveals a connection between exosomal and purinergic 
signaling events (44). More importantly, the nucleotides produced through non-canonical 
catalytic functions of TARS observed in Chapter 5 can be transported out of the 
exosomes more readily than the TARS protein itself, suggesting that they could mediate 
TARS’s extracellular function. Nonetheless, further experimentation is required to truly 
establish the role of exosomes in the secretion of angiogenesis-inducing TARS. 
 
Figure 39. Transmission electron migrographs of PC-3-derived exosomes 
Electron micrographs of exosomes isolated from PC-3 conditioned media. Exosomes were 
isolated using ExoQuickTM reagent.  
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6.4 Further investigation of non-canonical, catalytic functions of TARS 
 The identification of non-canonical, catalytic functions (ie. GTPase, ADP 
formation, and Ap4A synthesis) of TARS provides an alternative mechanism through 
which TARS can influence receptor-mediated angiogenic signals independent of direct 
protein-protein interactions. The importance of these reactions is emphasized by the 
ability of the P2Y1 specific inhibitor MRS2179 to inhibit TARS-mediated angiogenesis. 
Specifically, P2Y1 responds to extracellular ADP, which is produced by all of the 
angiogenic constructs tested either directly or indirectly through the breakdown of Ap4A 
(45,46). Although borrelidin and BC194 did not exhibit any significant effects on these 
reactions, the conformational changes associated with the binding of the compounds may 
prevent interactions essential for localizing TARS near the purinergic receptors. 
Previously, the binding of lysyl-tRNA synthetase to the MITF transcriptional regulator 
was shown to stimulate MITF’s release from its inhibitor HINT through the local 
generation of Ap4A (47). Moreover, the Ap4A production by human TARS can be 
enhanced by TARS phosphorylation suggesting that these TARS secondary reactions 
may serve a biological purpose (48). Despite these observations, however, the 
connections between these non-canonical activities remain speculative and could benefit 
from further investigations.  
 In order for the various nucleotide products of TARS to contribute to 
angiogenesis TARS would have to be brought into close contact with the necessary 
purinergic receptors. The most likely candidate receptor would be P2Y1 based on the 
MRS2179 inhibition data and the connection between P2Y1 and endothelial cell 
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migration (46). This putative connection between TARS and P2Y1 could be verified 
through co-localization studies using immunofluorescence. Additionally, P2Y1 functions 
by activating the downstream Gq signaling pathways, such as inositol 1,4,5-trisphosphate 
(IP3) and diacyl glycerol (DAG). These pathways subsequently activate calcium 
mobilization within the cell and protein kinase C (PKC) association with the cell 
membrane (reviewed in (49)). Evidence for P2Y1 activation by TARS can be monitored 
by Ca2+-responsive, UV-fluorescent dye or Western blotting of membrane fractions for 
activated PKC (50,51).  
 In addition to establishing the connection between TARS and purinergic 
receptors other investigations should focus on the reactions themselves. Based on 
previous studies of other ARSs, the Ap4A reaction of TARS likely occurs within the 
TARS catalytic site (52,53). The GTPase and ADP formation activities of TARS, 
however, have not been previously reported and occur in absence of the essential R442 
residue in the TARS aminoacylation active site. As such, these reactions could occur 
within a different site of the protein, specifically the editing domain. Therefore, 
characterization of these reactions would benefit from investigations of their activities in 
the ΔN1N2-TARS construct. The presence of activity in this construct would suggest that 
the reaction is catalyzed in the aminoacylation domain while absence, seeing as the 
isolated N1-domain has already been shown to lack GTPase activity, would indicate the 
editing domain. Once the proper domain has been established efforts could focus on the 
generation of point mutations that inhibit these effects for subsequent testing of their 
angiogenic potential through tube formation or CAM assays. Since Ap4A may also 
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contribute to the generation of ADP, these mutations would have to be paired with the 
R442A mutation to eliminate both ADP and Ap4A production.   
 
6.5 TARS is associated with ovarian and prostate tumor progression 
6.5.1 Angiogenesis is an essential process in tumorigenesis 
 The metastatic progression of many tumors is tightly coupled to their angiogenic 
potential (reviewed in (54,55)). Early in the tumorigenic process the size of these tumors 
is limited despite the presence of clear proliferative activities. The cause of this restriction 
appears to be connected to apoptosis initiated by the hypoxic and nutrient deprived state 
of the tissue. The hyperplastic nature of these tumor cells allows them to quickly grow 
beyond the support of the available vasculature, limiting their access to essential nutrients 
and oxygen. Eventually, however, small populations of cells within the tumor acquire the 
ability to induce the growth of new capillaries within the surrounding tissue and relieve 
the former constraint. This sudden increase of angiogenic potential by the tumor mass as 
a whole is referred to as the “angiogenic switch”.  
 In addition to re-supplying the tumor tissue with nutrients and oxygen from the 
blood, the angiogenic switch is also necessary for the tumor’s metastatic progression. 
Newly formed blood vessels within tumor tissue are often immature and hyperpermeable, 
allowing metastatic cells direct access to the blood stream (56). Furthermore, the 
activation of HIF1α, a major tumor-associated inducer of angiogenesis, is known to 
enhance the expression of the transcriptional repressors, such as SNAIL1, ZEB2, and 
E47, which subsequently down-regulate the cellular contact proteins E-cadherin, 
occludin, and claudin (57,58). Up-regulation of VEGF also disrupts pericyte coverage of 
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nascent vessels through its suppression of platelet-derived growth factor (PDGF) 
signaling (59). Normally, pericytes function to stabilize mature vessels through the 
release of anigopoietins and PDGF. Furthermore, the activation of extracellular matrix 
metalloproteinases (MMPS) facilitate the migratory nature of endothelial cells by 
breaking down components of the ECM (20). Overall, these processes contribute to the 
increased permeability associated with immature blood vessels in angiogenesis. 
Interestingly, this same reduction in cell-cell contacts and matrix integrity that permits 
new vasculature to work its way between the tissues also facilitates the epithelial to 
mesenchymal transition (EMT) associated with metastatic tumors (60,61). Specifically, 
the increase vessel permeability permits the invasion and dissemination of tumor cells to 
distal regions of the body. Therefore, the identification of new factors involved in this 
angiogenic switch would be beneficial the development of novel therapeutic techniques.  
 
6.5.2 The intracellular levels of TARS increases with advancing stages of ovarian 
and prostate cancers 
 The recent identification of angiogenic activity in TARS implicates the ARS as 
a potential factor involved in the progression of tumor development. In support of this 
hypothesis, data mined from the NIH Cancer Gene Anatomy Project (CGAP) project and 
published DNA array analyses reveal that TARS is upregulated relative to other ARSs in 
several types of metastatic cancer (62,63). Of particular interest, metastatic ovarian and 
prostate cancers are highly angiogenic and exhibit increased expression of TARS 
according to the above databases (64-66). Moreover, TARS is secreted by cells as part of 
its angiogenic function, suggesting that serum levels of TARS could be developed as a 
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potential diagnostic for the development and metastatic progression of ovarian and 
prostate cancers. 
 The possibility of TARS as a diagnostic marker for prostate and ovarian cancer 
have been recently investigated by the labs of Christopher Francklyn and Karen 
Lounsbury respectively. In these studies the levels of TARS in patient tissue and serum 
samples collected by the University of Vermont Medical Center were determined using 
immunohistochemistry and ELISA procedures.  The association between TARS and 
ovarian cancer was recently published (9). As hypothesized, TARS staining intensity was 
found to increase with advancing stages of ovarian cancer. Furthermore, this TARS 
staining was found to co-localize with VEGF in tumor sites close to nascent vasculature. 
However, while TARS was readily observed in all serum samples, there was no 
significant differences between TARS levels in lower and high stages of the disease. 
Therefore, further investigation is required if TARS is to be established as a diagnostic 
marker of ovarian cancer.  
 Currently, diagnosis and risk assessment of prostate cancer relies heavily on the 
expression of prostate serum antigen (PSA). Elevated levels of PSA in the blood 
following surgical or radiation therapy, known as PSA biochemical failure, is associated 
with a high risk of recurrence by the cancer and poor prognosis (67). However, the 
accuracy of PSA-based diagnoses can be improved though the inclusion of other markers, 
leading to the current investigations of TARS’s connection to prostate cancer. In these 
studies TARS protein levels were compared to the Gleason scores of prostate cancer 
samples at various stages of the disease. This Gleason score ranges from 2 to 10 and is a 
measurement of a prostate tumors’s likelihood to spread as determined by tissue 
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histology. Effectively, Gleason score increases as cellular morphology deviates from that 
of healthy cells. Immunohistochemical staining of patient prostate samples revealed that 
TARS stain intensity increased significantly as the tissue progressed from a primary 
Gleason score of 3 to 4. To further investigate the use of TARS as a prognostic marker, 
the Gleason scores and TARS levels were compared to the incidence of biochemical 
failure in the samples. Like with TARS, increasing Gleason scores correlated with a 
higher risk of PSA biochemical failure. Moreover, calculations of the ratio of the product 
of TARS stain intensity and the percentage of the tumor at a particular Gleason score 
over the product of the average TARS intensity and Gleason score percentage revealed a 
correlation between risk of biochemical failure and elevated TARS levels in Gleason 4 
and 5 tumors. Together the above data implicate TARS as a potential indicator of prostate 
cancer prognostic outcome and warrants further investigation.  
 A possible mechanistic connection between TARS and prostate cancer was 
demonstrated by Jon Ramsey when knockdown of TARS in a DU145 cancer cell line 
using anti-TARS siRNA disrupted the migratory ability of these cells in a wound healing 
assay. When considered with the vessel patterning defects observed with knockdown of 
TARS in zebrafish (Chapter 4, section 4.2.1) these data appear to indicate a role for 
TARS in cellular migration that is not limited to vascular cells. As such, the potential 
roles for TARS as a diagnostic marker in prostate cancer and as a general component of 
cellular migration warrant further investigation.  
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6.6 Selective inhibition of the malarial parasite Plasmodium falciparum 
Perhaps one of the greatest findings of this work is the mechanistic rationale 
behind the attenuation of borrelidin associated toxicity responses resulting from 
seemingly minor modifications to the compounds’ structures. As discussed in Chapter 3, 
the difference between intracellular and extracellular threonine pools may account for the 
seemingly contradictory observations that BC194 is more susceptible to threonine 
competition than borrelidin but remains equally potent at inhibiting angiogenesis.  A 
similar mechanism may also be able to explain the high selectivity recently reported for 
BC196 and BC220 towards the malarial parasite Plasmodium falciparum relative to 
humans (68). The modifications associated with these derivatives likely increases their 
susceptibility to threonine competition to a level that renders them ineffective at practical 
concentrations for inhibiting aminoacylation in human cells. However, as part of its life-
cycle the malarial parasite must infect host erythrocytes and obtain many of its amino 
acids from break-down of hemoglobin (69). Interestingly, P. falciparum lacks the 
traditional GCN-2 mediated amino acid starvation response and responds to nutrient 
deprivation by entering a hibernatory-like state in which the organisms metabolism and 
growth is significantly reduced (70). Furthermore, measurements of amino acid 
concentrations in isolated samples of the related avian malarial parasite, Plasmodium 
lophurae, revealed very low free levels of several amino acid species. Specifically, 
threonine levels were determined to be <20 μM (71).  Together, these observations 
suggest that erythrocytic malarial parasites are consistently subject to low levels of free 
amino acid concentrations. Therefore, the reduction in threonine competition within P. 
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falciparum relative to human cells may account for the increased efficacy of BC196 and 
BC220 against the malarial parasite.  
 
6.7 Final Remarks 
 The findings demonstrated by this dissertation work provide clear evidence for 
the role of TARS in angiogenesis both in vitro and in vivo.  The ability to disrupt these 
effects using TARS specific inhibitors underlies the potential use of TARS as a 
therapeutic target in angiogenesis associated diseases and, recently, parasite pathogenesis. 
However, like with other members of the ARS family, the efficacy of these treatments is 
negatively impacted by the associated toxicity stemming from their inhibition of the 
canonical aminoacylation reaction. Using a combination of biochemical, cellular, and 
organismal based methods we were able to successfully separate these toxicity-related 
responses from the desired effect on angiogenesis. Moreover, the application of similar 
techniques may allow for the development of other ARS inhibitors previously limited by 
their unintended side effects. Together, these findings unveil a novel role for TARS in 
normal vascular development and provide opportunities for the selective modulation of 
these effects by TARS-specific inhibitors. 
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APPENDIX I: IDENTIFICATION AND CHARACTERIZATION OF 
THREONYL-tRNA SYNTHETASE INTERACTION PARTNERS  
 
A1.1 Introduction 
 The Q566W TARS and A538W TARS mutations demonstrate a clear 
connection between borrelidin-induced conformational changes and the anti-angiogenic 
effects of the compound (see Chapter 4, section 4.2.6). Structural prediction software 
suggest that both mutations would shift a helix consisting of residues 492-547 into a 
conformation that mimics the structure of the TARS-borrelidin complex (1). Since 
neither of the TARS mutants exhibited the pro-angiogenic character of the wildtype 
protein, this conformational change alone seems responsible for borrelidin’s anti-
angiogenic mechanism. Furthermore, Q566W TARS is still able to catalyze the canonical 
aminoacylation reaction, suggesting that this conformational change is not important for 
the normal function of TARS in translation. Therefore, the most likely explanation is that 
borrelidin inhibits TARS-mediated angiogenesis by disrupting an interaction between 
TARS and another molecule. 
 The modular structure of TARS consists of four major domains. Three of these, 
N2, catalytic, and anticodon-binding domains, possess clear functions within the 
canonical role of the protein (See Chapter 1, section 1.3.1). Furthermore, the ability of 
ΔN1N2-TARS to rescue TARS inhibition (Min Guo, unpublished data) demonstrate that 
TARS’s aminoacylation function requires only the catalytic and anticodon-binding 
domains. In contrast, the fourth domain, known as the N1 or TGS domain, possesses an 
ubiquitin-like structure and is dispensable for canonical TARS function. Likewise, the 
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eukaryotic TARS N-terminal extension appears to be unstructured making it difficult to 
predict its purpose. However, the association of ubiquitin-like proteins and intrinsically 
disordered sequences as mediators of protein-protein interactions suggests that possibility 
that these structures are important for the non-canonical functions of TARS.  
Analysis of the eukaryotic TARS N-terminal 82 amino acid extension using the 
Prediction of Order and Disorder by machine LEarning (POODLE) system indicates a 
high probability of disorder (>50%) in amino acids 1-52 (2). The conformational 
plasticity of disordered proteins provide many benefits in the formation of protein-protein 
interactions. The less compact structure of these disordered regions can facilitate 
interactions through an extended capture radius and increased interaction surface area 
(3,4). Additionally, these regions can adopt new conformations upon complex formation 
allowing for induced fit interactions with several possible binding partners (5-7). 
Interestingly, around 70% of proteins involved in signaling functions are predicted to 
contain unstructured regions, implicating these regions in important biological functions 
(8).  
 Ubiquitin-like proteins (UBLs) represent a large and diverse superfamily of 
proteins recognizable by their characteristic β-grasp superfold (9). Several family 
members, such as the eponymous ubiquitin, SUMO, and Nedd, consist exclusively of the 
ubiquitin-like fold and modify target proteins through the formation of covalent adducts. 
Alternatively, other UBLs contain ubiquitin-like domains as part of their modular 
structure. Despite their common fold, however, the sequence and function of UBLs can 
vary greatly.  These variations between UBLs alter their surface properties and 
contributes to the specificity of their interactions with proteins containing ubiquitin-
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binding domains (UBDs). The binding affinities between UBDs and UBLs are relatively 
weak with Kd values ranging from 5-500 μM for single ubiquitin like domains but can be 
augmented through the attachment of additional UBL monomers or contributions from 
neighboring protein domain, allowing for both tight and transient binding events.  
Furthermore, like their corresponding UBLs, UBDs consist of a broad range of sequences 
and structures (10,11). Together, this great variance between ligand and binding partner 
allows for the highly specific interactions critical for their wide range of cellular 
functions (12). Therefore, protein-protein interactions appears to be a common 
characteristic of UBLs.  
 The combination of a disordered region, ubiquitin-like domain, and 
conformational dependent pro-angiogenic function emphasizes the importance of protein-
protein interactions in TARS’s secondary function. Unfortunately, the complexity of 
angiogenesis provides a list of potential candidate interactions too numerous to 
investigate individually within a reasonable amount of time. Using existing protein-
interaction databases and our own affinity purification followed by mass spectrometry 
experiments this list can be reduced to a manageable quantity. Based on literature 
searches three candidates were elected for further investigation: the von Hippel-Lindau 
tumor suppressor (VHL), eukaryotic elongation factor 1α (eEF1α), and poly (ADP-
ribose) polymerase 1 (PARP1).    
 
A1.2 Results 
A1.2.1 Characterizing the TAR-VHL interaction 
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One of the most important regulators of angiogenesis is the von Hippel Lindau 
(VHL) tumor suppressor protein, a master regulator of the potent angiogenesis-inducer 
hypoxia inducible factor 1α (HIF1α). HIF1α is constitutively expressed under most 
conditions; however, its cellular levels are strictly controlled by the Von Hippel Lindau 
E3-ligase system. During normoxia, a family of prolyl hydroxylases (PHDs) hydroxylate 
prolines P402 and P564 of HIF1α (13). VHL recognizes these hydroxyl groups and 
initiates the ubiquitination and eventual degradation of HIF1α. During hypoxia the 
activities of the PHDs are significantly reduced, rescuing HIF1α from VHL-mediated 
ubiquitination. This stabilization increases levels of HIF1α, which is transported into the 
nucleus to form an active transcription factor complex with HIF1β. This complex is then 
able to bind to hypoxia response elements (HRE), consequently up-regulating hypoxic 
response genes related to angiogenesis, such as vascular endothelial growth factor 
(VEGF), as well as genes involved in glycolysis and fermentation (14-16). This shift to 
fermentative processes under aerobic conditions, classically referred to as the Warburg 
effect, provides critical metabolic intermediates for macromolecule biosynthesis and 
emphasizes the significance of the VHL/HIF1α pathway dysregulation in cancer 
progression (17-19). Of particular interest to this work, a large scale protein-protein 
interaction study has identified interactions between the VHL tumor suppressor and 
TARS, suggesting that TARS’s non-canonical, angiogenic function could be related to 
the regulation of VHL.  
 As an E3 ubiquitin ligase, VHL serves as the target recognition component for 
protein complexes that catalyze the attachment of poly-ubiquitin chains to other proteins. 
In the regulation of HIF1α this requires forming a complex with Rbx-1, elongin C, 
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elongin B, and Cullin-2 (20).  Structural comparisons have revealed that one of these 
partners, elongin B, shares a similar ubiquitin-like fold with the N1-domain of TARS. As 
TARS has been shown to interact with VHL (21), it may be that elongin B is displaced by 
 
Figure 40. TARS may regulate VHL E3-ligase function. 
(A) Structure of VHL (yellow) in complex with elongin C (purple) and elongin B (cyan) 
(PDB: 1LQB). Inset – Superposition of TARS TGS domain (green; PDB: 1WWT) and 
elongin B (cyan; PDB: 1LQB). (B) Western blot for HIF1α and TARS from cell lysates under 
normoxic and hypoxic conditions at various concentrations of borrelidin or BC194. The prolyl 
hydroxylase inhibitor, CoCl2, was used as a positive control for HIF1α stabilization. Data were 
kindly provided by Karen Lounsbury. 
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the N1 domain of TARS and the assembly of the complex is mediated through elongin C 
(Figure 40A). Disruption of this interaction could then modify VHL’s ability to regulate 
HIF1α and, through it angiogenesis. In support of this data from the lab of Karen 
Lounsbury have shown that treatment of human embryonic kidney 293 cells (HEK293) 
with 10 nM of the TARS inhibitors borrelidin or BC194 reduces the protein levels of 
HIF1α under hypoxic conditions (Figure 40B), thereby establishing a connection between 
TARS and VHL function. Therefore, the TARS-VHL interaction was characterized in 
further detail.  
Initial validation of the TARS-VHL interaction was achieved by investigating 
the ability of various TARS constructs to “pull-down” VHL. Each TARS construct was 
cloned into an overexpression vector containing a BirA biotinylation site and an HA 
epitope and co-transfected into HEK293 cells with a plasmids encoding the biotin 
transferase BirA and c-Myc-tagged VHL. The presence of BirA would catalyze the 
biotinylation of the TARS construct, allowing for the protein to be affinity-purified by 
streptavidin-coated beads from the cell lysates along with anything currently interacting 
with it. Interactions are then identified by Western blot. To account for possible non-
specific binding to the streptavidin beads, the ability of VHL to recapitulate the TARS 
pull-down experiments was also performed pulling VHL out of solution with anti-c-Myc 
sepharose-conjugated beads and observing interaction partners by Western blot.  Both 
full length TARS (Figure 41A) and the isolated N1-domain (Figure 41B) were found to 
co-immunoprecipitate with VHL, affirming the TARS-VHL interaction and supporting 
the N1-domain as the specific action site. Interestingly, the bands for N1-TARS were 
noticeably more intense than those for the full-length protein, suggesting that the isolated 
 225 
N1-domain forms stronger interactions with VHL. However, it may also be that the 
smaller size of the N1-domain allows for its increased expression or reduces steric 
hindrance with other molecules during the pull-down process and warrants further 
investigation. While these data would support the hypothesis that TARS binds to VHL 
 
 
Figure 41. TARS interacts with VHL through its N1-domain. 
(A, B) Western blots of TARS and VHL following affinity purification (AP: Biotin) of Full 
length TARS (A) or N1-TARS (B) and VHL immunoprecipitation (IP: Myc). 
Immunoprecipition with IgG-coated beads was used as a control for VHL immunoprecipitation 
to demonstrate the specificity of the binding. (C) Western blots of TARS affinity-purified 
lysates treated with various concentrations of BC194 (0.01 to 1000 nM) for full-length TARS 
(IB: HA) and VHL (IB: Myc). Data in (C) were kindly provided by Joann Russo and Jason 
Botten. 
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through elongin C by displacing elongin B, additional information is required to confirm 
this interaction.  
Borrelidin and its derivative BC194 have been previously shown to inhibit 
TARS-mediated angiogenesis. Therefore, if the TARS-VHL interaction was important 
for TARS’s non-canonical role in angiogenesis, borrelidin’s anti-angiogenic properties 
may occur by disrupting this interaction. Since the borrelidin-binding site is located 
within the TARS catalytic domain, only the full-length TARS construct was investigated 
(Figure 41C). The addition of 0.01 nM, 10 nM, 100 nM, and 1000 nM of BC194 had no 
effect on the ability of TARS to pull-down VHL, suggesting that the interaction is not 
susceptible to inhibition by borrelidin and related compounds.  
Owing to its association with tumor angiogenesis and anaerobic metabolism, 
VHL is considered a tumor suppressor protein. The inhibition of alteration of normal 
VHL function through point mutations in the protein have been associated with the onset 
of several tumor types. Several of these mutations are located along the VHL-elongin C 
interface. Therefore, it may be possible that these mutations could disrupt normal VHL 
function by destabilizing its interaction with elongin C. Since elongin B binds through 
elongin C it seems likely that these mutations would also disrupt the TARS-VHL 
interaction if it truly binds by displacing elongin B.  To test this hypothesis, three 
mutations were introduced into VHL, R167A, R167W, and C162A, corresponding to the 
two most-common pathogenic mutations at the VHL-elongin C interface, and 
subsequently investigated for their ability to disrupt interactions between full-length 
TARS (Figure 42A) and N1-TARS (Figure 42B) (22). The C162A mutation appeared to 
disrupt the interactions between VHL and both the full-length TARS and N1-domain. 
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Additionally, R167W also was found to inhibit the N1-domain interaction with VHL 
(Likely R167W would have inhibited the VHL interaction with full-length TARS as well, 
but due to a sample processing error these data were not obtained). Together, these data 
support the hypothesis that TARS interacts with VHL through elongin C by displacing 
elongin B with its N1-domain. However, it should be noted that these experiments were 
only performed once and should be repeated for confirmation. Furthermore, a stronger 
band was anticipated for the N1-TARS-WT VHL interaction than was received (see 
Figure 41B), suggesting that an error may have occurred in the isolation of this sample.  
 
 
Figure 42. TARS interacts with VHL by displacing elongin B. 
(A, B) Western blots of TARS (IB:HA) and VHL (IB: Myc) following affinity purification 
(AP: Biotin) of Full length TARS (A) or N1-TARS (B). Where indicated the wildtype myc-
tagged VHL plasmid was substituted with plasmids encoding myc-tagged R167A, R167W, 
or C162A VHL constructs.  
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As an alternative method to demonstrate that TARS binds to VHL by displacing 
elongin B, previous reports indicate that peptides mimicking the elongin C component of 
the elongin C-VHL interface could disrupt both elongin B and C interactions with VHL. 
Single amino acid alanine substitutions in the peptide, notably L158, were able to block 
the effect of this compound, which indicates the importance of these residues for this 
interaction (23). Unfortunately, this study was not discovered until after the above 
experiments were performed and suggests that future repetitions of these experiments 
could be improved using a L158A peptide. 
 
A1.2.2 Identifying the TARS interactome through mass-spectrometry  
Since the interaction between VHL and TARS appeared to be unaffected by 
borrelidin, the ability of TARS to interact with other proteins partners was investigated 
using mass spectrometry. Specific emphasis was placed on any interaction with ties to 
angiogenesis or VHL function and were subsequently investigated by Western blot to 
determine the effects of borrelidin. For these experiments HEK293 cell lysates over-
expressing HA- and biotin-tagged TARS alone (condition 1) or with myc-tagged VHL 
(condition 2) were affinity purified using streptavidin coated beads. Unbound proteins 
were removed through successive washing and the prey proteins identified through mass 
spec analysis of SDS-PAGE resolved bands. Non-specific interactions were determined 
using an empty vector control and removed from subsequent analyses. High confidence 
was given to any interaction with a cross-correlation value (XC) greater than 20.00. 
Observed interactions are shown in Table 13. 
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Table 13. Interactions for affinity purified TARS identified by mass spectrometry 
Translation Related 
Name XC Peptides Condition Function 
TARS 218.32 36 1,2 Threonyl-tRNA Synthetase (cytoplasmic) 
TARSL2 38.28 4 1,2 Likely TARS isoform 
EPRS 30.19 4 2 Bifunctional aminoacyl-tRNA synthetase 
RPS15A 10.22 1 2 40S Ribosomal protein 
RPS20; SNORD54 10.18 1 1,2 40S Ribosomal protein 
RPS3A; SNORD73A 10.18 1 1 40S ribosomal protein S3a 
eEF1A1 10.16 2,1 1,2 Elongation factor 1-alpha 1 
MARS 10.15 1 2 Methionyl-tRNA Synthetase (cytoplasmic) 
LARS 10.14 1 1 Leucyl-tRNA Synthetase (cytoplasmic) 
eEF1G 10.11 1 1 Elongation factor 1-gamma 
TARS2 8.13 1 1,2 Mito TARS 






Sim. E2D2-2 10.13 1 2 Similar to Ubq-conjugating enzyme E2D 2 
Med8 10.10 1 1 E3-ligase- Elongin B,C, cullin, rbx based 
VHL-1 10.10 1 1 24kDa 
VHL-3 10.10 1 1 18kDa 






SLC25A5 20.22 3 2 ADP/ATP Translocase 2 
GAPDH 10.16 1 1 
Glyceraldehyde-3-phosphate 
dehydrogenase 
ENO1 10.15 1 1 Alpha-enolase 
ENO2 10.15 1 1 Gamma-enolase 
ENO3 10.15 1 1 Beta-enolase 
HSPD1 10.15 1 2 Mito Heat shock protein 






eEF1A1 10.16 1 1,2 Elongation factor 1-alpha 1 
NUP107 10.15 1 2 Nuclear pore protein 
     
Name XC Peptides Condition Function 
PARP1 30.16 4 1 Poly [ADP-ribose] polymerase 1 
Isoform 3 Myosin 1C 20.18 2 1 Myosin-Ic 
HNRNPC 20.18 2 1 Heterogeneous nuclear RNPs C1/C2 
POTEE 20.14 2 1  POTE ankyrin domain family member E 
CALD1 10.18 1 1 Caldesmon 
DHx30-1 10.17 1 1 
Putative ATP-dependent RNA helicase 
DHX30 
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DHx30-2 10.17 1 1 
Putative ATP-dependent RNA helicase 
DHX30 
DHx30-3 10.17 1 1 
Putative ATP-dependent RNA helicase 
DHX30 
HNRNPU 10.14 1 1 Heterogeneous nuclear ribonucleoprotein U 
RUVBL1 10.14 1 1 RuvB Like 
NEFM 10.13 1 1 Neurofilament medium polypeptide 
PRPH 10.13 1 1 Peripherin 
ILF2 10.11 1 1 Interleukin enhancer-binding factor 2 
HSP90AB3P 8.16 1 1 Putative heat shock protein HSP 90-beta-3 
CLTB 8.15 1 1 Clathrin light chain B 
TDRD6 8.13 1 1 Tudor domain-containing protein 6 
ALMS1 8.11 1 1 Alstrom syndrome protein 1 
1Condition 1 - Over-expressed TARS; Condition 2 - Over-expressed TARS and VHL 
 
Several notable interactions were identified in these experiments including many 
related to metabolism, protein translation, and nuclear-cytoplasmic trafficking. Although 
XC values indicated low confidence, the results once again confirmed the previously 
identified interactions with VHL. Furthermore, several members of the multi-synthetase 
complex were observed even though TARS itself is not recognized as a component of the 
complex (24). Specifically, high confidence was observed for its interaction with the 
glutamyl/prolyl-tRNA synthetase (EPRS) and less confidently with leucyl-tRNA 
synthetase (LARS) and methionyl-tRNA synthetase (MARS). Interestingly, both EPRS 
and LARS are reported to be key components of various survival responses through 
GAIT and mTOR mediated responses respectively (25,26). The significance of these 
interactions is not yet apparent, but may indicate a higher degree of cross-talk between 
the translational machinery than previously known. Finally, two other interactions were 
also of interest: poly(ADP-ribose)polymerase1 (PARP1) and eukaryotic elongation factor 
1α1 (eEF1A1). 
 
A1.2.3 Characterizing TARS’s interaction with PARP1 
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Canonically, PARP1 is viewed as a member of the DNA-damage response in eukaryotic 
cells. In response to genotoxic stress PARP1 will homodimerize and catalyze the 
attachment of ADP-ribose polymers to itself (27,28). The presence of this modification 
recruits other factors to the damaged site to initiate the necessary repair events (29,30). 
However, over the last decade the functions of PARP1 have expanded beyond DNA 
repair and stability including inflammation and angiogenesis. Over ADP-ribosylation by 
PARP1 can lead death associated pathways due to the depletion of ATP from the 
synthesis of NAD+ (31,32). Alternatively, direct modification of inflammatory genes can 
lead to their activation, such as NF-κB (33,34).  While the connection between 
inflammation and angiogenesis has been well established PARP1 also appears to have a 
more direct connection as well. Treatment with several PARP1 inhibitors was found to 
decrease angiogenesis as determined by in vitro HUVEC tube-formation and aortic ring 
branching assays as well as in vivo rat matrigel plug assays (35,36). Specifically, these 
inhibitors disrupted endothelial cell migration, similar to the effects observed with TARS 
inhibition.  Furthermore, PARP1 has been demonstrated to form protein-protein 
interactions with the potent angiogenic factor HIF1α and synergistically up-regulates 
genes under its control (37). The importance of this connection to TARS’s secondary 
function is only made greater by the interaction with the master regulator of HIF1α, 
VHL, established above. Finally, PARP1 has been associated with the non-canonical 
functions of another ARS, WARS, with known angiostatic properties. PARP1 and 
WARS have been shown to form a nuclear protein complex with DNA-dependent protein 
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kinase following stimulation by interferon γ (IFNγ) (38). Not only does this observation 
reveal a role of PARP1 in ARS secondary function but IFNγ itself is also known to 
regulate the expression of WARS and other angiostatic signals, implicating a role of this 
pathway in the regulation of angiogenesis as well (39). Together, these findings 
emphasize PARP1 as a strong candidate to mediate the angiogenic functions of TARS.  
 
 
Figure 43. TARS interacts with poly(ADP-ribose) polymerase 1 (PARP1). 
(A,B) Plasmids encoding HA-tagged TARS with BirA biotinylation site and BirA were 
transfected into HEK cells. After 48 hours, TARS was “pulled-down” with streptavidin-
coated beads. (A) Western blots of TARS affinity-purified lysates analyzed using 
antibodies against PARP1 (IB: PARP1) and β-tubulin (IB: Tubulin) at various 
concentrations of BC194 (1-1000 nM). (B) Quantification of PARP1 relative to β-tubulin 
by densitometric analysis; n=1. Without repetitions, no meaningful analysis of statistics 
can be performed.  
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The TARS-PARP1 interaction identified by mass-spectrometry was subsequently 
confirmed by Western blot of affinity-purified TARS lysate samples (Figure 43A). 
Treatment with BC194 appeared to disrupt this interaction at concentrations of 10 nM 
and 100 nM, maintaining only 73% and 3% of the interaction exhibited uninhibited 
condition respectively. Interestingly, the disruption of this interaction was not observed at 
higher concentrations of BC194 since the interaction returned to 61% relative to the 
uninhibited conditions in lysates treated with 1000 nM. It should be noted, however, that 
these data have not been repeated (Figure 43B). Additionally, the input samples, 
representing the original PARP1 present in the lysate before TARS affinity-purification, 
appear to vary with BC194-treatment concentrations as well. While these signals are 
clearly saturated, as demonstrated by the empty space in the middle of each band, and 
may not be completely accurate, it could be that the apparent reduction in TARS-PARP1 
interaction is due to a reduction in PARP1 levels rather than a disruption of protein-
protein interactions. Therefore, repetitions are required to validate this result.  
 
A1.2.4 Characterizing TARS’s interaction with eEF1A1 
The protein eEF1A became a target of interest for several reasons: 1) a truncated 
version of eEF1A is referred to as prostate tumor inducer (PTI) for its relation to 
cancer (40); 2) eEF1A is known to interact with ubiquitin (41); 3) eEF1A1 is known 
to assist in the nuclear export of VHL (42); and 4) a population of eEF1A has been 
found to function as an extracellular membrane receptor (a component that is 
currently lacking from the extracellular TARS-mediated angiogenesis model) (43). 
All of these functions can be connected in some way to angiogenesis and, therefore, 
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could be putatively modified through interactions with TARS. Before investigating 
any of these individual effects the interaction between eEF1A1 and TARS was 
verified by TARS affinity purification and Western blot methods similar to VHL 
 
 
Figure 44. TARS interacts with eukaryotic elongation factor 1α1 (eEF1A1). 
(A) Plasmids encoding HA-tagged TARS with BirA biotinylation site and BirA were 
transfected into HEK cells. After 48 hours, TARS was “pulled-down” with 
streptavidin-coated beads. The presence of eEF1A1 was determined by western blot of 
TARS affinity-purified lysates using antibodies against eEF1A1 (IB: eEF1A1) and β-
tubulin (IB: Tubulin) at various concentrations of BC194 (1-1000 nM). (B) GTPase 
activity of eEF1A1 (blue), TARS (red), or combined eEF1A1 and TARS (green) as 
determined by formation of GDP per pmol of enzyme per minute. Human TARS or 
eEF1A1 (2 μM) was incubated with [α-32P]-GTP and quenched at various time points. 
Reaction products were resolved via thin-layer chromatography, and the formation of 
GDP over time was quantified by phosphorimaging; mean ± SD, n≥3. 
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except that a plasmid encoding for a C-terminally myc-tagged eEF1A1 constructs 
was used in place of VHL. The samples appeared to confirm the TARS-eEF1A1 
interaction indicated by the mass spectrometry data (Figure 44A). Exposure of these 
lysates to BC194, however, had no effect over all at the concentrations investigated. 
As the highest concentration, 1 μM, is well above the 4.09 nM predicted Kiapp there 
should be plenty of compound available to inhibit this interaction if it were capable. 
Like with the PARP1 observations, more repetitions are necessary to confirm these 
results. However, effects of BC194 have been investigated at least one other time at a 
concentration of 1 μM (data not shown) without any effect, suggesting BC194 does 
not inhibit the eEF1A1’s interaction with TARS.  
While BC194 treatment did not seem to affect the TARS-eEF1A1 interaction, 
the possibility that TARS could influence the GTPase activity of the enzyme was also 
investigated. Canonically, eEF1A functions to transport charged-tRNA to the ribosome 
and regulates this transport using guanine nucleotide cycling (44). This GTPase activity 
has also been proposed to be involved in eEF1A non-canonical activities (40,42). In 
support of this mechanism, a recent report demonstrated that leucyl-tRNA synthetase 
(LARS) stimulates the GTPase activity of the mTOR regulator, RagD, in response to 
changes in amino acid concentrations (45). Furthermore, as established in Chapter 5, 
TARS itself possesses a cryptic GTPase activity of unknown function. Therefore, we 
investigated if TARS influences the guanine nucleotide cycling of eEF1A (Figure 44B). 
Individually, both TARS and eEF1A1 were found to exhibit slow GTPase activity. 
However, when the proteins were combined the rates were only additive, indicating that 




A1.3.1 Possible contributions of the TARS-VHL interaction to the regulation of 
angiogenesis. 
The connection between conformational changes in TARS and the inhibition of 
angiogenesis strongly supports the role of protein-protein interactions in TARS-
mediated angiogenesis. Using affinity-purification and mass spectrometry several 
cellular binding partners for TARS have been identified. Based on literature searches 
indicating potential connections to angiogenesis three of these interactions have been 
chosen for further investigation, including the E3 ligase VHL, eEF1A1, and PARP1.    
The interaction between TARS and VHL opens up several opportunities through which 
TARS could regulate angiogenesis. The regulation of the VHL/HIF1α pathway is notably 
complicated and includes post-translational modification and transportation based 
mechanisms, some of which could possibly be influenced through interactions with 
TARS (15,46,47).  The presence of cellular localization signals in TARS has not been 
fully studied, however, some immunofluorescence and Western blot data provide some 
evidence of TARS peri-nuclear and nuclear localization (See Chapter 6, section 6.2.2). 
As such, complex formation with TARS may provide VHL with a sub-cellular 
localization signal that leads to its sequestration from HIF1α and allows for angiogenesis 
to occur. Alternatively, TARS’s interaction with VHL may alter the formation of the 
Table 14. eEF1A1 and TARS GTPase activity 
Condition Activity (min-1) 
eEF1A1 0.1132 ± 0.02033 
TARS 0.04745 ± 0.002536 
Both 0.1771 ± 0.01632 
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canonical VHL E3-ligase complex by disrupting the binding of elongin B, a hypothesis 
supported by the disruption of TARS-VHL interaction through the introduction of 
mutations along the VHL-elongin C interface shown above.  The resulting loss of VHL 
E3-ligase function would then, in turn, stimulate angiogenesis through HIF-mediated 
upregulation of VEGFA expression. Therefore, future experiments investigating the 
effects of TARS on HIFα stabilization and VHL E3-ligase activity would be beneficial.  
The inability of BC194 to disrupt the interaction between TARS and VHL is not 
surprising.  The interaction appears to be mediated by the N1-domain, which is located 
two domains away from the borrelidin binding site in the TARS catalytic domain. 
Therefore, it seems unlikely that any conformational change induced by borrelidin would 
be propagated to the N1-domain interaction interface. Alternatively, if TARS was 
essential for bridging VHL with another protein essential in the regulation of 
angiogenesis, borrelidin might be able to elicit an anti-angiogenic response through 
disruption of this second TARS interaction. The loss of angiogenic potential by the 
Q566W TARS, borrelidin-binding mimetic (Chapter 4, Section 4.2.6) already supports 
the role of borrelidin-induced conformational changes as the mechanism of the 
compound’s anti-angiogenic properties. However, no interaction has been identified that 
is disrupted by this structural change.  
 
A1.3.2 Possible contributions of the TARS-eEF1α and TARS-PARP1 interactions. 
The identification of interactions with eEF1A1 and PARP1 appeared interesting owing to 
a variety of different reports tying these proteins to angiogenesis. Although the 
experiments need to be repeated, preliminary investigations suggest that the PARP1-
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TARS interaction might be susceptible to disruption by borrelidin treatment.  However, 
the dose-responsive nature of this effect is complicated by prominent re-establishment of 
an interaction from 100 nM to 1000 nM BC194. One possible explanation for this 
observation is that 1000 nM is the lowest concentration observed to induce amino acid 
starvation with BC194 (Chapter 3, section 3.2.1). Therefore, it may be possible that 
amino acid starvation initiates an effect that overrides BC194’s inhibition of this 
interaction. Conversely, while Western blot analyses appear to confirm the TARS-
eEF1A1 interaction identified in mass-spectrometry experiments, there is no clear 
connection between TARS-angiogenesis and complex formation with eEF1A1. 
Additionally, BC194 treatment showed no effect on eEF1A1 GTPase activity as well.  
However, the recent development of a negative-control database for experiments that 
couple affinity purification with mass spectrometry, referred to as the contaminant 
repository for affinity purification-mass spectrometry data (CRAPome), suggests that the 
promiscuity and abundance of both eEF1A1 and PARP1 leads to their frequent 
appearance as non-specific interactions in whole interactome studies (48). Therefore, 
subsequent investigations of these interactions may be valuable, but should be undertaken 
with caution. 
 
A1.4 Experimental Procedures 
A1.4.1 Affinity and Immunoprecipitation Procedures 
Culture dishes were seeded with 2x106 human embryonic kidney cells (HEK293) and 
maintained in DMEM (Mediatech) supplemented with 10% fetal bovine serum (Gibco, 
Carlsbad, CA), penicillin/streptomycin (Gibco), and L-glutamine (Gibco) at 37°C and 5% 
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CO2 in a humidified incubator. Cells were transfected by polyethylenimine (0.05 mg/ml 
per μg DNA) with plasmids (3 μg each) encoding a TARS construct with C-terminal HA 
tag and BirA biotinylation site an C-terminally myc-tagged VHL or eEF1A1 as required. 
Additionally, a BirA plasmid was included in all experiments using the TARS construct 
to ensure biotinylation of the protein. Control experiments substituted an empty vector 
plasmid for the TARS construct. Following a 48 hour incubation, cells were lysed with 
1% Triton X, 0.5% NP-40, 140 mM NaCl, 25 mM Tris-HCl pH 7.6, and 1 Complete 
Mini protease inhibitor tablet (Roche) per 10 ml and the entire lysate mixed with 100 μl 
(1 mg) of streptavidin-coated magnetic beads (Invitrogen, Dynabeads MyOne 
Streptavidin) or 60-70 μl of EZviewTM Red Anti-c-Myc Affinity Gel (Sigma-Aldrich) to 
pull down TARS or VHL and eEF1A1 respectively. As a non-specific control for anti-c-
Myc experiments, separate lysates were treated with 60-70 μl of rabbit IgG-coated 
agarose beads (Sigma-Aldrich). Unbound proteins were washed away with three 
exchanges of lysis buffer. The bound proteins were eluted from the beads through boiling 
and resolved on a reducing, SDS-PAGE gel for use in Western blotting or mass 
spectrometry experiments.  
 
A1.4.2 Mass spectrometry analysis of affinity purified TARS from cell lysate 
Major bands from SDS-resolved TARS affinity purified samples and the empty vector 
controls were detected using SilverSNAP Stain Kit II (Pierce) and excised. Fragments 
were trypically digested using the in gel procedure for ProteaseMAX Surfactant 
(Promega) according to the manufacturers specifications. Briefly, free cysteines were 
alkylated by incubation with 55 mM iodoacetamide:50 mM NH4HCO3 followed by 
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trypsin digestion (2 ng/µl) in 0.01% ProteaseMAX surfactant:50 mM NH4HCO3. 
Peptides were analyzed by electospray ionization (ESI) liquid chromatography mass 
spectrometry (LC-MS). Samples were resolved over a fused-silica microcapillary 
MagicC18 LC column (12cm x100 µm i.d.) using a 5-50% acetonitrile gradient in 0.1% 
formic acid. Spectra were obtained using collision-induced dissociation with an LTQ 
linear quadrupole ion trap-Orbitrap mass spectrometer (Thermo Electro, San Jose, CA) 
and analyzed using SEQUEST (Bioworks software package, version 3.3.1; Thermo 
Electron, San Jose, CA). Acquired TARS data were compared to empty vector 
equivalents in order to identify non-specific interactions. 
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